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ABSTRACT 
Introduction: 
The main contributor of mortality in Duchenne muscular dystrophy (DMD) patients is 
cardiorespiratory failure. The beta-1 adrenergic receptor (ADRB1) has been shown to 
play a functional role in cardiomyocyte function with ADRB1 stimulation increasing 
cardiac rate, contractility, and work. Multiple polymorphisms of the ADRB1 have been 
identified such as the Gly49 polymorphism that includes at least one glycine (Gly) for 
serine (Ser) substitution at amino acid 49 resulting in either homozygous for Gly 
(Gly49Gly) or heterozygous (Gly49Ser) polymorphisms and a Gly for Arg substitution at 
amino acid 389 resulting in either homozygous for Gly (Gly389) or heterozygous 
(Arg389). Heart failure patients with these polymorphisms (Gly49 and Arg389) have 
been shown to have improved cardiac function and decreased mortality risk. 
Furthermore, the beta-2 adrenergic receptor (ADRB2) has been shown to influence 
respiratory muscle strength and function. Multiple polymorphisms of the ADRB2 have 
been identified as including a glycine (Gly) for arginine (Arg) substitution at amino acid 
16. The Gly16 polymorphism has been shown to have higher receptor density on 
lymphocytes, be more resistant to receptor downregulation, and functionally demonstrate 
improved respiratory function when compared with the Arg16 genotype in humans. 
Purpose: 
The purpose of this dissertation was to assess the functional consequences of ADRB1 
genotypes on cardiac function and ADRB2 genotypes on pulmonary function in patients 
with DMD. We hypothesize DMD patients with the Gly389 polymorphism would have a 
lower incidence of cardiac events compared with those expressing Arg389 polymorphism 
and that DMD patients with the Gly16 polymorphism would have a reduced risk of 
nocturnal ventilation (NV) use at any given age compared with those patients expressing 
the Arg16 polymorphism. 
Methods: 
For study 1, we performed genotyping of the ADRB1 (amino acid 49) and high-intensity, 
steady-state exercise on 71 healthy subjects (Ser49Ser = 52, Gly49Ser = 19). For study 2, 
we performed genotyping of the ADRB2 (amino acid 16) and high-intensity, steady-state 
exercise on 77 healthy subjects (AA = 18, AG = 25, GG = 34). Data from CINRG-DNHS 
including 175 DMD patients (ages 3-25 yrs) with up to 9.7 years follow-up were 
analyzed focusing on ADRB1 and ADRB2 functional variants for studies 3 and 4. We 
performed Cox proportional hazard and Kaplan-Meier time to event analyses for the age 
of NV use and the age of cardiac outcomes and interventions.  
Results: 
There were no differences between ADRB1 genotype groups in age, height, weight, BMI, 
or watts achieved in the healthy patients. Additionally, there were no differences between 
genotype groups for cardiac output (CO), systolic blood pressure (BPsys), or diastolic 
blood pressure (BPdias) at rest, maximal exercise, or in change from rest to maximal 
exercise. There were, however, differences between genotype groups for resting CI and 
SVR and for HR at peak exercise (HRmax) with the Gly49Ser genotype presenting 
improved CI and a lower SVR at rest, and a higher HR at peak exercise. There was a 
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trend towards significance (p = 0.058) for the change in stroke volume from rest to peak 
exercise (∆SV) with the Ser49Ser genotype demonstrating a larger change in SV. There 
were no differences between ADRB2 genotype groups in age, height, weight, or BMI in 
the healthy patients. The genotype groups differed significantly in watts, and watts/VO2 
with heavy exercise with the Gly16 genotype achieving higher workloads.  There was a 
trend towards significance (p=0.058) for watts/kg. There were no differences between 
ADRB1 genotype groups in age, height, weight, number of ambulatory patients, or age of 
loss of ambulation in our DMD cohort. The Arg389 polymorphism demonstrated a higher 
mean corticosteroid use compared with the Gly389 polymorphism. The genotype groups 
differed significantly (P<0.05) in the risk of diuretics use with the Gly389 polymorphism 
demonstrating a 5.01-fold increased risk of diuretics use at any age compared with the 
Arg389 polymorphism. There were no differences between ADRB2 genotype groups in 
age, height, weight, corticosteroid use, number of ambulatory patients, or age of loss of 
ambulation in our DMD cohort. The Gly16 polymorphism demonstrated a higher 
probability (P<0.05) for the use of NV assistance at any given age compared with the 
Arg16 polymorphism. The genotype groups differed significantly in the risk of NV use 
with the Gly16 polymorphism demonstrating a 2.77-fold increased risk of using NV at 
any given age compared with the Arg16 polymorphism. 
Conclusion:  
These data suggest genetic variation in the ADRB1 gene may influence the age of 
diuretics use in DMD patients with DMD patients expressing the Gly389 polymorphism 
being more likely to use diuretics compared with patients expressing the Arg389 
polymorphism. Additionally, these data suggest genetic variation in the ADRB2 gene 
may also influence the age of NV use in DMD patients. Specifically, DMD patients 
expressing the Gly16 polymorphism were more likely to use NV at any given age 
compared with patients expressing the Arg16 polymorphism. 
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Duchenne muscular dystrophy (DMD) is the most commonly inherited X-linked 
disease with a 1 in 3500 birthrate incidence in males [1]. DMD is characterized by 
progressive muscle weakness as a result of degeneration of skeletal, cardiac, and 
respiratory muscles, and infiltration of fibrofatty deposits. These mechanisms all 
contribute to a functional decrease in the contractile ability of muscles [2]. Progressive 
muscle weakness and degeneration typically confines DMD patients to wheelchairs by 
age twelve [1]. In patients with DMD, death resulting from cardiopulmonary failure 
associated with dilated cardiomyopathy and restrictive pulmonary disease typically 
occurs in one’s mid to late-twenties [1]. 
Major clinical milestones in DMD patients include adverse cardiac events and the 
use of cardiac interventions. Additional important clinical milestones include the loss of 
sufficient respiratory pressure generation leading to the emergence of sleep disordered 
breathing (SDB) and nocturnal ventilation (NV) use [3, 4]. With respiratory treatment for 
DMD improving and patients living longer, the implications of cardiomyopathies in 
DMD is becoming more clinically relevant [5]. In fact, an estimated 20% of DMD 
patients will die of congestive heart failure (HF) as a result of left ventricular failure [6]. 
In fact, left ventricular dysfunction is a strong predictor of mortality in patients with 
DMD [7]. Subclinical cardiomyopathies associated with DMD, typically left ventricular 
failure, are first evident at ten years of age and are present in almost all DMD patients 
over the age of 18 [5, 8]. However, approximately 70% of patients with DMD remain 
asymptomatic at cardiomyopathy diagnosis [9].Given the current clinical guidelines to 
delay cardiomyopathy treatment until the emergence of symptoms, cardiomyopathy in 
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DMD patients remains less often treated at diagnosis than other dilated cardiomyopathies, 
allowing for further cardiac progression [9].. Of particular clinical importance is the 
concomitant decline in respiratory and cardiac function in DMD patients — this linear 
decline may arise from interdependent or independent pathologies [4, 10, 11]. The 
relationship between reduced cardiac function and reduced respiratory function and all-
cause mortality suggests the incidence of adverse cardiac events and age of 
cardiomyopathy diagnosis are important clinical milestones for DMD patients. 
The mechanism of cardiac involvement in DMD is similar to that of skeletal 
muscle in the disease. This includes a  loss of muscular integrity, fiber necrosis, and 
replacement of contractile tissue with fibrotic tissue or fat [12]. The fibrotic region in 
cardiomyocytes will gradually stretch, become thinner and lose contractility, resulting in 
cardiac dilation [13]. Clinically, this cardiac dilation presents as increased ventricular 
volume, decreased ejection fraction, and decreased systolic function [12, 13]. The result 
of this systolic dysfunction is decreased cardiac output and hemodynamic 
decompensation and is the major contributor to the left ventricular dysfunction 
accompanying DMD [13]. The systolic dysfunction associated with DMD can be 
attributed to two main mechanisms: increased inflammatory response and altered Ca
2+
 
handling [12-14]. 
The inflammatory response, initated by cardiomyocyte cell death in patients with 
DMD, results in significant fibrofatty depositions in cardiac muscles [12]. These 
fibrofatty depositions appear initially in the left ventricular wall behind the posterior 
mitral valve leaflet and progressively spreads to affect the entire ventricle [13]. As noted 
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above, the fibrotic region will gradually stretch, become thinner and lose contractility, 
resulting in dilation, ,reduced contractility, and disruption of conduction pathways 
secondary to fibrosis, are the primary contributors to cardiomyopathy in patients with 
DMD [13]. 
Furthermore, in patients with DMD, dystrophin-deficiency disrupts the function 
of membrane ion channels, and as a result of impaired sarcolemmal integrity, 
sarcolemmal stretch-activated channels are particularly affected [14]. When dystrophin-
deficient cardiomyocytes stretch during ventricular filling, stretch-activated channels do 
not open appropriately, resulting in increased Ca
2+
 flux [13]. These resulting Ca
2+
 
influxes will activate calpains, Ca
2+
-dependent, non-lysosomal proteases, a significant 
component of the dystrophic pathway, which further compromises cardiomyocyte 
contractile ability [13]. Calpain-mediated damage of membrane proteins allows 
additional Ca
2+
 loading; this chronic Ca
2+
 loading leads to further cardiomyocyte damage 
[13]. This Ca
2+
 leak into the cardiomyocyte can also modulate L-type Ca
2+
 channels, 
causing unnecessary contractions and further Ca
2+
 loading [14]. In addition, dystrophin-
deficient cardiomyocytes exhibit a reduction in the Ca
2+
 binding proteins [15]. This 
suggests that in addition to increased Ca
2+
 loading in cardiomyocytes, the 
cardiomyocyte’s ability to handle Ca2+ is also dysfunctional, further disrupting Ca2+ 
homeostasis. The altered Ca
2+
 homeostasis in DMD affected cardiomyocytes contributes 
significantly to the cardiomyopathy in DMD patients. 
One pathway that has been identified as capable of preserving cardiac function in 
patients with DMD is the β1-adrenergic receptor (ADRB1) coupled pathway [16-20]. The 
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ADRB1 subtype is found primarily in the heart, comprising about 80% of total beta 
adrenergic receptors in the heart and playing a role in cardiac function [16, 21-23]. 
Furthermore, ADRB1 activity has been shown to influence cardiac: (i) inotropy, 
lusitropy, and chronotropy [24, 25]; (ii) nuclear and perinuclear Ca
2+
 handling [26]; (iii) 
reuptake of cytosolic Ca
2+
 [27]; and (iv) cardiomyocyte relaxation [22, 28]. Given the 
above mentioned mechanisms, the ADRB1 may play a role in preserving cardiac function 
in patients with DMD. 
 A polymorphism of the ADRB1 that affects functionality has been identified as a 
glycine (Gly) for arginine (Arg) substitution at amino acid 389 [16, 17, 22, 23]. 
Specifically, the Gly389 polymorphism demonstrates: decreased receptor density, cAMP 
accumulation, and a dampening response to norepinephrine infusion [16, 22, 23]. 
Functionally, HF patients with the Gly389 polymorphism have significantly lower 
diastolic, systolic, and mean arterial blood pressure — contributing to improved cardiac 
function and decreased mortality risk [17-19, 29]. Furthermore, literature demonstrates 
autoantibodies against ADRB1 are associated with more favorable myocardial recovery 
in patients with recent-onset cardiomyopathy [20]. The association between the Gly389 
polymorphism and more favorable cardiac measures and outcomes in HF patients suggest 
a therapeutic target for preserving cardiac function and delaying cardiomyopathy in 
patients with DMD. However, to date, there is no literature investigating the relationship 
between ADRB1 genotype and cardiac events in DMD patients. 
As mentioned previously, another major clinical milestone in DMD is the use of 
ventilatory assistance, particularly NV [3]. Sleep-disordered breathing (SBD) tends to 
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precede daytime hypoventilation in DMD and has been associated with significant 
increases in cardiac morbidity and neurocognitive deficits [3, 30]. Research has shown a 
correlation between lung function and SDB. DMD patients with nighttime 
hypoventilation present significantly worse lung function than normocapnic patients [31]. 
The negative consequences of nighttime hypoventilation support the need for early and 
effective NV intervention. As the DMD pathology progresses, respiratory muscles will 
weaken to the point of constant alveolar hypoventilation in DMD and the need for either 
part- or full-time daytime invasive or noninvasive ventilation is indicated [32]. The need 
for ventilatory assistance, whether that is NV, part, or full-time daytime ventilation, is 
considered an important respiratory event in the clinical analysis of disease severity in 
DMD. 
Ventilatory assistance in DMD is indicated by progressive respiratory muscle 
weakness. Clinically, this respiratory muscle weakness in DMD is characterized by a 
progressive loss of inspiratory pressures, slow and forced vital capacities, forced 
expiratory volume at one second (FEV1), forced expiratory flow (FEF), and peak cough 
flow (PCF) [33, 34]. Decreases in pressure and flow generation in DMD can be attributed 
to diaphragm remodeling [33]. This remodeling in DMD is characterized by an increased 
resting diaphragm thickness (pseudo-hypertrophy) and decreased contractility [33]. An 
increase in resting diaphragm thickness decreases mechanical contractility in two ways. 
First, increased thickness due to non-contractile properties alters the length tension 
relationship; second, this increase in thickness may also decrease the mechanical 
advantage of the diaphragm.  [35]. Further, DMD patients have shown an increase in 
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diaphragmatic tension-time index (a measures of the diaphragm’s load capacity) after age 
14, suggesting a higher likelihood of diaphragm fatigue [36]. This is due in part to the 
diaphragmatic remodeling present in this population. These data suggest diaphragmatic 
remodeling and the resultant weakness is an important contributor to respiratory muscle 
weakness in DMD. 
Diaphragmatic fiber necrosis has been shown to be a major contributor to the 
DMD respiratory pathology [33, 35, 36]. Diaphragmatic cell death results in the 
formation of scar tissue and fibrosis in the diaphragm. Fibrotic tissue formation is 
coupled with the infiltration of connective tissues as well as fat deposits and results in 
diaphragm remodeling [33]. Fiber necrosis and diaphragmatic remodeling in DMD can 
be attributed to three primary mechanisms: decreased mucilliary clearance, increased 
inflammatory response, and increased proteolytic pathway activation. 
Respiratory muscle weakness in DMD has been associated with impaired 
mucociliary clearance and an increase in inflammatory response [34]. The ability for 
mucociliary clearance is important in the DMD pathophysiology due to their impaired 
respiratory secretion clearance and increased susceptibility to pulmonary infections [34]. 
Impaired mucociliary clearance is associated with an increased inflammatory response, 
fibrosis, and hospitalization due to pulmonary complications [37]. The impaired ability to 
clear inhaled particulates in DMD is primarily due to decreased PCF and results in 
particulate settling in the small airways [38]. This particulate settling stimulates an 
inflammatory cascade and is associated with increased levels of circulating interleukin-6 
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(IL-6) and tumor necrosis factor-α (TNF-α) [39]. Furthermore, ineffective clearance has 
been shown to hasten the onset of respiratory failure in neuromuscular disorders [37].  
The upregulation of proteolytic pathways also contribute significantly to 
respiratory muscle weakness in DMD, particularly Ca
2+
-modulated pathways. Decreased 
sarcolemmal integrity, mechanical cell membrane tears, and Ca
2+
 channel dysregulation 
associated with DMD have been shown to result in increased Ca
2+
 flux and calpain 
concentration and activity [40]. Calpains initiate myofibrillar protein degradation which 
decreases myofibrillar protein integrity [40]. The increased activation of these pathways 
is considered a primary contributor to muscle degradation and fiber necrosis in DMD 
[41]. Muscle fiber necrosis, as a result of impaired mucociliary clearance, increased 
inflammatory responses, and increased proteolytic activity, is a major contributor to the 
diaphragmatic remodeling present in DMD.  
Due to the progressive nature of respiratory muscle weakness in DMD, it is 
imperative that target pathways are identified to slow respiratory muscle degradation. 
One novel pathway that has been identified as capable of combatting muscle degradation 
is the β2-adrenergic receptor (ADRB2) coupled pathway. β2-adrenergic receptors play a 
functional role in muscle size, strength and muscle regeneration [42-44]. Additionally, 
ADRB2 knockout mice had an increased inflammatory response to damage, particularly 
macrophage migration, a significant component of the dystrophic pathway in skeletal, 
cardiac, and respiratory muscles [43]. Furthermore, ADRB2 stimulation has also been 
shown to: (i) increase diaphragmatic cross-sectional area, strength, and contractility [43, 
45, 46], (ii) improve mucociliary clearance [47-52], (iii) inhibit inflammatory pathways 
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[53-61], and (iv) to directly and indirectly inhibit calpain activity and concentration [62-
69]. These data suggest the ADRB2 may play a significant role in the protection of 
respiratory muscles from the dystrophic pathways and provide a novel therapeutic target 
in DMD. 
Given that both cardiac and respiratory function are significant contributors to 
mortality  in DMD patients, we sought to investigate the influence of ADRB1 and 
ADRB2 genotype on clinically derived cardiorespiratory outcomes, specifically the risk 
adverse cardiac events, cardiac medication intervention, and NV use in these patients. 
Considering the reduction in cardiac function over time in patients with DMD, and that 
the ADRB1 Gly389 polymorphism is associated with improved cardiac function and 
favorable outcomes in HF patients, we hypothesized DMD patients with the Gly389 
polymorphism would have a lower risk of cardiac events when compared with DMD 
patients expressing  the Arg389 polymorphism. Furthermore, given that ADRB2 
stimulation has been shown to: increase diaphragmatic contractility [43, 45, 46], improve 
mucociliary clearance [47-52], inhibit inflammatory pathways [53-61], and inhibit 
calpain activity [62-69], we hypothesized DMD patients with the more functional 
(Gly16) polymorphism would have an increased time to NV compared with DMD 
patients with the less functional (Arg16) polymorphism. 
   
1.1 Aims and Hypotheses 
Study 1. Influence of Beta-1 Adrenergic Receptor Genotype on Cardiovascular Response 
to Exercise in Healthy Subjects  
10 
 
Aim 1: To examine the influence of ADRB1 genotype on cardiac response to 
exercise in healthy patients. 
Related Hypotheses: Given the positive influence of the Gly49 polymorphism of 
the ADRB1, we hypothesize that healthy patients expressing the Gly49 
polymorphism would have decreased cardiac output, stroke volume, and blood 
pressure at maximal exercise compared with patients with the Ser49 
polymorphism. Furthermore, we hypothesize that healthy patients expressing the 
Gly49 polymorphism would have decreased cardiac index, heart rate, and 
systemic vascular resistance at maximal exercise compared with patients with the 
Ser49 polymorphism. 
Study 2. Beta-2 Adrenergic Receptor Genotype Influences Power Output in Healthy 
Subjects 
Running Title: ADRB2 Variants Influence Power Output in Healthy Subjects. 
Aim 1: To examine the influence of ADRB2 genotype on power output in healthy 
subjects. 
Related Hypotheses: Given the positive influence of the Gly16 polymorphism on 
skeletal muscle strength and function, we hypothesize that healthy patients 
expressing the Gly16 polymorphism would have increased absolute and relative 
power output compared with patients expressing the Arg16 polymorphism. 
Further, healthy patients expressing the Gly16 polymorphism would report 
decreased indices of relative and perceived intensity at a given workload 
compared with patients expressing the Arg16 polymorphism.  
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Study 3. Influence of Beta-1 Adrenergic Receptor Genotype on Incidence of Cardiac 
Events in Patients with Duchenne Muscular Dystrophy. 
Aim 1: To examine the influence of ADRB1 genotype on the risk of adverse 
cardiac events in DMD patients. 
Aim 2: To examine the influence of ADRB1 genotype on the risk of cardiac 
medication intervention in DMD patients. 
Related Hypotheses: Given the positive influence of the Gly389 polymorphism 
of the ADRB1 on cardiac outcomes in HF patients, we hypothesize DMD patients 
expressing the Gly389 polymorphism would have a lower risk of cardiac events 
when compared with patients expressing the Arg389 polymorphism. Additionally, 
we hypothesize those DMD patients expressing the Gly389 polymorphism would 
have a lower risk of cardiac medication intervention compared with patients 
expressing the Arg389 polymorphism. 
Study 4. Influence of β2 Adrenergic Receptor Genotype on Risk of Nocturnal Ventilation 
in Patients with Duchenne Muscular Dystrophy. 
Aim 1: To examine the influence of ADRB2 genotype on the risk of NV use at 
any given age in patients with DMD. 
Related Hypothesis: Given the positive influence of the Gly16 polymorphism of 
the ADRB2 on respiratory strength and function, we hypothesize that DMD 
patients expressing the Gly16 polymorphism would have a lower risk of NV use 
at any given age when compared with patients expressing the Arg16 
polymorphism. 
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2.1 Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked, inheritable disease with a 1 
in 3500 male-birthrate, making it the most common lethal X-linked disease [1, 70]. DMD 
is characterized by progressive muscle weakness and degeneration of skeletal, cardiac 
and respiratory muscles. Muscle degeneration is accompanied by infiltration of fatty acid 
and bone mineral deposits, rendering the affected muscle functionally compromised [2]. 
Patients with DMD are diagnosed at an early age when their physical ability deviates 
significantly from their age-matched peers. Progressive muscle weakness and 
degeneration is symmetrical and affects the lower limbs before the upper limbs, 
progresses proximally to distally, and typically confines patients to wheelchairs by age 
twelve [70]. Death results from cardiopulmonary failure associated with dilated 
cardiomyopathy and restrictive pulmonary disease typically occurring in the late teens to 
mid-twenties [70]. 
DMD is caused by a deletion of the dystrophin gene that encodes for the 
dystrophin protein. Dystrophin acts as a membrane stabilizing protein by linking 
cytoskeletal proteins to sarcolemmal glycoproteins to form the dystrophin-associated 
glycoprotein complex (DAGC) [2]. This functional link between muscle fiber 
cytoskeletal proteins, most notably actin, to the sarcolemmal glycoproteins, allows for the 
distribution of forces associated with myofibril contraction across the sarcolemma, 
limiting mechanical stress [2]. Normal contractions in healthy muscle cause myofibrillar 
micro tears and an influx of Ca
2+
 that activates degenerative pathways via calpains. 
Calpains, comprised of two main isoforms m-calpain and μ-calpain, tend to be 
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concentrated on the Z band of the sarcomere where protein disassembly begins [71]. 
Calpains do not degrade proteins to amino acids or even small peptide, but rather initiate 
myofibrillar protein degradation by disassembling the outer layer of proteins, thus 
releasing them as myofilaments, further decreasing myofibrillar protein integrity [40]. 
Due to the lack of dystrophin in DMD, the Ca
2+
 influx to the intracellular space is 
augmented by the lack of DAGC and a resulting loss of selective permeability to Ca
2+
 in 
the cellular membrane. Additionally, repeated injurious events eventually exhaust the 
regenerative capacity of dystrophic muscles. Infiltration of adipose and connective tissue 
ensues leading to progressive functional impairments in affected patients [2]. Effectively, 
DMD renders muscle fibers fragile and susceptible to damage during contractions. 
 
2.2 DMD and Skeletal Muscle 
 In DMD, not only is the functional link between the DAGC and actin 
compromised due to dystrophin deficiency, the proteins that comprise the DAGC are also 
greatly affected [72]. This reduction in DAGC proteins augments the distribution of 
contractile forces across the sarcolemma, rendering the sarcolemma more prone to 
mechanical tears. These tears result in increased membrane permeability and Ca
2+
 influx 
due to a loss of myofibril integrity during contraction and relaxation [73]. The DAGC 
also plays a role in Ca
2+ 
channel stabilization, whereby the deformation of the DAGC due 
to dystrophin deficiency results in Ca
2+
 channel dysfunction [74]. In addition to 
mechanical tears, Ca
2+
 channel dysfunction is also believed to be a source of Ca
2+
 
homeostasis dysregulation [74]. This increased Ca
2+ 
influx results in the activation of 
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calpains, a Ca
2+
 dependent ubiquitous-proteasome, which degrades muscle protein. In 
addition to the activation of calpains, Ca
2+
 flux into the mitochondria can also lead to 
swelling and bursting of the mitochondria; mitochondrial death is followed by cell death 
and necrosis [1]. Following cell death and necrosis, muscle cells are infiltrated by 
macrophages and, due to decreased membrane stabilization, fibrofatty tissue and Ca
2+ 
deposits [1]. This macrophage and fibrofatty infiltration results in muscle weakness, loss 
of muscular control, and loss of ambulatory abilities. This process of protein degradation 
and loss of functional strength seems to preferentially affect fast twitch muscle fibers 
[75].  
 In addition to Ca
2+
 channel dysfunction, research suggests there is an altered 
protein expression that may further increase cytosolic Ca
2+
 concentrations. Research has 
demonstrated the concentration and activity of key Ca
2+
-binding and shuttling proteins 
play a critical role in Ca
2+
 homeostasis dysfunction in the dystrophic pathway [76]. In 
mdx mice (a mouse model presenting with the DMD pathology) luminal sarcalumenin 
(SAR), the key Ca
2+
-shuttling protein of the sarcoplasmic reticulum, has been shown to 
be decreased by as much as 70% compared to healthy controls [76]. Research has also 
demonstrated a decreased concentration of calsequestrin (CSQ), the main Ca
2+
-binding 
protein in the sarcoplasmic reticulum, in mdx mice compared to healthy controls [76]. 
This research also shows a mechanical linkage between SAR and the 
sarcoplasmic/endoplasmic-reticulum Ca
2+
-ATPase 1 (SERCA1). However, dystrophic 
membrane preparations have not shown a relative decrease in SERCA1 [76]. 
Additionally, impaired Ca
2+
-shuttling between SERCA units and CSQ clusters via SAR 
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and decreased luminal Ca
2+
-binding capacity may amplify cytosolic Ca
2+
 levels. This 
suggests that the reduction in SAR and CSQ plays a significant role in the skeletal muscle 
dystrophic pathway. 
Furthermore, DAGC dysfunction not only results in decreased membrane 
stabilization and increased Ca
2+
 flux, it may also render the muscles ischemic during 
exercise [77]. Neuronal nitric oxide synthase (NOS) is localized to the sarcolemma as 
part of the DAGC and the loss of sarcolemmal integrity results in a loss of NOS [72, 78]. 
Specifically, without dystrophin to anchor the DAGC, NOS disassociates from the 
sarcolemma and is no longer functional. During exercise, nitric oxide has been shown to 
play a role in blunting exercise-induced vasoconstriction due to α-adrenergic receptor 
activation [79]. This protective mechanism is defective in DMD resulting in unopposed 
vascular vasoconstriction during exercise further contributing to the pathogenesis of 
DMD [79, 80]. 
 Functional skeletal muscles have the ability of regeneration, but due to the 
upregulation of contraction-induced injuries and cell necrosis in DMD, this ability is 
overwhelmed. In DMD, the ability to regenerate skeletal muscle is surpassed by the 
muscle cell degradation pathways in DMD. Not only do DMD patients experience 
progressive muscle weakness due to cell death and necrosis, but functional capacity is 
limited as a result of ischemia [79, 80]. This rampant cell death and necrosis results in 
DMD patients being wheel chair bound by their early teens and experiencing a severe 
decline in quality of life [2]. 
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2.3 DMD and the Heart 
With recent advances in DMD treatment, patients are living longer, resulting in 
cardiac involvement becoming more prevalent [5]. It is believed the mechanism of 
cardiac involvement in DMD is similar to that of skeletal muscle — loss of integrity, 
fiber necrosis, and replacement of contractile tissue with connective tissue or fat [12]. 
Similar to skeletal muscle, loss of DAGC stability results in a loss of membrane stability 
and Ca
2+
 channel dysfunction [81]. However, there are cardiac-specific mechanisms 
affected by DMD: the absence or mutation of dystrophin disrupts the function of 
membrane ion channels, particularly the sarcolemmal stretch-activated channels [14]. 
When cardiomyocytes with augmented dystrophin levels stretch during ventricular 
filling, the stretch-activated channels do not open appropriately, leading to an increased 
influx of Ca
2+
 [14]. These resulting Ca
2+
 influxes will activate calpains which degrades 
troponin I and compromises cardiomyocyte contractile ability. Further, this calpain-
mediated damage of membrane proteins allows additional Ca
2+
 influx; this chronic Ca
2+
 
loading leads to cardiomyocyte necrosis [13]. Additionally, Ca
2+
 leak into the 
cardiomyocyte can modulate L-type Ca
2+
 channels, causing unnecessary contractions and 
further Ca
2+
 loading which contributes to cell death [14]. Similarly to skeletal muscles, 
DMD affected cardiomyocytes exhibit a reduction in the Ca
2+
-binding proteins, namely 
CSQ [15]. This suggests that in addition to increased Ca
2+
 loading in cardiomyocytes, 
their ability to handle Ca
2+
 is also dysfunctional, further disrupting Ca
2+
 homeostasis. 
Cardiomyocyte cell death initiates an inflammatory response wherein 
macrophages migrate to the damaged area to clear the cell of debris. This process is 
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followed by fibroblast invasion of the damaged area and the formation of scar tissue and 
fibrosis in the heart [12]. Myocardial fibrosis associated with DMD initially appears in 
the left ventricular wall behind the posterior mitral valve leaflet and progressively spreads 
inferiorly towards the apex and will gradually affect the entire ventricle. The fibrotic 
region will gradually stretch, become thinner and lose contractility [13]. Cardiac dilation 
results in an increased ventricular volume, decreased ejection fraction, and decreased 
systolic function. Mitral valve regurgitation is also a common pathology as fibrosis 
spreads to encompass this area. The result of this systolic dysfunction is decreased 
cardiac output and hemodynamic decompensation and is the major contributor to the left 
ventricular dysfunction accompanying DMD [13]. 
 Subclinical cardiomyopathies associated with DMD are first evident at ten years 
of age and are present in all DMD patients over the age of 18 [5]. Cardiomyopathy, most 
typically left ventricular failure, is very prevalent in DMD patients and is the cause of 
mortality in an estimated 20% of this population [5, 6]. Additionally, Corrado et al (2001) 
determined that 71% of their DMD patients had evidence of electocardiographic 
abnormalities with 32% of those having frequent premature ventricular complexes, 28% 
with ventricular late polarizations and 35% having left ventricular systolic dysfunction 
[7]. After a 76 month follow-up period, they concluded that left ventricular dysfunction 
as determined by an echocardiograph is a strong predictor of mortality. This suggests that 
if left ventricular systolic dysfunction can be identified and treated, it could improve 
DMD life span. 
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2.4 Cardiac Diagnosis in DMD 
Assessment of cardiac function should be initiated at six years of age and occur at 
least once every two years until the age of 10. Annual complete assessments should begin 
at the age of 10 or at the onset of cardiac signs and symptoms if they occur earlier [82]. 
Clinically, these assessments include electrocardiograms (ECG) and echocardiograms 
(ECHO). Continual ECG screenings may help to identify and diagnose cardiomyopathies 
that may need further screening or treatment [82]. The prevalence of ECG abnormalities 
is common. Early DMD can be characterized by multiple ECG changes including 
tachycardia. This tachycardia presents itself secondarily to a reduced ejection fraction 
caused by fibrosis and a dilated cardiomyopathy to maintain cardiac output [83]. Another 
early ECG change is a large R/S ratio in V1 and large Q waves in leads I, II and V5 
which is likely caused by the dilated cardiomyopathy and the loss of conductive cardiac 
cells due to fibrosis. These ECG abnormalities are present with a decreased excursion of 
the left ventricular posterior wall and interventricular septum as well as a decreased rate 
of ventricular relaxation [83]. 
As DMD progresses, ECG abnormalities become more prevalent. One common 
ECG change is a short PR interval, affecting about 50% of patients [1, 70]. This may be 
due to Lown-Ganong-Levine syndrome caused by a pre-excitation of the ventricles from 
augmented L-type Ca
2+
 channels or an accessory pathway. Conversely, research has 
suggested this shortened PR interval may be due to a compensatory autonomic influence 
rather than pre-exctiation [84]. While typically this is not a dangerous abnormality, it 
may degrade into ventricular fibrillation, leading to sudden cardiac death. Another 
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common ECG change is a prolonged QTc interval (≥ 450 ms). As DMD in the 
cardiomyocytes is associated with fibrosis-induced conduction problems, as well as 
cardiomyocyte dilation, especially in the ventricles, the QTc interval is commonly 
lengenthed suggesting a decreased relaxation time of the ventricles. Additionally, it is not 
uncommon to see prominent Q waves in leads I, II, III, aVL, aVF, V5 or V6 [84]. This is 
mainly due to the dilation of the left and right ventricles caused by pulmonary 
hypertension and increased preload and afterload, resulting in a stretching of the fibrotic 
cardiomyocyte. This may also be due to irregular conduction patterns caused by fibrotic 
regions [1, 70]. Further, ST segment depressions, defined as >0.5mm, are common ECG 
changes associated with DMD. The cause of this is similar to myocardial infarction, 
where there is a partial or full loss of conductive cardiac tissue associated with an 
increase in the fibrotic region [85]. Interestingly, Thrush et al (2009) did not find ECG 
changes to be determinant of dilated cardiomyopathy; ECG changes were similar in 
DMD patients with or without dilated cardiomyopathy [85].  
 With advanced DMD fibrosis, serious arrhythmias, can be detected by an ECG. 
These include atrial fibrillation, atrioventricular block, ventricular tachycardia and 
ventricular fibrillation [13]. These are believed to be caused by advanced dilated 
cardiomyopathy and the associated decreased ejection fraction as well as irregular 
conductions due to fibrosis. Addtionally, postmortem studies determined selective 
scarring at the posterobasal region of the heart resulting in a loss of posteriorly directed 
forces and creating electrically silent regions [86]. Such rhythms can be lethal and are a 
major cause of cardiac arrest and death in DMD. 
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These ECG changes can help professionals to not only diagnose 
cardiomyopathies, but to also determine their severity. Fayssoil, Nardi, and Orlikowski 
(2009) determined mean QRS duration was 117 ± 29 ms in DMD patients with ejection 
fraction greater than 35% whereas mean QRS duration was 98 ± 17 ms in DMD patients 
with ejection fraction less than 35% [87]. However, once a cardiomyopathy is determined 
via an ECG, further screening is needed to determine the full extent of the damage and 
the effect on cardiac hemodynamics. 
If an ECG abnormality suggesting a cardiomyopathy is determined in screening, it 
is recommended that the patient has an ECHO done to further determine the damage and 
the resulting cardiac decompensation [86]. One major concern with DMD is left 
ventricular dysfunction resulting in cardiac failure. This dysfunction manifests itself as a 
dimished contractile excursion of the left ventricular posterior wall and interventricular 
septum accompanied by a decreased rate of relaxation of the left ventricular posterior 
wall [86]. This presents itself mechanically as a diminished change in left ventricular 
diameter from diastole to systole and a reduced ejection fraction. Additionally, an ECHO 
may determine a decreased rate of circumferential fiber shortening and reduced maximal 
systolic velocity [83]. Again, this ventricular dysfunction is due to myocardial dilation 
and fibrosis resulting in diminished contractile ability. The resultant loss in ejection 
fraction is especially dangerous for DMD as left ventricular dysfunction is a major 
predictor of mortality. 
 Further, Fayssoil et al (2009) sought to quantify ECHO changes associated with 
DMD [87]. They determined mean indexed left ventricular end diastolic diameter was 30 
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mm/m
2
, which is far below normal, suggesting severe left ventricular dysfunction. This 
augmented diameter was accompanied by a severely attenuated ejection fraction ranging 
from 10 to 62% with almost a quarter of their patients have an ejection fraction of less 
than 35%. Additionally, Fayssoil et al (2009) found interventricular asynchrony in 12% 
of their patients with an ejection fraction of less than 35% and only 2.6% of patients with 
an ejection fraction more than 35% [87]. This suggests that, as the disease progresses and 
the left ventricle becomes more dilated and fibrotic, patients not only lose the ability to 
eject blood, but their ventricles fall out of synchrony. This may further attentuate left 
ventricular systolic function. 
 
2.5 Cardiac Management in DMD 
 As improvements have been made in the respiratory management in DMD, 
cardiomyopathy has become an increasing contributor to mortality. Progressive left 
ventricular dysfunction is inevitable in patients with DMD. However, the onset of 
cardiomyopathy is highly variable, with the Pediatric Cardiomyopathy Registry Study 
Group reporting ages ranging from seven to 27 years of age at onset with a mean age of 
14.8 ± 4.6 years [12]. Possible factors influencing the age of cardiomyopathy onset may 
include modifier genes, age and duration of corticosteroid treatment, and use of nocturnal 
ventilatory support [12]. While corticosteroid use has been demonstrated effective in 
preserving skeletal muscle strength and function in DMD, it remains unclear what effect 
corticosteroids truly have on the prevention or progression of cardiomyopathy in DMD 
patients. Research has demonstrated corticosteroid use to be cardioprotective, with one 
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study reporting Kaplan–Meier freedom from ventricular dysfunction was 93% for 
steroid-treated cases versus 53% for untreated cases at 1500 days of treatment [88]. 
However, multiple studies have contradicted this, reporting corticosteroid use to 
negatively affect the progression of cardiomyopathy in patients with DMD [89, 90]. 
 While there are contradicting views on the effect of corticosteroid use on 
cardiomyopathy in DMD, multiple studies have demonstrated the efficacy of angiotensin-
converting enzyme (ACE) inhibitors. According to the European Society of Cardiology 
(ESC) guidelines, angiotensin-converting enzyme inhibitors are recommended as a first-
line treatment for DMD patients with reduced left ventricular systolic function [91]. The 
decreased afterload associated with ACE inhibitors is believed to be the primary 
contributor to this beneficial effect. Duboc and colleagues (2007) randomly assigned 29 
DMD patients to a perindopril treated group and 28 patients to a placebo group for 3 
years, followed by open label treatment for up to 10 years [92]. At the 10 year follow up, 
survival for treated patients was 92.9% and for untreated was 65.5%. Angiotensin-
converting enzyme inhibitors have also been demonstrated to be an effective treatment 
for normalizing shortening fraction [93]. According to the ESC, beta-blockers (BB) are 
indicated for patients with symptomatic, stable systolic function [91]. The addition of BB 
therapy to ACE inhibitors has been shown to be beneficial in DMD patients’ long term 
survival (assessed at 5 to 7 year follow-up) when they present with left ventricular 
dysfunction [94]. Additionally, DMD patients treated with an ACE inhibitor with or 
without the addition of a BB were shown to have improved cardiomyopathy at a six to 12 
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months follow up, compared to the pretherapy group [95]. These data suggest an ACE 
inhibitor and BB can delay cardiomyopathy in DMD patients. 
 Furthermore, the American College of Cardiology and American Heart 
Association have long recommended the use of diuretics in the treatment of HF with 
reduced left ventricular function [96]. Consequently, the American Academy of 
Pediatrics recommends considerations to be given to the use of diuretics in the treatment 
of cardiomyopathy in DMD patients [97]. Current literature suggests the use of diuretics 
to treat tachycardia and lipothymia in later stages of cardiac involvement in DMD 
patients [98]. Despite the efficacy of diuretic therapy in the treatment of HF and 
recommendations for diuretic considerations in DMD patients, clinical adoption is slow 
[99]. 
 Unfortunately, cardiac management in DMD patients is reactive rather than 
proactive. This treatment paradigm must change as the deleterious effects of cardiac 
decompensation are present before symptoms arise [84]. Additionally, cardiac 
management strategies for patients with DMD are highly variable and remain 
underutilized in this population [9, 100]. Currently, there is no clinical consensus 
regarding the proper timing and type of pharmacological therapy intervention in DMD 
patients [101]. Further complicating this is the fact that symptoms of cardiomyopathy in 
DMD are often masked by respiratory dysfunction [101]. As cardiomyopathies become 
increasingly contributory to DMD mortality, additional prospective studies are warranted 
to evaluate the benefit of ACE inhibitors, BBs, aldosterone antagonists, or other 
transforming growth factor-β inhibitors in DMD. Furthermore, additional investigations 
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looking for other early indicators of cardiomyopathies can help guide therapy before the 
development of overt ventricular dysfunction should be conducted. 
 
2.6 DMD and the Lungs 
 Respiratory muscle weakness tends to exhibit itself in the second decade of life 
and is the major contributor to mortality in DMD [35]. DMD associated respiratory 
impairment is the result of deterioration and necrosis of the diaphragm, which has similar 
contractile properties of skeletal muscle and also involves DAGC dysregulation [102, 
103]. Similar to skeletal muscle, the loss of dystrophin to stabilize the DAGC results in 
reduced membrane integrity, Ca
2+
 channel dysfunction, and reduced expression of Ca
2+
-
handling proteins [102]. The implications of diaphragmatic deterioration are important in 
DMD because this is the primary muscle responsible for respiration. Similar to skeletal 
muscle deterioration, it is believed the resultant Ca
2+
 flux from either Ca
2+
 channel 
dysregulation or mechanical tears in the sarcolemma are the main contributors to 
diaphragm muscle cell death [104]. Unlike skeletal muscle, mdx diaphragm strips have 
revealed regucalcin as the main Ca
2+
-dependent protein involved in diaphragmatic Ca
2+
 
dysregulation. Regucalcin, a cytosolic Ca
2+
-binding protein involved in intracellular 
signaling is the main Ca
2+
-binding protein in the liver. However, research has identified 
regucalcin of 33.9 kDa and pl5.2 also exists in the diaphragm. Similar to the reduction of 
SAR and CSQ in affected skeletal muscle, there is a 2-fold reduction of regucalcin in 
mdx diaphragm [105]. This reduction results in disturbed intracellular signaling due to 
abnormal handling of cytosolic Ca
2+
, an insufficient maintenance of Ca
2+
 homeostasis, 
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and abnormal regulation of Ca
2+
-dependent enzymes [105]. This suggests that Ca
2+
 
homeostasis plays a significant role in the dystrophin-associated pathology of the DMD 
diaphragm. 
Clinically, muscle fiber necrosis of the diaphragm presents itself in progressive 
loss of inspiratory pressures and vital capacity in patients with DMD [33]. DMD patients 
have also been shown to have compromised lung function and volumes, including 
reduced forced expiratory volume at one second (FEV1), forced expiratory flow (FEF), 
and forced vital capacity (FVC) when compared to healthy, non-DMD patients [33]. 
Decreases in pressure and flow generation in DMD can be attributed to diaphragm 
remodeling [33]. This remodeling in DMD is characterized by an increased resting 
diaphragm thickness (pseudo-hypertrophy) and decreased contractility resulting from two 
primary mechanisms. First, diaphragm cell death results in an inflammatory response 
wherein macrophages migrate to the damaged area to clear the cell of debris. Macrophage 
migration is followed by fibroblast invasion of the damaged area and the formation of 
scar tissue and fibrosis in the diaphragm. Second, infiltration of connective tissues as well 
as fat deposits has been shown to increase resting diaphragm thickness and decrease its 
contractility [33].  
An increase in resting diaphragm thickness decreases mechanical contractility in 
patients with DMD in two ways. First, increased thickness due to non-contractile 
properties alters the length tension relationship; second, this increase in thickness may 
also decrease the mechanical advantage of the diaphragm [35]. Accordingly, research 
suggests mdx mice present a significant increase in the extracellular matrix protein 
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collagen in the diaphragm [106]. Furthermore, DMD patients have shown an increase in 
diaphragmatic tension-time index after age 14, suggesting a higher likelihood of fatigue 
[35]. This is due in part to diaphragmatic remodeling present in this population. In the 
canine model of DMD, diaphragmatic remodeling was demonstrated such that the 
primary role of the diaphragm becomes the passive elastic storage of energy transferred 
from the abdominal walls. This results in the expiratory muscles sharing in the generation 
of inspiratory pressure and flow. The diaphragm remodeling present in patients with 
DMD is also associated with the loss of sarcomeres in series and an almost 900-fold 
increase in stiffness [107]. In addition to increased fatigue, DMD patients have 
demonstrated a decrease in gastric pressure with cough, suggesting the onset and 
advancement of respiratory muscle weakness [36]. 
 
2.7 Respiratory Diagnosis in DMD 
 The American Thoracic Society recommends that clinics treating DMD patients 
be capable of performing pulmonary function tests (PFT), capnography, peak cough flow, 
maximal inspiratory and expiratory pressures, pulse oximetry, and arterial blood gas 
sampling and analysis for diagnostic testing [82, 108-110]. The most common clinical means 
of evaluating and diagnosing respiratory muscle weakness in DMD are PFTs. These tests 
consist of the patient breathing into a mouthpiece in a sitting position to prevent the risk of 
fall; patients are advised to not smoke for at least one hour before testing, not eat a large 
meal two hours before testing, and not wear tight fitting clothing as these may adversely 
affect testing [111]. PFTs consist of three types of measurements. The first measurements 
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are flows, maximal forced expiratory flow (FEFmax), forced expiratory flow from 25-75% 
of forced vital capacity (FEF25-75), and forced expiratory flow at 50% of forced vital 
capacity (FEF50), which may be useful in diagnosing and monitoring obstructive airway 
disease but have shown to not significantly contribute to clinical decision making [112, 
113]. The second types of measurements consist of assessment of lung volumes, vital 
capacity (VC) and tidal volume (TV), and can be useful in the diagnosing and monitoring 
of restrictive lung disease. The third set of measurements are volume against time 
measurements, forced expiratory flow in 1 second (FEV1), FVC, and forced expiratory 
volume in 1 second over forced vital capacity (FEV1/FVC); these tests can be useful in 
the diagnosing and monitoring of both obstructive and restrictive lung diseases [113]. 
These measurements can be useful in the monitoring of respiratory decline in DMD as 
these patients have been shown to have compromised FEV1, FEF, and FVC [33]. 
 Capnographs are used to measure partial pressures of CO2 in respiratory gases. 
They work on the principle that CO2 absorbs infrared radiation and that an infrared light 
passing through CO2 results in a reduction in the amount of light falling on a sensor 
[114]. It is recommended that capnography and pulse oximetry are performed during the 
course of a neuromuscular disease to detect respiratory insufficiency and can be a 
sensitive measurement of respiratory impairment even when artificial ventilation is being 
used [115]. This is important in DMD patients because as respiratory muscles weaken, 
they become more susceptible to nocturnal hypercapnia and the proper use of inspiratory 
and expiratory aids can prolong survival and decrease pulmonary morbidity [37, 116]. 
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 In addition to monitoring pulmonary gas tensions, the evaluation of peak cough flow 
(PCF) is extremely important in DMD. This is done using a peak flow meter and 
pneumotachograph to measure peak flow during a maximal expiration against a closed glottis 
[117]. As the respiratory muscles weaken, DMD patients lose the ability to adequately 
produce pressures for airway clearance and it is suggested that PCF should be measured 
when FVC < 2.1 L or FEV1 < 2.1 L/sec so that techniques to assist in mucociliary clearance 
can be effectively used [118]. Furthermore, PCF has been correlated to maximal inspiratory 
pressure (MIP) and maximal expiratory pressure (MEP) in DMD patients and could be a 
useful measure to evaluate respiratory muscle weakness [119]. 
 Arterial blood gas sampling is often used in conjunction with capnography to 
determine CO2 clearance and blood gas tension which may be predictors of sleep 
hypoventilation in patients with DMD. This may be useful in determining nocturnal 
hypercapnia [120]. Additionally, arterial blood gas samples can be used to determine the 
effectiveness of nocturnal ventilatory assistance, which can improve treatment and prolong 
life [121]. 
 One effective measurement of respiratory muscle strength, of the diaphragm in 
particular, is esophageal balloon transdiaphragmatic (Pdi) measures; however, it is not often 
used clinically due to its invasive nature. This test is done via catheter placement through 
either the nose or mouth to measure esophageal and gastric pressures and it is believed 
esophageal balloon measures of diaphragmatic strength can provide a better 
understanding of respiratory function than some traditional measurements [122]. 
Additionally, research suggests sniff Pdi pressure measures are more reproducible than 
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MIP and MEP, providing more accurate monitoring of maximal pressure tests [123]. Pdi 
can also be conducted during hypoxia, hypercapnia, chemical airway stimulation, 
spontaneously occurring breaths, sustained airway or tracheal occlusion, and maximal 
efforts produced by phrenic nerve stimulation, demonstrating its functionality as a 
measure [124]. Further, Pdi measurements make it feasible to individualize the level of 
muscle effort during mechanical ventilation [125]. With so many respiratory function 
tests available, it is important to note that individual tests of inspiratory, expiratory, and 
diaphragm muscle function tend to over diagnose respiratory muscle weakness. It is 
recommended to use a combination of tests to improve diagnostic precision to determine 
disease progression and treatment [126]. 
 
2.8 Respiratory Management in DMD 
 A majority of DMD patients die due to respiratory failure and that respiratory 
muscle weakness tends to exhibit itself in the second decade of life [35]. DMD associated 
respiratory impairment is a result of deterioration and necrosis of the diaphragm [102, 
103]. The implications of diaphragmatic deterioration are of importance in DMD because 
this is the primary muscular organ responsible for respiration and production of cough 
pressures. 
 The management of respiratory muscle weakness in patients with DMD is 
dependent on disease progression. One of the first steps of respiratory management in 
DMD patients is glucocorticoid treatment while ambulatory which is often continued 
after loss of ambulation [127]. The goal of glucocorticoid treatment is the preservation of 
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skeletal muscle strength and delaying the decline in respiratory and cardiac function [128, 
129]. Further, steroid-treated DMD patients have exhibited an improved PCF and MEP 
compared to non-steroid treated DMD patients, with one study citing PCF values to be 27 
L/min higher in steroid-treated patients with DMD [109, 130]. Prednisone and 
deflazacort treatment is believed to work similarly in reducing respiratory function 
decline in patients with DMD [131, 132]. 
 As the pathology of DMD progresses, patients lose diaphragm contractility. This 
is important in DMD because the pulmonary system is the body’s first line of defense 
against infection; it is the only place where the inside of the body interfaces with 
microbes and particulates from the environment. Inhaled particulates tend to settle in the 
small airways as air velocity slows [38]; this settling stimulates an inflammatory cascade 
and is associated with increased levels of circulating interleukin-6 (IL-6) and tumor 
necrosis factor-α (TNF-α) [39]. Further, an increase in circulating IL-6 has been 
correlated to pulmonary hypertension [133, 134]. In addition to IL-6, TNF-α is another 
important pulmonary cytokine associated with inflammation and has been shown to 
modulate cardiac remodeling [135, 136].  
 Ineffective clearance has been shown to hasten the onset of respiratory failure; 
however, early detection and intervention can prevent hospitalization due to pneumonia 
[37, 116]. As mentioned previously, in children with DMD PCF should be measured 
when FVC < 2.1 L or FEV1 < 2.1 L/sec [118]. The assessment of cough effectiveness can 
be done using MIP, MEP, PCF, inspiratory capacity, or vital capacity. However, PCF is 
preferred as it has been shown to correlate directly to the effectiveness to clear airways 
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[137]. While PCF values below 160 L/min have been shown ineffective for mucociliary 
clearance, values above 160 L/min may not be adequate either as respiratory function 
deteriorates during infection [37, 116, 138]. Therefore, a PCF of 270 L/min has been 
recommended to identify DMD patients who could benefit from assisted cough 
techniques [116]. The ability to generate adequate flow for clearance has been correlated 
to MEPs of 60 cm H2O and is absent below 45 cm H2O [139]. Pulse oximetry can also be 
used to determine changes in gas diffusion associated with lower airway complications 
and as a screening tool to increase cough therapy [116]. This demonstrates the 
importance of using multiple respiratory function tests to evaluate clearance 
effectiveness.  
 When respiratory pressures deteriorate to the point that cough assistance is 
indicated, several cough assisting methods have been proposed for patients with 
respiratory muscle weakness including: manual cough assistance, mechanical cough 
assistance, functional electrical stimulation of respiratory muscles, and respiratory muscle 
training [140-142]. Manual assisted coughing involves inspiratory assistance followed by 
augmentation of the expiratory effort. This can be done with air stacking, increasing 
inspiratory capacity (IC) with glossopharyngeal breathing, positive pressure breathing 
with a bag and mask, and an intermittent positive pressure breathing device [110]. 
Mechanical assisted cough techniques involve simulating a cough by applying a positive 
pressure breath followed by a negative pressure exsufflation. This technique has been 
shown effective in clearing airways in DMD patients with inadequate cough pressures 
[110]. 
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 Another method of respiratory management for DMD patients is respiratory 
muscle training. Maximum insufflation capacity, the maximal air volume that can be held 
against a closed glottis, has been shown to improve in response to air stacking training in 
patients with DMD. This can be employed to improve the range of motion of the lung 
and chest wall and may help in assisted cough by increasing lung volume [141, 143]. The 
aim of respiratory muscle training is to improve respiratory muscle strength, thereby 
preserving function.  This could be beneficial in DMD patients as MEP and MIP have 
both been correlated to cough effectiveness and preserving these functions could prove 
useful in prolonging life [143]. However, the effectiveness of this method in doing so is 
not clear [144, 145]. Because neuronal nitric oxide synthase is localized to the 
sarcolemma as part of the DAGC, loss of sarcolemmal integrity results in loss of nitric 
oxide synthase [72, 78]. During exercise, nitric oxide has been shown to play a role in 
blunting exercise-induced vasoconstriction due to α-adrenergic receptor activation; this 
protective mechanism is defective in DMD resulting in unopposed vascular 
vasoconstriction during exercise which further contributes to the pathogenesis of DMD 
[79, 80]. This defective mechanism may contraindicate respiratory muscle training in 
DMD. 
 As respiratory muscle weakness progresses, DMD patients may present with SDB 
[146]. SDB has also been associated with significant increases in cardiac morbidity and 
neurocognitive deficits [30]. In healthy individuals during sleep, there is a dampening in 
the slope of the ventilatory response to both hypercapnia and hypoxia, as well as 
reduction in tonic activity of the intercostal muscles [147, 148]. However, due to 
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functional declines in diaphragm strength, the intercostal muscles must share in the 
generation of inspiratory pressures in DMD patients and in the face of reduced tonic 
activity of the intercostal muscles during sleep, the diaphragm may not be able to 
generate sufficient pressures for adequate ventilation. Research has shown a correlation 
between lung function and SDB with night hypercapnic DMD patients presenting 
significantly worse lung function than normocapnic patients [31]. Further, it has been 
demonstrated that arterial blood gases should be measured when FEV1 falls below 40% 
and that screening for SDB should be considered when Paco2 is greater than 45 mm Hg 
[120]. Once SDB is identified, the best treatment option is a mechanical ventilator which 
has been shown effective in the treatment of SDB in DMD patients [149]. Treatment with 
non-invasive NV has been shown to improve sleep, improve day-time gas exchange, and 
slow the decline of respiratory function [150]. It is also important to note that NV and 
assisted cough techniques have been shown to prolong life in DMD [151-153]. 
 As the disease progresses, respiratory muscles will weaken to the point of 
constant hypoventilation in DMD patients and the need for either daytime invasive or 
noninvasive ventilation is indicated. The most common type of ventilation is an 
intermittent positive pressure mouth piece which has been used successfully in patients 
with an FVC of 0.6 L for up to eight years [32]. Another method used is 
glossopharyngeal breathing, using oral muscles to inhale a small bolus of air until the 
patient reaches TV. This can be a useful technique to learn in the event of ventilator 
failure [154]. If patients show an aversion to the mouth piece ventilator, a pneumo-belt 
can be used. This involves a belt placed around the abdomen to create negative pressures 
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and drive inspiration [110]. In patients without the oromotor or neck control to use a 
mouthpiece, a tracheostomy is recommended. The benefits of this method are that it can 
provide higher ventilatory pressures and airway suctioning during an infection [138]. 
However, a tracheostomy tube may increase pulmonary secretions, make swallowing 
more difficult, increase risk of aspiration, and increase bypassing of airway defenses 
which increases risk of infection [155]. 
 
2.9 Beta-Adrenergic Receptor Structure and Function 
The β-adrenergic receptors (β-AR) are part of a family of membrane proteins 
known as G-protein coupled receptors which, upon binding of a catecholamine to the 
receptor, stimulate a conformational change in the β-AR that causes coupling with G-
proteins. G-proteins consist of α, β, and γ subunits; β-AR coupling leads to the 
dissociation of the G-protein into active Gα and Gβ subunits to mediate downstream 
signaling [156]. Moreover, β-AR agonist binding stimulates the dissociation of the Gαs 
protein [157, 158]. Gαs-bound guanine triphosphate (GTP) then phosphorylates the 
enzyme adenylyl cyclase (AC). Nine isoforms of AC are known to exist [159]. AC 
catalyzes the conversion of ATP to adenosine 3’-5’ monophosphate (cAMP) which 
phosphorylates protein kinase A (PKA) into its active form [160]. Both AC and cAMP 
have the ability to regulate downstream mechanisms via multiple internal cell signaling 
pathways [161-165]. Conversely, β-AR antagonist binding causes a competitive 
inhibition against catecholamine and sympathetic nervous stimulation, thereby inhibiting 
the dissociation of Gs proteins [166]. 
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2.9.1 Beta-Adrenergic Receptor Cardiac Signaling  
The ADRB1 subtype is found primarily in the heart and comprises 75-80% of β-
AR found in the heart with the ADRB2 subtype comprising the remaining 20-25% [21]. 
The G-protein signaling pathway associated with the β-AR is important in the modulation 
of several key target proteins. When activated, cardiomyocyte ADRB1 preferentially 
binds to the Gas protein which phosphorylates AC, generating the secondary messenger 
cAMP. Increased cAMP accumulation activates PKA [25]. Activated PKA then 
phosphorylates troponin I, the L-type Ca
2+
 channel, and phospholamban (PLB), 
increasing cardiac inotropy, chronotropy, and lusitropy [24].  
Research has also shown Gs activation can increase L-type Ca
2+
 current directly 
[166]. L-type Ca
2+
 channels play an integral role in cardiomyocyte excitability and 
contractility [156]. Phosphorylation of cardiac L-type Ca
2+
 channels by PKA results in an 
influx of Ca
2+
 into cardiomyocytes. The Ca
2+
 then binds to the sarco/endoplasmic 
reticulum Ca
2+
-ATPase (SERCA) triggering further sarcoplasmic Ca
2+
 loading resulting 
in the removal of troponin and tropomyosin inhibition of myosin binding sites [105, 167]. 
Additionally, research suggests the phosphorylation of phospholamban (PLB) via PKA, a 
downstream protein from β-AR stimulation, results in the removal of inhibition of 
SERCA. This increases the quantity and rate of reuptake of cytosolic Ca
2+
 in the 
sarcoplasmic reticulum [27]. Recent research also suggests PLB is not sequestered only 
to the sarcoplasmic reticulum but, rather, PLB pools exist in the nuclear envelope which 
allows them to regulate perinuclear/nuclear Ca
2+
 handling [26]. Troponin I is a regulatory 
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protein of cardiac myofibrils and its phosphorylation by PKA inhibits actomyosin 
ATPase activity resulting in relaxation of cardiomyocytes in response to catecholamines 
[22, 28]. Research has demonstrated genetic variation of the ADRB1 modulate the 
cardiac response to catecholamine binding regulating the aformentioned mechanisms of 
action. 
Further, ADRB2 stimulation has been shown to activate the Gi pathway in 
cardiomyocytes, depressing cAMP accumulation modulating downstream mechanisms 
[168, 169]. Gαi-linked Gβγ subunits activate the phosphoinositide 3-kinase-protein 
kinase-B (PI3K-Akt) signaling pathway [170]. The PI3K-Akt signaling pathway has been 
shown to regulate protein synthesis, gene transcription, cell proliferation, and cell 
survival [171, 172]. It has been demonstrated that Akt1 inhibits the forkhead box O 
transcription factors (FOXO) [173]. The activation of this pathway has been shown to 
have cardioprotective effects in HF [174]. 
 ADRB1 receptors have a high affinity for both epinephrine and norepinephrine 
while ADBR2 receptors have a high affinity for epinephrine and a low affinity for 
norepinephrine [175]. In cardiomyocytes, as compared to pulmonary tissue, ADRB1 is 
distributed much more densely than ADRB2. However, unlike pulmonary tissue, this 
does not necessarily indicate a large ADRB1 receptor reserve. In fact, research suggests 
there is no ADRB2 receptor reserve and a possible small ADRB1 receptor reserve for 
positive ionotropic effects in the heart, suggesting the primary influence of B-AR agonist 
treatment on cardiac function arises from ADRB1 activity [176-178]. 
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2.9.2 Beta-Adrenergic Receptor Pulmonary Signaling  
In human lungs, the ratio of ADRB2 to ADRB1 has been shown to be 
approximately 3:1 [179]. β-AR were shown to be widely distributed with a higher density 
over airway epithelium, alveolar walls, and submucosal glands and a lower density over 
airway and vascular smooth muscle. Similarly, the β-AR of both large and small airway 
smooth muscle was comprised entirely of the ADRB2 subtype [179, 180]. Conversely, 
both β-AR subtypes appear to coexist in bronchial submucosal glands and alveolar walls 
with ADRB1 accounting for 10% and 30% of β-AR in the submucosal glands and alveoli 
respectively with ADRB2 accounting for the remainder [179, 181]. 
One of the most important aspects of β-AR, ADRB2 in particular, in the 
pulmonary tissue is the regulation of alveolar fluid. The activation of β-AR results in the 
dissociation of GTP which phosphorylates AC, catalyzing the conversion of ATP to 
cAMP and the phosphorylation of PKA into its active form [160]. β-AR stimulation and 
the concomitant increase in cAMP is important in lung fluid balance [182]. The ADRB2 
are important in lung fluid regulation by the activation of epithelial Na
+
 channels (ENaC) 
located on the apical membrane of alveolar cells. The stimulation of ENaC has been 
shown to result in an increase in the number and open probability of ENaC as well as an 
increase in the likelihood of an interaction with the cystic fibrosis transmembrane 
conductance regulator (CFTR) [183]. This ENaC-CFTR interaction causes an 
augmentation in the function of the Cl
-
 channel on the apical membrane of alveolar cells, 
resulting in the transcellular apical to basolateral movement of salt and an associated 
osmotic movement of fluid [184]. Further, research suggests ADRB2 stimulation may 
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play a role in regulating Na
+
K
+
-ATPase resulting in smooth muscle relaxation of the 
pulmonary lymphatics, which can augment lung fluid clearance [185]. 
 Additionally, β-AR stimulation is important in the regulation of respiratory 
smooth muscle reactivity. AC is believed to be the principal effector of Gs-receptor 
transmembrane signaling. Gαs activation of AC catalyzes ATP to cAMP, which in turn 
dissociates and activates PKA. PKA then phosphorylates and regulates the activity of 
numerous proteins, most notably the transcription factor cAMP response element binding 
protein (CREB) [186]. Research suggests PKA activity is responsible for the majority of 
intracellular actions including relaxation, inhibition of cell growth, reduced airflow 
resistance, and ion channel gating [187-189]. Additionally, PKA can phosphorylate 
certain Gq-coupled receptors as well as phospholipase C (PLC), thereby inhibiting G 
protein-coupled receptor-PLC-mediated phosphoinositide (PI) generation, thus reducing 
Ca
2+
 flux. Further, PKA can also phosphorylate the inositol 1,4,5-trisphosphate (IP3) 
receptor to reduce its affinity for IP3 which further limits Ca
2+
 flux. Additionally, PKA 
phosphorylates myosin light chain kinase (MLCK) and decreases its affinity to Ca
2+
 
calmodulin, hence reducing activity and myosin light chain (MLC) phosphorylation [190, 
191]. This downstream regulation via PKA results in smooth airway relaxation and 
dilation. These mechanisms of action may be of clinical importance in DMD patients by 
decreasing respiratory load for sufficient alveolar ventilation and by improving 
mucociliary clearance. 
 
2.9.3 Beta-Adrenergic Receptor Vascular Signaling  
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Research suggests differential distribution of β-AR receptors in smooth muscle 
with ADRB2 functioning as the primary vasodilator of smooth muscle with ADRB1 
predominating and mediating vasodilation only in a few major blood vessels [192]. β-AR 
modulation of smooth muscle is achieved via receptor catecholamine binding and 
dissociation of the Gαs protein. Gαs-bound GTP then phosphorylates AC, catalyzing the 
conversion of ATP to cAMP which phosphorylates PKA into its active form [160, 193]. 
PKA has been shown to phosphorylate and inactivate myosin light chain kinase (MLCK), 
an enzyme involved in muscle contraction, resulting in smooth muscle relaxation [194]. 
Research suggests the phosphorylation of PLB via PKA, a downstream protein from β-
AR stimulation, results in the removal of inhibition of SERCA1. This increases the 
quantity and rate of reuptake of cytosolic Ca
2+
 in the sarcoplasmic reticulum, further 
contributing to smooth muscle relaxation [195, 196]. 
 ADRB2 represents a higher receptor density than does ADRB1 and is the 
predominant β-AR vasodilator in vascular smooth muscle. Research has shown the 
ADRB2 to have a high receptor reserve in vascular smooth muscle and a high binding 
affinity to epinephrine [175, 197, 198]. However, due to its low receptor density, ADRB1 
likely has little or no receptor reserve in vascular smooth muscle [192]. These 
mechanisms suggest β-AR receptors may play a functional role in mitigating the 
aforementioned α-adrenergic vasoconstriction in DMD patients, thereby improving blood 
flow to the skeletal, cardiac, and respiratory muscles. An improved blood flow in patients 
with DMD may reduce the inflammatory response associated with the DMD pathology.  
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2.10 Genetic Variations of the Beta-Adrenergic Receptor  
Multiple polymorphisms of the ADRB1 have been identified, including a glycine 
(Gly) for serine (Ser) substitution at amino acid 49 and a Gly for arginine (Arg) 
substitution at amino acid 389. Both the Gly49 and Gly389 polymorphisms has been 
shown to have decreased receptor density, decreased cAMP accumulation, and an 
improved agonist-promoted downregulation [22, 23]. Heart failure patients with these 
polymorphisms (Gly49 and Gly389) have also been shown to have improved cardiac 
function and decreased mortality risk [17, 199, 200]. This suggests the Gly49 and Gly389 
polymorphisms may have cardioprotective effects. 
Further, multiple polymorphisms of the ADRB2 have been identified as including 
a glycine (Gly) for arginine (Arg) substitution at amino acid 16. This polymorphism 
(Gly16) has been shown to have higher receptor density, be more resistant to receptor 
down regulation, and functionally demonstrate higher cardiac output and stroke volume, 
improved left ventricular function and ejection fraction, sustained bronchodilation 
following intense exercise, and better lung function in healthy and HF patients than 
Arg16 [187, 201, 202]. These studies suggest a protective effect of the Gly16 
polymorphism on cardiopulmonary function. 
 
2.10.1 Beta-1 Adrenergic Receptors and Heart Failure  
Research has suggested that ADRB1 and ADRB2 play important roles in 
mediating the progression of cardiomyopathies. Both ADRB1 and ADRB2 tend to be 
sequestered in cardiomyocyte microdomains close to their downstream targets mediated 
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by scaffolding of A-kinase anchoring domains [203]. Research has also demonstrated 
ADRB1 induced cAMP activation occurs throughout the cell, activating both PKA and 
PLB. Conversely, ADRB2 induced cAMP activation is highly compartmentalized, 
wherein it activates localized pools of AC and L-type Ca
2+
 channels [157]. This suggests 
that despite receptor concentration differences inherent in cardiomyocytes; these 
receptors have domain-specific differences in functionality. Furthermore, this suggests 
the ADRB1 activation has a global effect on cardiac function and is believed to be largely 
responsible for the cardiotoxic effects of sympathetic stimulation. These cardiotoxic 
effects are mediated through PKA and Ca
2+
/calmodulin dependent protein kinase 
(CaMK), increased intracellular Ca
2+
 and its downstream proteolytic enzymes, inhibition 
of the anti-apoptotic effects of protein kinase B (Akt), and phosphorylation of the 
ryanodine receptor which increases diastolic Ca
2+
 leak and arrhythmogenesis [157, 204, 
205]. This has been demonstrated in vitro with Β1-AR antagonist treatment shown to 
block catecholamine-induced cardiac apoptosis [206, 207]. 
The cardiomyopathies associated with DMD are similar to that of HF with the 
formation and growth of fibrotic tissue in the heart that gradually stretches, become 
thinner and loses contractility, resulting in an increased ventricular volume, decreased 
ejection fraction, and decreased systolic function. The result of this systolic dysfunction 
is decreased cardiac output and hemodynamic decompensation and is the major 
contributor to the left ventricular dysfunction accompanying DMD [13]. Additionally, 
left ventricular function as determined by an ECHO has been identified as a strong 
predictor of mortality [7]. 
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As the predominant β-AR in cardiomyocytes, ADRB1 plays a functional role in 
cardiac function. The Gly49 and Gly389 polymorphisms of the ADRB1 have been 
associated with negative ionotropy, improved cardiac function, and decreased mortality 
risk associated with HF [16, 17, 22, 23, 199, 208]. This is likely due to the decrease in 
cAMP accumulation associated with these polymorphisms. In fact, ADRB1 
overexpression in rat HF models has shown even more rapid cardiac deterioration than 
untreated rats [209, 210]. The influence of the Gly49 and Gly389 polymorphisms has 
been further supported by a decreased mortality risk and an improvement in left 
ventricular mass and shape with β1-AR antagonist treatment [18, 19, 29]. 
The Gly49 and Gly389 polymorphisms have been shown to have decreased 
receptor density, decreased cAMP accumulation, and a dampening response to the 
cardio-stimulant effect of norepinephrine infusion [16, 22, 23]. Additionally, patients 
with the Gly389 polymorphism have significantly lower diastolic and systolic blood 
pressure (BP) and mean arterial blood pressure (MAP) [17]. HF patients with these 
polymorphisms (Gly49 and Gly389) have also been shown to have improved cardiac 
function and decreased mortality risk [18, 19, 29]. Furthermore, studies have 
demonstrated autoantibodies against ADRB1 are associated with more favorable 
myocardial recovery in patients with recent-onset cardiomyopathy [20]. This suggests the 
Gly49 and Gly389 polymorphisms may have inherent cardioprotective effects similar to 
that of a BB. 
ADRB1 signaling has been shown to play an important role in HF with the degree 
of sympathetic activity being inversely correlated with survival [211]. Deleterious effects 
44 
 
of ADRB1 signaling include apoptosis, myocyte growth, fibroblast hyperplais, 
myopathy, fetal gene induction, and proarrythmia [206, 212]. Interestingly, the Arg389 
polymorphism has been shown to preferentially upregulate inflammatory and apoptotic 
signaling pathways [213]. As an adaptive mechanism in HF, cardiac ADRB1s become 
less responsive, either downregulating or uncoupling from the Gs pathway [214]. This 
suggests the less functional variants of the ADRB1 to be clinically important in HF. 
The influence of ADRB1 signaling in HF has been supported by association 
studies as well, demonstrating a statistically significant association between the Arg389 
polymorphism and acute myocardial infarction (AMI), suggesting ADRB1 genotype 
plays a role in the development of AMI [200]. Specifically, experimental models of HF 
suggest the Arg389 polymorphism is associated with a greater susceptibility to HF with 
an approximate 10.11 fold increase in risk [215]. 
 
2.10.2 Beta Blockers in DMD 
The efficacy of BB therapy has been demonstrated in non-DMD HF patients with 
long exposure to BB therapy decreasing mortality risk in congestive HF; BB therapy was 
also independently associated with decreased mortality and rates of rehospitalization in 
patients with decreased ejection fraction [216, 217]. These findings have also been 
extended to the DMD patient population. Retrospective analyses have demonstrated 
improved survival and cardiac parameters in DMD patients with BB use [94, 218]. 
Specifically, BB treatment resulted in significantly improved left ventricular shortening 
fraction with no increases in left ventricular end-diastolic dimensions [218]. Additionally, 
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BB use in DMD patients has been shown to decrease mortality and hospitalizations due 
to congestive HF [6]. Intervention studies with BB and ACE inhibitor combination 
therapy was demonstrated to relieve symptoms of cardiomyopathy in DMD patients and 
resulted in decreased levels of atrial natriuretic protein, brain natriuretic protein, 
norepinephrine, and left ventricular end-diastolic diameter [219]. Furthermore, this 
combination therapy increased left ventricular ejection fraction, suggesting the capability 
to reverse signs and symptoms of congestive HF in DMD patients [219]. Cumulatively, 
these data suggest early intervention with BB is effective in combatting cardiomyopathy 
and may delay the progression of cardiomyopathy in DMD [95]. 
The Gly49 and Gly389 polymorphisms have been shown to have decreased 
receptor density, decreased cAMP accumulation, and a dampening response to the 
cardio-stimulant effect of norepinephrine infusion [22, 23]. HF patients with the Gly49 
polymorphism have also been shown to have improved cardiac function and decreased 
mortality risk [18, 19, 29]. Furthermore, studies have demonstrated autoantibodies 
against ADRB1 are associated with more favorable myocardial recovery in patients with 
recent-onset cardiomyopathy [20]. This suggests the “less” functional ADRB1 
polymorphisms (Gly49 and Gly389) may have inherent cardioprotective effects similar to 
that of a BB and these polymorphisms may preserve cardiac function in DMD patients. 
 
2.10.3 Beta-2 Adrenergic Receptors and Heart Failure 
While Β2-AR agonists are typically contraindicated in HF, recent research 
suggests the ADRB2 may have a cardioprotective effect in HF. Interestingly, research has 
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demonstrated ADRB2 activation can switch between cardiotoxic and cardioprotective, 
the latter through Gi and PI3K-Akt pathways [158, 169, 206, 220]. However, recent 
research suggests the predominating effects of ADRB2 activation are cardioprotective. 
This has been shown in ADRB2 knockout mice demonstrating enhanced injury when 
treated with doxorubicin and an increased susceptibility to isoprotenerol cardiotoxicity, 
further supporting the cardioprotective mechanisms of ADRB2 stimulation [221, 222]. 
Additionally, ADRB2 knockout mice have also demonstrated increased p38 subunits of 
the mitogen-activated protein kinase (MAPK), resulting in apoptosis, while ADRB2 
stimulation inhibits the apoptotic effects of Akt [157, 221]. Furthermore, ADRB2 
overexpression has been shown to improve cardiac function in young mice; however, as 
the mice aged, overexpression resulted in dilated cardiomyopathy [223, 224].  
While this may suggest long term exposure to a Β2-AR agonist to be detrimental 
in cardiomyopathies, combination with an ultra-long acting Β2-AR agonist in 
conjunction with a Β1-AR  antagonist has been shown to decrease infarct size, reduce 
blood pressure and heart rate, and reverse the decrease in ejection fraction in rat models 
for HF [225-227]. This type of combination therapy of super-long acting Β2-AR agonists 
and Β1-AR -selective antagonists has been shown to reduce ischemic injury after cardiac 
artery ligation. These studies also suggest the efficacy of this combination therapy in HF 
surpasses that of the traditional BB and ACE inhibitor therapy [226, 228]. This may be 
attributed to the ADRB2s capacity to activate the Gi pathway, which depresses cAMP 
activity through activation of the Gi/PI3K/Akt signaling pathway. ADRB2 coupling to Gi 
proteins is upregulated in HF with the decrease in ADRB1 receptor density [168, 169]. 
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Further, research suggests the phosphorylation of PLB via PKA, a downstream protein 
from ADRB2 stimulation, results in the removal of inhibition of SERCA. This increases 
the quantity and rate of reuptake of cytosolic Ca
2+
 in the sarcoplasmic reticulum [27]. 
Recent research also suggests PLB is not sequestered only to the sarcoplasmic reticulum 
but rather, PLB pools exist in the nuclear envelope which allows them to regulate 
perinuclear/nuclear Ca
2+
 handling [26]. This suggests a genetic interaction between 
ADRB1 and ADRB2 for cardioprotective capacity, especially in regards to Ca
2+
 
handling, an integral part of the DMD pathology.  
 
2.10.4 Beta-2 Adrenergic Receptors and Pulmonary Function 
β-2 adrenergic receptors have been shown to: (i) play a functional role in 
diaphragmatic cross-sectional area, strength, and contractility [43, 45, 46]; (ii) improve 
mucociliary clearance [47-52]; (iii) inhibit inflammatory pathways [53-61]; and (iv) 
inhibit calpain activity and concentration [62-69]. β-2 adrenergic receptors are G-protein 
coupled receptors whose primary products from catecholamine binding are PKA and 
cAMP [160]. Both PKA and cAMP have the ability to regulate downstream mechanisms 
via multiple internal cell signaling pathways [165]. Functionally, the concentrations of 
these products reflect the density and activity of the ADRB2 suggesting the more 
functional polymorphism (Gly16) would result in increased PKA and cAMP 
concentration [43]. 
One of the main respiratory concerns in DMD is the loss of diaphragmatic 
contractility due to increased diaphragm fibrosis and pseudo-hypertrophy [33]. The 
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increase in diaphragm fibrosis in patients with DMD is a function of three main 
mechanisms: a decrease in mucociliary clearance, an increased inflammatory response, 
and the upregulation of Ca
2+
-modulated proteolytic pathways [34, 36, 58, 59, 229]. 
Impaired mucociliary clearance is also associated with increased fibrosis and 
hospitalization due to pulmonary complications in DMD patients [37]. Ineffective 
clearance has been shown to upregulate inflammatory pathways and hasten the onset of 
respiratory failure in neuromuscular disorders [37]. Dystrophin-deficient muscle cells 
have been shown to have increased IL-1β levels compared to healthy controls and 
research suggests significant levels of TNF-α were detected in 62% of human DMD 
tissue biopsies [53, 54, 58, 59]. Furthermore, decreased sarcolemmal integrity, 
mechanical cell membrane tears, and Ca
2+
 channel dysregulation associated with DMD 
have been shown to result in increased Ca
2+
 flux and increased calpain concentration and 
activity [40]. Calpains – Ca2+-dependent, non-lysosomal proteases – initiate myofibrillar 
protein degradation which decreases myofibrillar protein integrity [40]. The increased 
activation of these pathways is considered a primary contributor to muscle degradation 
and fiber necrosis in DMD [41].  
Β2-AR agonist treatment has been shown to improve airway clearance by 3-4 
times in humans and to have anti-inflammatory properties by inhibiting cytokine 
production including: TNF-α, IL-6, and IL-1β [49, 50, 53, 54]. It has also been 
demonstrated that Β2-AR agonist treatment can increase calpastatin, a calpain-specific 
inhibitor, and decrease calpain concentration and activity [64, 67-69].  Β2-AR agonist 
supplementation has also been shown to increase diaphragm protein concentration, 
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maximal tetanic force production, and transdiaphragmatic pressure in the mouse model 
[45, 46, 229]. Functionally, the increased receptor density and resistance to 
downregulation associated with the Gly16 polymorphism would result in increased 
cAMP accumulation, further upregulating these mechanisms [43]. Cumulatively, these 
data suggest the Gly16 polymorphism may result in: improved mucociliary clearance, 
decreased inflammatory pathways, inhibition of Ca
2+
-dependent proteolysis, and 
improved diaphragmatic function in DMD.  
  
2.10.4.1 Beta-2 Adrenergic Receptors and Mucociliary Clearance 
 The ability for mucociliary clearance is of particular importance in the 
pathophysiology associated with DMD due to patients’ impaired respiratory secretion 
clearance and susceptibility to pulmonary infections [34, 230]. For an effective cough, 
one must inspire a large amount of air and apply expiratory force against a closed glottis, 
generating high thoraco-abdominal pressures. As a result, when the glottis opens, there is 
a strong expiratory flow [132]. However, in DMD patients this ability is compromised 
due to the mechanisms described above. 
 Clinically, mucoactive agents are used to improve airway clearance in DMD 
patients. These mucoactive agents aim to improve clearance via: (i) reducing the 
viscosity and elasticity of airway secretions [231]; (ii) increasing cilia beat frequency 
[232]; and (iii) reducing the adhesivity of airway secretions through surfactant production 
[232]. However, most of these medications are ineffective at increasing airway water and 
those that are often are also mucus secretagogues, increasing both the volume of mucus 
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and water in the airways [233]. This could be deleterious as over-hydration has been 
shown to decrease mucociliary clearance [234]. 
Β2-AR  agonist treatment has been shown to act similarly to mucoactive agents 
by improving airway clearance [50]. Research has shown an up to 5-fold increase in 
ciliary beat frequency with Β2-AR agonist treatment [47, 51]. This increase cilia beat 
frequency results in an increase in the number of metachronal waves moving across the 
epithelial and could aid in mucociliary clearance [235]. Β2-AR agonist treatment has also 
been shown to enhance mucus secretion and these secretions were shown to have higher 
viscosity and lower elasticity, properties that allowed for improved ability for clearance 
with cough [52, 236]. This suggests that even with impaired respiratory strength, patients 
with DMD could be more efficient in airway clearance with Β2-AR agonist treatment. 
Additionally, treatment with an Β2-AR  agonist has been shown to increase the 
production of surfactant by increasing the incorporation of choline and is effective in 
restoring phosphatidylcholine to normal levels in bronchoalveolar lavage fluid and lung 
tissue in septic lungs [237]. Research has also shown ADBR2 stimulation enhances the 
rate of release of newly synthesized surfactant into the alveoli [238]. This may be of 
clinical significance in DMD as surfactant improves airway patency, aiding in clearance 
[48]. Furthermore, the ability of the ADRB2 to regulate lung water via the mechanisms 
discussed above has been shown to increase mucociliary clearance by 3-4 times after 
agonist treatment [49]. These data suggest Β2-AR agonists may work similarly to 
mucoactive agents and could be beneficial in improving airway clearance in DMD 
patients. 
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 The influence of ADRB2 stimulation on improving mucus and lung fluid 
clearance has also been demonstrated in various disease states. Improved mucus 
clearance following Β2-AR agonist treatment has been demonstrated in asthma and 
chronic bronchitis [239-241]. Further, ADRB2 genotype has been associated with lung 
fluid accumulation. Research suggests subjects with the Arg16 polymorphism have a 
greater susceptibility for lung fluid accumulation than those with the Gly16 
polymorphism. The ability of ADRB2 to regulate lung fluid clearance has been 
demonstrated in disease states as well. Β2-AR agonist treatment has been shown effective 
in lung fluid clearance in HF with pulmonary edema, acute lung injury, and acute 
respiratory distress syndrome [183, 242, 243]. 
 
2.10.4.2 Beta-2 Adrenergic Receptors and Inflammation 
ADRB2s have also been shown to play a functional role in inflammatory 
responses. Β2-AR agonists have anti-inflammatory properties by inhibiting cytokine 
production, TNF-α, IL-6, and interleukin-1β (IL-1β), and by inhibiting the nuclear factor-
κB (NFκB) pathway through the production of cAMP and PKA [53, 54]. This may be of 
clinical importance in DMD as dystrophin-deficient muscle cells have been shown to 
produce significant levels of IL-1β and research suggests significant levels of TNF-α 
were detected in 62% of DMD tissue biopsies [58, 59]. Further, a positive correlation 
between cytokine levels and fibrosis was observed in the dystrophin-deficient diaphragm 
suggesting TNF-α may serve as a marker of dystrophy in the diaphragm [60]. This is 
consistent with mdx mouse studies demonstrating that inhibiting TNF-α production 
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delayed the appearance of muscle pathology [61]. This relationship has been 
demonstrated functionally as well. Research has shown with the treatment of an Β2-AR  
agonist, there is a reduction in plasma leakage and reduction in the number of neurophils 
and eosinophils that adhere to sites of inflammation on the endothelium [55]. 
Additionally, cells treated with cAMP, a downstream product of ADRB2 stimulation, 
have decreased IL-1β and TNF-α levels [56, 57]. These data suggest the ADRB2 may 
play a significant role in reducing the inflammatory response associated with DMD and 
thereby slow the emergence of dystrophinopathies in DMD patients. 
 
2.10.4.3 Beta-2 Adrenergic Receptors and Calpain Inhibition 
 The mechanism whereby ADRB2 activation may inhibit proteolysis is via calpain 
inhibition. ADRB2s are G-protein coupled receptors where upon binding of a 
catecholamine to the receptor stimulates a dissociation of the Gαs protein from the tightly 
associated β and γ subunits. Gαs-bound GTP then phosphorylates AC. Adenylyl cyclase 
produces cAMP which phosphorylates PKA into its active form [160]. Both cAMP and 
phosphorylated PKA can either directly or indirectly inhibit calpain activity. Research 
has shown a non-hydrolysable cAMP analog along with the activation of ADRB2 inhibits 
Ca
2+
-dependent protein degradation in both rats and chicks, suggesting cAMP may 
directly phosphorylate calpains to inhibit activity [63, 196]. Further, it has been 
demonstrated that the calpastatin promoter sequence between nt -1653 and +130 contains 
a single cAMP binding site located at nt -76 [244]. This suggests a direct pathway 
whereby cAMP signaling can lead to increased calpastatin gene transcription (a calpain 
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inhibitor) thus reducing calpain-mediated protein degradation. Further, multiple 
phosphorylation sites have been identified directly on calpastatin, particularly those 
found in the L and XL domain coded by exon 6, providing additional evidence for the 
direct phosphorylation of calpastatin via cAMP [245]. Research also suggests PKA has 
the ability to phosphorylate calpains. Studies in rat models have demonstrated a 
phosphorylation site at serine 369 which would restrict domain movement and keep m-
calpain in an inactive state, suggesting direct phosphorylation of calpain by PKA to have 
a negative-control effect on calpain activation [65, 246]. In addition to its ability to 
phosphorylate calpains, research suggests the C-domain of PKA can also directly 
phosphorylate calpastatin [66]. PKA and cAMP phosphorylation and increased gene 
transcription of calpastatin are of importance to DMD as calpastatin overexpression has 
been shown to result in skeletal muscle hypertrophy and to protect against atrophy in rats, 
suggesting calpastatin is also important in the regulation of skeletal muscle protein 
turnover [67, 68]. 
B2-AR agonist supplementation has also been shown to reduce calpain activity. 
Research has indicated a decreased rate of protein degradation following epinephrine 
supplementation that was prevented by propranolol, a non-selective beta-antagonist and 
by M ICI 118.551, a Β2-AR antagonist in rat skeletal muscle models. Additionally, 
dibutyryl cAMP and isobutylmethylxanthine reduced proteolysis in both soleus and 
extensor digitalis longus muscles [62]. Similar results have been shown in bovine species 
as well. B2AR agonist treatment of Friesian steer was shown to induce hypertrophy as 
well as increase calpastatin-specific activity by 76% with an overall 96% increase in 
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calpastatin mRNA levels [247]. In fact, following clenbuterol administration in the rat 
model, there was an approximate 50% decrease in the muscle Ca
2+
-dependent proteolytic 
pathway with no resultant change in the activations of the lysosomal or ubiquitin-
proteasome pathways, further supporting that the activity and gene expression of 
calpastatin are increased after Β2-AR agonist supplementation [64, 69, 247]. 
Additionally, evidence supports the role of adrenergic tonus on the inhibition of 
proteolysis. After chemical and surgical sympathectomy, rat models demonstrated an 
increase in Ca
2+
-dependent proteolytic pathways, suggesting adrenergic tonus exerts its 
effect via Ca
2+
-dependent pathway inhibition [195, 196]. 
 
2.10.5  Beta-2 Adrenergic Receptors and Other Myogenic Effects 
Research has demonstrated exogenous ADRB2 stimulation may also demonstrate 
other myogenic actions. ADRB2 stimulation has been found to stimulate the production 
of growth factors such as insulin-like growth factors (IGF) and transforming growth 
factor β (TGF-β) which play an integral role in muscle development, growth and 
regeneration [248, 249]. Additionally, catecholamine administration has demonstrated a 
significant increase in cell proliferation associated with a mitogen activated protein 
kinase (MAPK)-dependent increase in cell cycle proteins cyclin E and D1 and cyclin-
dependent kinase 2 and 4 (CDK2 and CDK4) [250]. Further, previous work suggests the 
Gαi-linked Gβγ subunits activate the phosphoinositide 3-kinase-protein kinase-B (PI3K-
AKT) signaling pathway [170]. An isoform of this pathway (AKT1) has been shown to 
inhibit the forkhead box O transcription factor (FOXO), which has been implicated in 
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muscle atrophy [170, 173]. These data suggest the PI3K-AKT signaling pathway may 
regulate protein synthesis, gene transcription, cell proliferation, and cell survival. 
Additional myogenic effects of ADRB2 stimulation include the regulation of CREB and 
its downstream products via phosphorylation by the free C-subunits of PKA [162]. 
Increased CREB activity has been associated with increased activity of the transcription 
factor myocyte enhancer factor-2 (MEF2) and increased expression of neuron-derived 
orphan receptor-1 (NOR-1), both of which play roles in cell proliferation, differentiation, 
adaptation, and survival [161, 251]. In addition to these actions, NOR-1 expression was 
associated with a significant increase in the levels of myostatin expression. Myostatin is a 
member of the transforming growth factor-β superfamily and the primary negative 
regulator of muscle mass [251]. These data suggest the ADRB2 may directly modulate 
muscle size through various mechanisms independent of the DMD pathology, providing 
evidence of the therapeutic benefits of B2-AR agonism and by extension, the Gly16 
polymorphism. 
 
2.10.6  Beta-2 Adrenergic Receptors and Vascular Function 
 The dystrophin associated glycoprotein complex (DAGC) dysfunction associated 
with DMD may render the muscles ischemic during exercise [77]. Because neuronal 
nitric oxide synthase is localized to the sarcolemma as part of the DAGC, loss of 
sarcolemmal integrity results in loss of nitric oxide synthase [72, 78]. Nitric oxide during 
exercise has been shown to play a role in blunting exercise-induced vasoconstriction due 
to α-adrenergic receptor activation. This protective mechanism is defective in DMD 
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resulting in unopposed vascular vasoconstriction during exercise further contributing to 
the pathogenesis of DMD [79, 80]. The Gly16 polymorphism of the ADRB2 has shown 
improved vasodilation. Research using a non-selective β-AR antagonist has shown an 
increase in renin production thus increasing angiotensin II formation and upregulating its 
vasoconstrictive activity [252, 253]. This suggests the ADRB2 plays a functional role in 
not only promoting vasodilation but also in opposing vasoconstriction. Additionally, 
ADRA1 and ADRA2 have similar binding affinities for epinephrine and norepinephrine 
but still have a lower affinity for epinephrine than does the ADRB2. This suggests the 
physiologic plasma levels of epinephrine associated with the Gly16 polymorphism may 
be beneficial in opposing α-adrenergic vascular vasoconstriction in DMD patients. 
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Background & Aims: The beta-1 adrenergic receptor (ADRB1) has been shown to play 
a functional role in cardiomyocyte function and accounts for up to 80% of the cardiac 
tissue adrenergic receptors with ADRB1 stimulation increasing cardiac rate, contractility, 
and work. Multiple polymorphisms of the ADRB1 have been identified such as the Gly49 
polymorphism that includes at least one glycine (Gly) for serine (Ser) at amino acid 49 
resulting in either homozygous for Gly (Gly49Gly) or heterozygous for Gly (Gly49Ser) 
polymorphisms. Heart failure patients with this polymorphism (Gly49) have been shown 
to have improved cardiac function and decreased mortality risk, but if there is an effect in 
healthy subjects is less clear.  
Purpose: The purpose of this study was to determine the effects of the Gly/Ser 
polymorphism at position 49 of the ADRB1on the cardiovascular response to exercise in 
healthy subjects. Methods: We performed genotyping of the ADRB1 (amino acid 49) 
and high-intensity, steady-state exercise on 71 healthy subjects (Ser49Ser = 52, Gly49Ser 
= 19).  
Results: There were no differences between genotype groups in age, height, weight, 
BMI, or watts achieved (age = 28.9 ± 5.6yrs., 30.6 ± 6.4yrs., height = 173.6 ± 9.9cm, 174 
± 7.5cm, weight = 74.4 ± 13.3kg, 71.9 ± 13.5kg, BMI = 24.6 ± 3.5, 23.6 ± 3.3, and watts 
= 223.8 ± 76.8, 205 ± 49.4, for Ser49Ser and Gly49Ser respectively). Additionally, there 
were no differences for genotype groups for cardiac output (CO), systolic blood pressure 
(BPsys), or diastolic blood pressure (BPdias) at rest, maximal exercise, or in change from 
rest to maximal exercise. The genotype groups differed significantly in heart rate (HRmax) 
at maximal exercise and cardiac index at rest (CI) (HRmax = 184.2 ± 9.5bpm, 190.7 ± 
10.6bpm, CI = 0.063 ± 0.014, 0.071 ± 0.013, for Ser49Ser and Gly49Ser respectively). 
There was a trend towards significance (p = 0.058) for the change in stroke volume from 
rest to peak exercise (∆SV) (0.016 ± 0.018L, 0.0076 ± 0.012L, for Ser49Ser and 
Gly49Ser respectively).  
Conclusion: These data suggest genetic variations of the ADRB1 may influence 
cardiovascular responses to exercise in healthy subjects. 
Keywords: Exercise; ADRB1 polymorphism; Cardiovascular; Beta-1 genotype; Healthy 
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INTRODUCTION 
The β-adrenergic receptors (β-AR) are part of a family of membrane proteins 
known as G-protein coupled receptors where, upon binding of a catecholamine to the 
receptor, stimulates a conformational change in the β-AR that causes coupling with G-
proteins. G-proteins consist of α, β, and γ subunits and β-AR coupling leads to the 
dissociation of the G-protein into active Gα and Gβ subunits to mediate downstream 
signaling [156]. Moreover, β-AR agonist binding results in a dissociation of the 
stimulatory Gα (Gαs) protein [193]. Gαs-bound guanine triphosphate (GTP) then 
phosphorylates the enzyme adenylyl cyclase (AC). Both AC and cAMP have the ability 
to regulate downstream mechanisms via multiple internal cell signaling pathways [161-
165]. Conversely, β-AR antagonist binding causes a competitive inhibition against 
catecholamine and sympathetic nervous stimulation, thereby inhibiting the dissociation of 
Gs proteins [166]. 
One subtype of the β-ARs is the beta-1 adrenergic receptor (ADRB1). The 
ADRB1 subtype has been shown to play a functional role in cardiomyocyte function and 
accounts for approximately 70% of the cardiac tissue adrenergic receptors in the atria, 
80% in the ventricles, and 95% in the sinoatrial (SA) node [176]. Research has 
demonstrated that ADRB1 stimulation increases cardiac rate, contractility, and work 
[199, 208]. Multiple polymorphisms of the ADRB1 have been identified as including a 
glycine (Gly) for serine (Ser) at amino acid 49 resulting in either homozygous for Gly 
(Gly49Gly) or heterozygous for Gly (Gly49Ser) polymorphisms. The Gly49 
polymorphism has been shown to have decreased receptor density, decreased cAMP 
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accumulation, and a dampening response to the cardio-stimulant effect of norepinephrine 
infusion [22, 23]. Heart failure (HF) patients with this polymorphism (Gly49) have also 
been shown to have improved cardiac function and decreased mortality risk [18, 19, 29]. 
Furthermore, studies have demonstrated autoantibodies against ADRB1 are associated 
with more favorable myocardial recovery in patients with recent-onset cardiomyopathy 
[20]. This suggests the Gly49 polymorphism may have inherent cardioprotective effects 
similar to that of a beta-blocker. 
 While many studies have demonstrated the cardioprotective effect of the Gly49 
polymorphism in HF, little is known of the effect of this polymorphism in healthy 
subjects or on the function in response to endogenous agonist (catecholamine) changes. 
Additionally, there is a lack of research exploring the effect of the Gly49 polymorphism 
on cardiovascular response to exercise in healthy subjects. This study aimed to identify 
the effect of ADRB1 polymorphisms on resting cardiovascular function and on 
cardiovascular response to exercise in healthy subjects. 
 
METHODS 
Subjects 
Data analyzed for this article were part of a larger study on adrenergic receptor 
genotypes and cardiopulmonary function at rest and during exercise but the data have not 
been assessed as presented in this study [44, 201]. This study received approval by the 
appropriate ethics committee and has therefore been performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. 
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Appropriate consent has been obtained pursuant to law, and the subjects were informed 
of the benefits and risks of the investigation before signing an institutionally-approved 
informed consent prior to participation. Seventy-one untrained subjects, ages 20–40, 
agreed to participate and were genotyped for Gly49Ser polymorphisms of the ADRB1. 
All subjects were healthy nonsmokers and not on medication. 
Procedures 
Subjects underwent baseline screening tests including pulmonary function testing, 
an incremental cycle ergometry test to exhaustion on a cycle ergometer, a blood draw for 
a complete blood count (to rule out anemia) and in women, a pregnancy test. The 
baseline exercise study, served as an initial familiarization session, was used to determine 
work intensities for subsequent sessions, and acted as a screening study to rule out 
myocardial ischemia and abnormal arrhythmias. After these initial tests, subjects met 
with the Clinical Research Center (CRC) nutritionist and were put on a controlled sodium 
diet (3,450 mg·d
−1
) for three days with a 24-hour urine collection to confirm sodium 
intake. Subjects subsequently returned to the CRC on two occasions for exercise testing 
while maintaining a salt neutral diet. 
The next session consisted of a cycle ergometry test similar to the first visit but 
with the additional measurement of Q using a previously validated open-circuit acetylene 
uptake method [254]. This session served as a further familiarization with the 
measurements to be made on the final study day and also allowed for confirmation of 
workloads for the final visit. 
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On the last study visit, resting measurements of Q, heart rate (HR), stroke volume 
(SV), and arterial blood pressure (BP) were made. Cardiac output was measured with the 
open-circuit acetylene method, BP was measured via an arterial catheter, HR was 
measured via a 3-lead EKG, and SV was calculated by dividing Q by HR, and CI was 
calculated by dividing Q by weight. Subjects then exercised for 9 minutes at ∼40% and 9 
minutes at ∼75% of their peak workload achieved during the initial exercise studies 
while measurements were repeated every 2–3 minutes. Nine minutes of exercise was 
performed because pilot data suggested that this was an adequate time frame to obtain 
three sets of measures and brought the subjects close to exhaustion with the higher 
workload with minimal physiologic drift in VO2 and cardiovascular function. All visits 
were conducted in the morning to account for testing variability. 
ADRB1 genotyping 
Buffy coat, obtained from whole blood collected on EDTA, was used for genomic 
DNA extraction using the Gentra Puregene DNA Isolation Kit (Gentra Systems Inc., 
Minneapolis, MN, USA), and DNA samples were sent to the University of Arizona 
Genomics Core for genotype analysis. A polymerase chain reaction (PCR) was conducted 
according to standard methods, using the following primer sequences (e.g., for 
Ser49Gly): (forward) 5′-CCG GGC TTC TGG GGT GTT CC-3′ and (reverse) 5′-GGC 
GAG GTG TGG CGA GGT AGC-3′, resulting in a PCR product 564 bps in length. For 
genotype analysis, a plate of sample DNA was normalized to 1ng/uL. 10uL of this stock 
DNA was plated into an AB1400/W reaction plate (Thermo Fisher) and was vacuum 
desiccated. A reaction mixture of Taqman Fast Advance Mastermix (Life Technologies), 
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reaction-grade water (Thermo Fisher), and pre-designed Taqman SNP genotyping assays 
(Life Technologies) was created and pipetted into the wells containing vacuum dried 
DNA. The plate was sealed with AB1170 Absolute qPCR Plate Seals (Thermo Fisher), 
centrifuged, and pre-read in an ABI 7300 qPCR instrument. The plates were relocated to 
a BioRad Tetrad Thermocycler system (BioRad) and reacted. The thermocycling protocol 
was as follows: 1 cycle of 15m at 45°C, 3m at 95°C, followed by 40 cycles of 15s at 
95°C and 60s at 58°C. The reacted PCR plates were cooled to 4°C, centrifuged, and post-
read on the ABI 7300 instrument. The data was analyzed using the SDS 1.4.1 software. 
The Ser49Ser homozygous genotype is represented by a single 564 bp band and the 
Ser49Gly by 2 products of 219 and 343 bp. 
Statistical analyses 
All statistical comparisons were made using a statistical software package (SPSS; 
SPSS Inc, Chicago, IL, USA, version 19). Group demographics were compared with a 1-
way ANOVA using an α level of 0.05 to determine statistical significance. Genotype 
differences in performance were compared with an ANOVA to detect differences among 
the specific genotype groups. An α level of 0.05 was used for the ANOVA and post hoc 
analyses. An α level of 0.05 was used for the ANOVA and post hoc analyses. 
 
RESULTS 
Subject characteristics 
Seventy-one subjects were enrolled in this study (36 male and 35 female). 
Genotyping for ADRB1 was completed for amino acid position 49 with individuals who 
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were homozygous for serine (Ser49Ser, n = 52) or heterozygous (Gly49Ser, n = 19) at 
codon 49. There was no statistically significant difference between genotype groups for 
age, height, weight, BMI, or peak watts achieved, during the maximal exercise test (Table 
1). 
Cardiac output, stroke volume, and blood pressure 
There were no statistically significant differences between genotype groups for 
cardiac output (Q) or systolic blood pressure (BPsys) at rest, peak exercise, or in change 
from rest to peak exercise (Figure 1). There were no significant differences between 
genotype groups for diastolic blood pressure (BPdias) or stroke volume (SV) at rest or 
peak exercise (Fig 1). There was a trend towards significance between genotype groups 
for change in SV (p = 0.058) from rest to peak exercise. Furthermore, while not 
statistically significant (p = 0.08), there was a clinically significant difference between 
genotype groups for change in BPdias from rest to peak exercise (-5.5 ± 15.4 and 1.3 ± 
11.5 mmHg for Ser49Ser and Gly49Ser respectively) (Figure 1). We have defined this as 
clinically significant as small changes in BP (~5 mmHg) can drastically influence 
survival in HF patients [255]. 
 
Cardiac index, heart rate, and systemic vascular resistance 
There were no statistically significant differences between genotype groups for 
cardiac index (CI) at peak exercise or for change in CI from rest to peak exercise. Nor 
were there any differences between genotype groups for resting heart rate (HR) or for 
change in HR from rest to peak exercise. Further, there were no statistically significant 
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differences between genotype groups in systemic vascular resistance (SVR) at peak 
exercise or for change in SVR from rest to peak exercise. There were, however, 
differences between genotype groups for resting CI (p = 0.037) and SVR (p = 0.046) and 
for HR at peak exercise (HRmax) (p = 0.016), with the Gly49Ser genotype presenting 
improved CI and a lower SVR at rest, and a higher HR at peak exercise (Figure 2). 
 
DISCUSSION 
In the present study, we demonstrate that genetic variation of the ADRB1 is 
associated with differences in some components of the cardiovascular responses to peak 
exercise in healthy subjects. Individuals with one glycine allele (Gly49Ser) at amino acid 
49 demonstrate a trend towards significance for change in SV from rest to peak exercise. 
The Gly49Ser polymorphism demonstrated a blunted response in SV in response to peak 
exercise and a significant change in BPdias from rest to peak exercise and the Gly49Ser 
polymorphism demonstrated a greater increase in BPdias and the Ser49Ser polymorphism 
demonstrating a decrease in BPdias. Further, the Gly49Ser polymorphism demonstrated an 
improved CI at rest, an increased HRmax at peak exercise, and a lower SVR at rest 
compared to the Ser49Ser polymorphism. 
The ADRB1 subtype is found primarily in the heart and comprises 75-80% of 
total β-AR found in the heart and approximately 95% of β-AR in the SA node [21]. The 
G protein signaling pathway associated with the β-AR is important in the modulation of 
several key target proteins. When activated, cardiomyocyte ADRB1 preferentially binds 
to the Gas protein which phosphorylates AC, generating the secondary messenger cAMP. 
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Increased cAMP accumulation activates PKA [25]. Activated PKA then phosphorylates 
troponin I, the L-type Ca
2+
 channel and phospholamban (PLB), increasing cardiac 
inotropy, chronotropy, and lusitropy [24].  
Research has also shown Gs activation can increase L-type Ca
2+
 current directly 
[166]. L-type Ca
2+
 channels play an integral role in cardiomyocyte excitability and 
contractility [156]. Phosphorylation of cardiac L-type Ca
2+
 channels by PKA results in an 
influx of Ca
2+
 into cardiomyocytes. The Ca
2+
 then binds to the sarco/endoplasmic 
reticulum Ca
2+
-ATPase (SERCA) triggering further sarcoplasmic Ca
2+
 loading resulting 
in the removal of troponin and tropomyosin inhibition of myosin binding sites [105, 167]. 
Additionally, the phosphorylation of phospholamban (PLB) via PKA, a downstream 
protein from β-AR stimulation, has been shown to result in the removal of inhibition of 
SERCA. This increases the quantity and rate of reuptake of cytosolic Ca
2+
 in the 
sarcoplasmic reticulum [27]. Recent research also suggests PLB is not sequestered only 
to the sarcoplasmic reticulum but, rather, PLB pools exist in the nuclear envelope which 
allows them to regulate perinuclear/nuclear Ca
2+
 handling [26]. Troponin I is a regulatory 
protein of cardiac myofibrils and its phosphorylation by PKA inhibits actomyosin 
ATPase activity resulting in relaxation of cardiomyocytes in response to catecholamines 
[22, 28]. 
Genetic variants of the ADRB1 have been shown to modulate the cardiac 
responses to catecholamine binding; the Gly49 polymorphism has been shown to produce 
a dampening effect to these responses. These data suggest genetic variations of the 
ADRB1 may influence cardiovascular responses to exercise in healthy subjects. In the 
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present study, subjects with the Gly49Ser polymorphism present with a statistically 
significantly improved cardiac index as compared to the Ser49Ser polymorphism at rest; 
this difference is abolished at peak exercise. This suggests improved cardiac function at 
rest with no deleterious effect on cardiac function at peak exercise. Additionally, there is 
a statistically significant difference between the two polymorphisms for HRmax and no 
difference at rest, with the Gly49Ser polymorphism demonstrating a higher HRmax. This 
suggests the Gly49Ser polymorphism has an improved HR reserve. Further, this 
polymorphism (Gly49Ser) also demonstrated a lower SVR at rest, suggesting the 
Gly49Ser polymorphism has decreased cardiac work at rest. This coupled with the 
abolishment of this difference at peak exercise suggests subjects with the Gly49Ser 
polymorphism have an improved cardiac work reserve. Furthermore, the trend towards 
significance in change in stroke volume from rest to peak exercise, with the Gly49Ser 
polymorphism presenting a dampened increase, in addition to there being no difference in 
HR at rest and improved CI at rest, suggests an improved left ventricular contractility in 
the Gly49Ser polymorphism. It is interesting to note the clinically significant difference 
between genotype groups in change in BPdias rest to peak exercise may suggest a systemic 
influence of the ADRB1 genotype, particularly in the typically observed arterial 
vasodilation observed in response to aerobic exercise. These data suggest the Gly49Ser 
polymorphism to have improved cardiovascular function at rest and peak exercise. 
ADRB1 signalling has been shown to play an important role in HF with the 
degree of sympathetic activity being inversely correlated with survival [211]. Deleterious 
effects of ADRB1 signalling include apoptosis, myocyte growth, fibroblast hyperplais, 
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myopathy, fetal gene induction, and proarrythmia [206, 212]. As an adaptive mechanism 
in HF, cardiac ADRB1s become less responsive, either downregulating or uncoupling 
from the Gs pathway [214]. This suggests the less functional variant of the ADRB1 to be 
clinically important in HF and our data confirms that further study is certainly warranted. 
The present study did not demonstrate as large of an effect of ADRB1 
polymorphisms on cardiovascular parameters in healthy subjects as the current research 
has demonstrated in HF. We postulate this may be due to the change in β-AR ratios in HF 
and epinephrine/norepinephrine binding affinities for ADRB1 and ADRB2. Previous 
work has demonstrated a decrease in cardiomyocyte ADRB1 concentration by as much as 
61% in HF with no or little corresponding decrease in ADRB2 concentrations [214, 256-
258]. Furthermore, ADRB1 receptors have a high binding affinity for both epinephrine 
and norepinephrine while ADBR2 receptors have a high binding affinity for epinephrine 
and a low binding affinity for norepinephrine [175]. Additionally, there is little to no 
ADRB1 receptor reserve for positive cardiovascular ionotropic effects [176, 177, 259]. 
This decrease in β-AR concentration, particularly ADRB1 concentration, and successive 
decreased catecholamine sensitivity coupled with a low ADRB1 reserve, suggests this 
decrease in ADRB1 receptor concentrations is a protective mechanism in HF and 
modulates the effect of ADRB1 polymorphisms on cardiovascular parameters. 
Current research suggests a cardioprotective effect of the Gly49 polymorphism in 
HF and other cardiac pathologies. This present study supports this notion, suggesting 
improved cardiovascular function at rest and response to peak exercise in healthy subjects 
and supporting the use of beta-blockers to improve exercise tolerance in HF patients. 
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These findings may be clinically important as exercise is an essential aspect of cardiac 
rehabilitation following cardiac exacerbations. The ability to improve exercise tolerance 
in this population may prove integral in improving the efficacy and adherence to exercise 
as a part of cardiac rehabilitation.  
 
LIMITATIONS 
There are inherent limitations regarding genetics studies including sample size 
and genotype distribution. Limited statistical power because of the modest sample size 
and different genotype distribution in the present study (N = 71) may have played a role 
in limiting the significance of some of the statistical comparisons conducted. A post hoc 
power analysis revealed the power to detect statistically significant differences between 
groups for CI at rest and HRmax to be .625 and .613 respectively at α = 0.05, suggesting 
sufficient sample size for the present study. Furthermore, our study population was void 
of the homozygous Gly49Gly genotype. This can be explained by the genotype frequency 
of the three genotypes present at amino acid 49 (0.69, 0.29, and 0.04 for Ser49Ser, 
Gly49Ser, and Gly49Gly respectively) but may vary among different racial/ethnic groups 
[260]. However, present research has demonstrated the Gly49Ser and Gly49Gly 
polymorphisms function similarly, suggesting there is no additive effect of an additional 
glycine present at amino acid 49 and that the Gly49Ser polymorphism may be 
representative of the Gly49 polymorphism as a whole for ADRB1 [176, 208]. 
 
CONLCUSIONS 
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 The present study examined the influence of ADRB1 genotype on cardiovascular 
response to exercise in healthy subjects. Our data demonstrated the Gly49Ser genotype 
has a blunted SV response to peak exercise and a significant change in BPdias from rest to 
peak exercise compared to the Ser49Ser genotype. Additionally, the Gly49Ser 
demonstrated improved CI at rest, increased HRmax at peak exercise, and a lower SVR at 
rest compared to the Ser49Ser genotype. The current study suggests improved 
cardiovascular function at rest and response to peak exercise in healthy subjects and 
provides further evidence to the cardioprotective effect of the Gly49 polymorphism in a 
healthy population. 
 
COMPETING INTERESTS 
All authors declare they have no competing interests. 
 
GRANT SUPPORT 
This study was funded by National Institute of Health (NIH) grants: HL108962-06.  
 
FINANCIAL DISCLOSURE 
All authors declare they have no conflict of interest. 
 
 
 
 
72 
 
TABLES 
Table 1. Subject characteristics (mean ± standard deviation, N or p-value) 
Study Demographics 
 N Mean ± SD p-value 
Sex (Male/Female) 
Ser49Ser 
 
Gly49Ser 
 
Total 
 
26/26 
 
10/9 
 
36/35 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Age (yrs) 
Ser49Ser 
 
Gly49Ser 
 
Total 
 
52 
 
19 
 
71 
 
28.9 ± 5.6 
 
30.6 ± 6.4 
 
29.3 ± 5.8 
 
0.25 
Height (cm) 
Ser49Ser 
 
Gly49Ser 
 
Total 
 
52 
 
19 
 
71 
 
173.6 ± 9.9 
 
174 ± 7.4 
 
173.7 ± 9.3 
 
0.87 
Weight (kg) 
Ser49Ser 
 
Gly49Ser 
 
Total 
 
52 
 
19 
 
71 
 
74.4 ± 13.3 
 
71.9 ± 13.5 
 
73.8 ± 13.3 
 
0.5 
BMI 
Ser49Ser 
 
Gly49Ser 
 
Total 
 
52 
 
19 
 
71 
 
24.6 ± 3.5 
 
23.6 ± 3.3 
 
24.3 ± 3.4 
 
0.33 
Watts 
Ser49Ser 
 
Gly49Ser 
 
Total 
 
52 
 
19 
 
71 
 
223.8 ± 76.8 
 
205 ± 49.4 
 
218.7 ± 70.6 
 
0.33 
Subject characteristics (N, mean ± standard deviation, and p-value) 
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Ser49Ser = genotype (homozygous for ADRB1 resulting in serine at amino acid 49), 
Gly49Ser = genotype (heterozygous for ADRB1 resulting in one glycine and one serine 
at amino acid 49). BMI – body mass index. There were no statistically significant 
differences in demographic data 
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FIGURE LEGENDS 
 
Table 1. Subject characteristics (mean ± standard deviation, N or p-value) 
Subject characteristics (N, mean ± standard deviation, and p-value) 
Ser49Ser = genotype (homozygous for ADRB1 resulting in serine at amino acid 49), 
Gly49Ser = genotype (heterozygous for ADRB1 resulting in one glycine and one serine 
at amino acid 49). BMI – body mass index. There were no statistically significant 
differences in demographic data 
 
Figure 1 
Panels depict the change from rest to peak exercise in (A) Cardiac Output (Q), (B) 
Systolic Blood Pressure (BPsys), (C) Diastolic Blood Pressure (BPdias), and (D) Stroke 
Volume (SV). The error bars represent the SE of the mean.  
† Trend towards significance for change in SV (p =0.058) from rest to peak between 
genotype groups.  
∫ Clinically significant difference between genotype groups for change in BPdias from rest 
to peak exercise (-5.5 ± 15.4 and 1.3 ± 11.5 for Ser49Ser and Gly49Ser respectively). 
 
Figure 2 
Panels depict the change from rest to peak exercise in (A) Cardiac Index (CI), (B) Heart 
Rate (HR), and (C) Systemic Vascular Resistance (SVR). The error bars represent the SE 
of the means. 
*p<0.05 for Ser49Ser vs Gly49Ser pairwise comparisons. 
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FIGURES 
Figure 1. Change from rest to peak exercise in Cardiac Output (Q), Systolic Blood 
Pressure (BPsys), Diastolic Blood Pressure (BPdias), and Stroke Volume (SV). 
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Figure 2. Change from rest to peak exercise in Cardiac Index (CI), Heart Rate (HR), and 
Systemic Vascular Resistance (SVR). 
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ABSTRACT 
The purpose of this study was to determine the effects of ADRB2 genotypes on muscle 
function (absolute power and relative power) in healthy subjects. We performed 
genotyping of the ADRB2 (amino acid 16) and high-intensity, steady-state exercise on 77 
healthy subjects (AA = 18, AG = 25, GG = 34). There were no differences between 
genotype groups in age, height, weight, or BMI (age = 28.9 ± 5.7yrs, 27.9 ± 5.7yrs, 29.2 
± 5.9yrs, height = 170.7 ± 8.6cm, 174.9 ± 8.7cm, 173.4 ± 9.6cm, weight = 68.5 ± 13.0kg, 
75.0 ± 12.9kg, 74.4 ± 12.9kg, and BMI = 23.4 ± 3.9, 24.4 ± 2.9, 24.7 ± 3.4, for AA, AG, 
and GG, respectively). The genotype groups differed significantly in watts, and 
watts/VO2 with heavy exercise (watts = 186.3± 54.6, 237.8 ± 54.4, 219.4 ± 79.5, 
watts/VO2 = 0.08 ± 0.006, 0.09 ± 0.005, 0.08 ± 0.006). There was a trend towards 
significance (p=0.058) for watts/kg (2.7 ± 0.4, 3.2 ± 0.5, 2.9 ± 0.8, for AA, AG, and GG, 
respectively). These data suggest that genetic variation of the ADRB2 may influence 
relative strength in healthy subjects and may become an important genetic determinant of 
muscular strength and functional capacity in patients with diseases that result in a loss of 
muscle strength.  
Keywords: exercise; ADRB2 polymorphism; strength; beta-2 genotype; beta-2 receptor 
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INTRODUCTION 
Muscular strength and power are important aspects to athletic performance. β2 
agonist supplementation has been shown to increase power and increases the rates of 
glycolysis and glycogenolysis during sprinting in men (16). Further, Kalsen et al (2015) 
also demonstrated increased mean and peak power during the sprint with increased 
anaerobic adenosine-triphosphate (ATP) utilization following β-agonist administration. In 
this same study, β-agonist administration preserved whole muscle ATP concentrations 
with no difference in phosphocreatine breakdown. These findings suggest the β2 
adrenergic receptors (ADRB2) influence anaerobic power and capacity, possibly 
improving anaerobic performance in power athletes.  
The β2 adrenergic receptor plays a functional role in muscle size, strength and 
muscle regeneration (7, 30). Church et al, (2014) demonstrated reduced peak twitch 
force, rate of contraction, maximal force along with significantly reduced rates of 
regeneration in ADRB2 receptor knockout mice compared to controls. Further, 
supplementation with β2 agonists has demonstrated enhanced sarcoplasmic reticulum 
Ca
2+
 release rates, maximal voluntary contraction strength and peak Wingate power in 
trained human and rat models (5, 14, 25). Hodge et al, (2002), also demonstrated that 
denervation-induced atrophy was attenuated through β2 agonist treatment in rats. These 
data suggest the ADRB2 regulates muscular size, strength, contractility and protects 
against denervation-induced atrophy, suggesting ADRB2 may play a functional role in 
reducing disuse atrophy associated with injury. 
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The mechanisms by which ADRB2 stimulation may increase muscle size, 
strength, and contractility are associated with its role in internal cell signalling. The 
activation of the ADRB2 results in the formation of adenosine 3’-5’ monophosphate 
(cAMP), a secondary messenger that plays many roles in the body. An increase in 
ADRB2 density has been correlated with increased cAMP accumulation in animal 
models (11, 30). Skeletal muscle cAMP signaling is shown to regulate contractility, 
sarcoplasmic Ca
2+
 dynamics, and recovery from sustained contractile activity. The net 
result of cAMP activation is characterized by increased contractile force and rapid 
recovery of ion balance.  
Further, in rodent DMD models, cAMP production was shown to slow 
degeneration as well as promote regeneration of skeletal muscles (2). This previous work 
suggests individuals with the more functional variant of the ADRB2 may have increased 
cAMP accumulation, resulting in improved skeletal muscle contractile activity and ability 
to recover as well as an attenuated degeneration of skeletal muscle. Multiple 
polymorphisms of the ADRB2 have been identified as including a glycine (Gly) for 
arginine (Arg) substitution at amino acid 16. The Gly16 polymorphism has been shown 
to have higher receptor density on lymphocytes, be more resistant to receptor down 
regulation, and functionally demonstrate higher cardiac output, stroke volume, left 
ventricular function, ejection fraction and vascular function when compare to the Arg16 
genotype in humans (9, 13, 32, 34, 35). 
Although not specifically studied previously, demographic data from previous 
studies demonstrate that subjects with the Gly16 polymorphism tend to have a greater 
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body mass index, despite higher fitness levels, possibly suggesting greater muscle mass. 
Therefore, the Gly16 polymorphism may not only have a protective effect on the cardiac 
muscles, but may also attenuate skeletal muscle degeneration through other down stream 
mechanisms.  
Although the clinical implications of ADRB2 genotypes on muscular 
development and strength are important, the influence of ADRB2 genotype on 
performance may identify novel supplementation for improvement of sports performance. 
Currently, little research has investigated the direct effect of ADRB2 genotype on 
skeletal muscle function. Therefore, the purpose of this study was to determine the effects 
of ADRB2 genotypes on muscle function (absolute power and relative power) in healthy 
subjects. 
 
METHODS 
 
Experimental Approach to the Problem 
 This study used a one way ANOVA to compare genotype groups for indices of 
intensity, power (watts, watts/kg, and watts/kg), and perceived intensity (watts/hr) at high 
intensity cycling for healthy, untrained subjects. Peak measures were compared for 
genotype groups for dependent variable measures. Subjects attended three sessions of 
testing with 72 hours between sessions one and two on a controlled low-sodium diet and 
at least 24 hours between sessions two and three. 
Subjects  
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Data analyzed for this manuscript were part of a larger study on ADRB2 
genotypes and cardiopulmonary function at rest and during exercise but the data have not 
been assessed as presented in the present study (32, 33). This study received Institutional 
Board approval for the research and appropriate consent has been obtained pursuant to 
law and the subjects were informed of the benefits and risks of the investigation prior to 
signing an institutionally approved informed consent document to participate. Seventy-
seven untrained subjects, ages 20 to 40, agreed to participate and were genotyped for 
Arg16Gly polymorphisms of the ADRB2. Individuals who were homozygous for 
arginine (ArgArg, n = 18), glycine (GlyGly, n = 34) or heterozygous (ArgGly, n = 25) at 
codon 16 agreed to participate in the study. All subjects were healthy non-smokers and 
not on medication. 
Procedures 
Subjects underwent baseline screening tests including pulmonary function testing, 
an incremental cycle ergometry test to exhaustion on a lode cycle ergometer, a blood 
draw for a complete blood count (to rule out anemia) and, in women, a pregnancy test. 
The baseline exercise study served as an initial familiarization session, was used to 
determine work intensities for subsequent sessions, and acted as a screening study to rule 
out myocardial ischemia and abnormal arrhythmias. Following these initial tests, subjects 
met with the Clinical Research Center (CRC) nutritionist and were put on a controlled 
sodium diet (3450 mg day−1) for 3 days with a 24-h urine collection to confirm sodium 
intake. This controlled sodium diet was used because previous studies have suggested 
that the ADRB2 may be sensitive to changes in dietary sodium (31, 18). Subjects 
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subsequently returned to the CRC on two occasions for exercise testing while 
maintaining a salt neutral diet.  
 
The next session consisted of a cycle ergometry test similar to the first visit but 
with the additional measurement of Q using a previously validated open-circuit acetylene 
uptake method (15). This session served as a further familiarization with the 
measurements to be made on the final study day and also allowed for confirmation of 
workloads for the final visit. 
On the last study visit, resting measurements of Q, HR, SV and arterial BP were 
made. Subjects then exercised for 9 min at ∼40% and 9 min at ∼75% of their peak 
workload achieved during the initial exercise studies while measurements were repeated 
every 2–3 min. Nine minutes of exercise was performed because pilot data suggested that 
this was an adequate time frame to obtain three sets of measures and brought the subjects 
close to exhaustion with the higher workload. All visits were conducted in the morning to 
account for testing variability. 
ADRB2 Genotyping 
β2 adrenergic receptor genotyping was PCR-based according to methods of Bray 
et al (2000). Buffy coat, obtained from whole blood collected on EDTA, was extracted 
using the Gentra Puregene DNA Isolation Kit (Gentra Systems Inc., Minneapolis, MN, 
USA). The PCR reaction was conducted according to standard methods, using the 
following primer sequences (e.g. for Arg16Gly): (forward) 5′-AGC CAG TGC GCT 
TAC CTG CCA GAC-3′ (at −32) and (reverse) 3′-CA TGG GTA CGC GGC CTG GTG 
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CTG CAG TGC-5′, resulting in a PCR product 107 base pairs in length. The reaction 
included 30 ng of DNA, 1.5 mM magnesium chloride, 0.5 U taq polymerase (Invitrogen, 
Carlsbad, CA, USA), 8.5% DMSO and standard concentrations of nucleotides and buffer 
in a 20 µl reaction volume. After initial denaturation at 94°C for 4 min, the fragments 
were amplified by 35 cycles of 1 min at 94°C, 1 min at 61°C, 1 min at 72°C, followed by 
5 min at 72°C and 5 min at 98°C. The amplicons were then digested by exposure to 5 U 
of the restriction enzyme KpnI, followed by electrophoretic separation on 3% aragose 
gels, staining with ethidium bromide and visualization using UV light. The ArgArg 
homozygous genotype is represented by a single 107 bp band, the ArgGly group is 
represented by 25, 82 and 107 bp bands, and the GlyGly homozygous group by 82 and 25 
bp bands. 
Statistical Analyses 
 
All statistical comparisons were made using a statistical software package (SPSS; 
SPSS Inc; Chicago, IL, version 19). Group demographics were compared with a one-way 
analysis of variance (ANOVA) using an α level of 0.05 to determine significance. 
Genotype differences in performance were compared with an ANOVA using a Tukey 
post hoc test to detect differences among the specific genotype groups. An α level of 0.05 
was used for the ANOVA and post hoc analyses.  
 
RESULTS 
Subject Characteristics 
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There was no difference between genotype groups in age, weight, height, body 
mass index (BMI), or body surface area (BSA) (Table 1). 
 
(Table 1 here) 
Power Measures 
There were no differences in any of the power parameters (watts, watts/VO2, 
watts/kg) with light exercise. With heavy exercise, there were significant effects of 
genotype on power parameters (pANOVE<0.05) (Figure 1). Specifically, following post-
hoc analysis, it was determined that the Arg/Gly group achieved significantly higher 
watts (p=0.04) than the Arg/Arg group (237.8 ± 54.4, 186.3 ± 54.6, for AG and AA 
respectively, SE=20.67, 95% CI (2.00, 100.82)). Additionally, the Arg/Gly group had 
significantly greater relative power as measured by watts/kg (p=0.046) than the Arg/Arg 
group (3.2 ± 0.5, 2.7 ± 0.4, for AG and AA respectively, SE=0.202, 95% CI (0.007, 
0.97)). Further, the Arg/Gly group demonstrated significantly greater watts/VO2 
(p=0.034) than the Gly/Gly group (0.09 ± 0.005, 0.08 ± 0.006, for AG and GG 
respectively, SE=0.002, 95% CI (0.0003, 0.008)). There was no difference in watts/VO2 
between the Arg/Gly and Arg/Arg groups, nor were there any differences in VO2 
between genotype groups.  
 
(Figure 1 here) 
Intensity Measures 
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 Similar to power indices, there were significant genotype differences in indices of 
relative and perceived intensity. The Arg/Gly group demonstrated significantly higher 
watts/hr (p=0.019) than the Arg/Arg group (1.3 ± 0.3, 0.99 ± 0.3, for AG and AA 
respectively, SE=0.119, 95% CI (0.046, 0.62)) (Table 2). This is likely due to the ability 
of the Arg/Gly group to exercise at a lower relative intensity (higher peak watts while 
maintaining lower heart rates) (p=0.038; 181 ± 9.7, 189 ± 9.9, for AG and AA 
respectively,SE-2.97, 95% CI (0.35, 14.57)). Further, the Arg/Gly group reported lower 
RPEs (p=0.032) than the Arg/Arg group (18.6 ± 0.51, 18.9 ± 0.24, for AG and AA 
respectively, SE=0.15, 95% CI (0.03, 0.74)) despite producing higher watts (Figure 2). 
 
(Table 2 here) 
(Figure 2 here) 
DISCUSSION 
 
 In the present study we demonstrate that genetic variations of the ADRB2 are 
associated with differences in muscular power, efficiency and intensity. Individuals with 
one arginine and one glycine allele (Arg/Gly) demonstrated significantly higher peak 
power (watts), relative power (watts/kg), muscular efficiency (watts/VO2) and exercise 
intensity (watts/hr) during heavy, steady-state exercise. Interestingly, despite producing 
higher peak watts, the Arg/Gly group also reported significantly lower rating of perceived 
exertion (RPE). Similar to previous observations, although not statistically significant, 
individuals with at least one glycine allele (Arg/Gly and Gly/Gly) were heavier than 
those homozygous for arginine (68.5 ± 13.1, 75.1 ± 12.9, 74.4 ± 12.9, for AA, AG and 
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GG respectively). These findings may be due to the regulation of several downstream 
mechanisms by the ADRB2. 
 
 There are several pathways by where activation of the ADRB2 may regulate 
skeletal muscle size and strength. One such pathway is through phosphorylation by 
catecholamines. ADRB2s are g-coupled protein receptors where upon binding of a 
catecholamine to the receptor stimulates a dissociation of the guanine protein which 
phosphorylates adenylyl cyclase (AC). Adenylyl cyclase produces cAMP which 
phosphorylates protein kinase A (PKA) into its active form (2).  
 
The first process whereby ADRB2 activation may increase muscular size and 
strength is binding of a catecholamine to the ADRB2 resulting in dissociation of the 
guanine-linked subunits. Further, previous work suggests the Gαi-linked Gβγ subunits 
activate the phosphoinositide 3-kinase-protein kinase-B (PI3K-AKT) signaling pathway 
(28). The PI3K-AKT signaling pathway has been shown to regulate protein synthesis, 
gene transcription, cell proliferation, and cell survival (3, 12). Although there are three 
distinct isoforms of AKT, the predominant skeletal muscle isoform is AKT1. It has been 
demonstrated that AKT1 inhibits the forkhead box O transcription factors (FOXO) (36). 
This is significant because FOXO has been implicated in muscle atrophy (17). Thus, by 
phosphorylating and inactivating FOXO, AKT1 blocks the induction of FOXO-mediated 
atrophy signaling. Additionally, ADRB2 activation has been found to reduce the 
expression of FOXO-mediated atrophy signaling in skeletal muscle from denervated and 
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hindlimb-suspended rats (17). This suggests that the ADRB2 plays a functional role in 
attenuating skeletal muscle atrophy in addition to promoting skeletal muscle growth. 
Further study of the genotypes in disease models is certainly warranted. 
 
Another process by which ADRB2 stimulation may increase muscular size and 
strength is by phosphorylation of PKA via cAMP. PKA phosphorylation into its active 
state results in dissociation of the PKA subunits. It has been demonstrated that the free C-
subunits of PKA diffuse passively into the nucleus, where they have the capability for 
direct phosphorylation of multiple regulator genes of the cAMP response element binding 
protein (CREB) (6). CREB is a nuclear transcription factor that is universally expressed 
and has many processes, including cell proliferation, differentiation, adaptation, and 
survival (21). Current research suggests CREB plays a role in mediating the activity of 
the transcription factor myocyte enhancer factor-2 (MEF2), a family of transcription 
factors that play a key role in the differentiation of muscle cells (1). ADRB2 activation is 
also associated with an increased expression of neuron-derived orphan receptor-1 (NOR-
1) (24). Pearen et al (2006) also demonstrated siRNA-mediated inhibition of NOR-1 
expression was associated with a significant increase in the levels of myostatin mRNA. 
Myostatin is a member of the transforming growth factor-β superfamily and the primary 
negative regulator of muscle mass (24). This suggest the ADRB2 plays a functional role 
in the regulation of muscle mass through increased NOR-1 expression resulting in 
decreased myostatin levels promoting skeletal muscle growth. Collectively, these data 
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suggest the ADRB2 plays multiple roles in regulating skeletal muscle growth through 
downstream signaling. 
 
In addition to the mediation of internal cell signaling, stimulation of the ADRB2 
can also regulate Ca
2+
-mediated proteolysis. Both cAMP and phosphorylated PKA can 
either directly or indirectly inhibit calpain activity. Calpains are Ca
2+
-mediated proteases 
degrade myofibrils and by inhibiting calpain activity, myofibril size and integrity are 
preserved. This would decrease muscle damage and loss due to increased Ca
2+
 flux from 
exercise. Research has shown using a nonhydrolyzable cAMP analog and activation of 
ADRB2 to inhibit protein degradation in both rats and chicks, suggesting cAMP may 
directly phosphorylate calpains to inhibit activity (22, 23). Research also suggests PKA 
demonstrates the ability to phosphorylate calpains, which is important in the context of 
this study because increased ADRB2 activation attributed to the Gly16 genotype would 
result in increased PKA concentrations and decreased calpain activity and myofibril 
degradation. Studies in rat models have demonstrated a phosphorylation site at serine 369 
which would restrict domain movement and keep m-calpain in an inactive state, 
suggesting direct phosphorylation of calpain by PKA to have a negative-control effect on 
calpain activation (27, 29). The ability of cAMP and PKA to modulate calpain 
concentrations and activity suggests a mechanism whereby the Gly16 genotype may 
influence muscular size and strength. 
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Furthermore, ADRB2 stimulation may also regulate calpastatin activity, a 
calpain-specific inhibitor, thereby decreasing calpain concentrations and activity. Recent 
research has demonstrated that the calpastatin promoter sequence between nt -1653 and 
+130 contains a single cAMP binding site located at nt -76 (8). This suggests a direct 
pathway whereby cAMP signaling can lead to increased calpastatin gene transcription 
reducing calpain-mediated protein degradation. Further, multiple phosphorylation sites 
have been identified on calpastatin, particularly those found in the L and XL domain 
coded by exon 6, suggesting cAMP to have the ability to directly phosphorylate 
calpastatin (37). In addition to its ability to phosphorylate calpains, research suggests the 
C-domain of PKA can also directly phosphorylate calpastatin (25). These data suggest 
another pathway whereby ADRB2 stimulation may inhibit calpain activity and regulate 
muscle size and strength. 
 
Hence, there are multiple pathways whereby ADRB2 activation may increase 
muscle size, strength, and contractility as well as protect against disuse atrophy. These 
implications suggest ADRB2 stimulation as a viable supplementation site, thus 
improving sport performance and attenuating muscular loss resulting from injury. In the 
current study, the Arg/Gly polymorphism demonstrated significantly higher power 
measures, muscular efficiency, and exercise intensity. This suggests the more functional 
polymorphism of the ADRB2 may have an effect on these measures and that ADRB2 
stimulation may improve muscular size, strength, and contractility. 
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PRACTICAL APPLICATIONS 
 
There are many pathways by which the ADRB2 can influence muscular 
development and strength. This study suggests that genetic variations of the ADRB2 are 
associated with muscular power and efficiency. We hypothesize the improved muscular 
function in the Arg/Gly group could be due to increased lymphocyte density and 
resistance to downregulation associated with the Gly16 polymorphism resulting in 
increased accumulation of downstream products which have been implicated in the 
regulation of muscle size and strength. These findings may imply a novel, safe approach 
to the attenuation of muscle degradation associated with disuse atrophy resulting from 
injury and to the improvement of muscular power and efficiency in athletes. 
 
LIMITATIONS 
There are inherent limitations regarding a genetics study including sample size 
and genotype distribution. Limited statistical power because of the modest sample size 
and different genotype distribution in the present study (N = 77) may have played a role 
in limiting the significance of some of the statistical comparisons conducted. A post hoc 
power analysis revealed the power to detect statistically significant differences between 
groups for watts, watts/kg, and watts/VO2 to be .84, .95, and 1.00 respectively at α = 
0.05, suggesting sufficient sample size for the present study. Additionally, time of day 
and time of year for testing as well as training background were not controlled for in the 
present study, which may affect test-retest reliability. An intraclass correlation coefficient 
analysis revealed the test-retest reliability for watts, watts/kg, and watts/VO2 to be 0.52, 
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0.49, and 0.59 respectively, suggesting fair test-retest reliability. Therefore, we cannot 
rule out the influence of uncontrolled for variables on these measures. 
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TABLES 
 
Table 1. Subject characteristics (mean ± standard deviation, N or p-value) 
Study Demographics 
 N Mean SD p-value 
Age (years)             
Arg/Arg 
             Arg/Gly 
             Gly/Gly             
Total 
 
18 
24 
34 
76 
 
28.9 
27.9 
29.2 
28.7 
 
5.67 
5.74 
5.94 
5.76 
 
0.708 
Height (cm) 
          Arg/Arg 
             Arg/Gly 
             Gly/Gly             
Total 
 
18 
24 
34 
76 
 
170.8 
175 
173.5 
173.3 
 
8.61 
8.79 
9.67 
9.17 
 
0.341 
Weight (kg) 
          Arg/Arg 
             Arg/Gly 
             Gly/Gly 
Total 
 
18 
24 
34 
76 
 
68.5 
75.1 
74.4 
73.2 
 
13.06 
12.96 
12.93 
13.07 
 
0.214 
BMI (kg/m
2
)             
Arg/Arg 
             Arg/Gly 
             Gly/Gly 
Total 
 
18 
24 
34 
76 
 
23.4 
24.4 
24.7 
24.3 
 
3.85 
2.91 
3.39 
3.35 
 
0.448 
BSA (m
2
)           
Arg/Arg 
             Arg/Gly 
             Gly/Gly 
Total 
 
18 
24 
34 
76 
 
1.79 
1.90 
1.88 
1.87 
 
0.19 
0.20 
0.19 
0.20 
 
0.189 
VO2 (mL/min)          
Arg/Arg 
             Arg/Gly 
             Gly/Gly 
Total 
 
18 
24 
34 
76 
 
2257.83 
2712.12 
2613.41 
2562.34 
 
761.19 
629.37 
872.19 
784.55 
 
0.152 
VO2/KG             
Arg/Arg 
             Arg/Gly 
             Gly/Gly             
Total 
 
18 
24 
34 
76 
 
32.35 
36.29 
35.11 
34.85 
 
5.98 
5.61 
8.50 
7.18 
 
0.200 
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Arg/Arg = genotype (homozygous for ADRB2 resulting in arginine at amino acid 16), 
Arg/Gly = genotype (heterozygous for ADRB2 resulting in one arginine and one glycine 
at amino acid 16), and Gly/Gly = genotype (homozygous for ADRB2 resulting in glycine 
at amino acid 16). BMI = body mass index; BSA = body surface area; VO2 = maximal 
oxygen consumption; VO2/KG = maximal oxygen consumption corrected for kilogram. 
There were no statistically significant differences in demographic data. 
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Table 2. Indices of intensity (mean ± standard deviation, N or p-value) during peak 
exercise 
Indices of Intensity 
 N Mean SD p-value 
HR (beats/min) 
Arg/Arg 
Arg/Gly 
Gly/Gly 
Total 
 
18 
24 
34 
76 
 
188.5 
181.0 
186.9 
185.4 
 
9.89 
9.68 
9.43 
9.98 
 
0.024* 
RPE 
Arg/Arg 
Arg/Gly 
Gly/Gly 
Total 
 
18 
24 
34 
76 
 
18.94 
18.56 
18.76 
18.74 
 
0.24 
0.51 
0.55 
0.49 
 
0.039* 
RER 
Arg/Arg 
Arg/Gly 
Gly/Gly 
Total 
 
18 
24 
34 
76 
 
1.16 
1.15 
1.15 
1.15 
 
0.015 
0.010 
0.010 
0.006 
 
0.836 
RR 
(breaths/min) 
Arg/Arg 
Arg/Gly 
Gly/Gly 
Total 
 
18 
24 
34 
76 
 
43.17 
40.84 
39.74 
40.90 
 
2.10 
1.38 
1.21 
0.86 
 
0.295 
HR = heart rate; RPE = rating of perceived exertion; RER = respiratory exchange ratio; 
RR = respiratory rate.  
*p< 0.05  
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FIGURE LEGENDS 
 
Figure 1. 
Panels depict the maximum values during peak exercise for A) Watts, B) Relative power 
(Watts/KG), and C) Muscular efficiency (Watts/VO2). The error bars represent the SE of 
the mean.  
*p<0.05 for Arg/Arg vs Arg/Gly pairwise comparison.  
**p<0.05 for Arg/Gly vs Gly/Gly pairwise comparison. 
 
Figure 2. 
Depicts maximal watts corrected for heart rate at peak exercise. The error bars represent 
the SE of the mean.  
*p<0.05 for Arg/Arg vs Arg/Gly pairwise comparison. 
 
Table 1. 
Arg/Arg = genotype (homozygous for ADRB2 resulting in arginine at amino acid 16), 
Arg/Gly = genotype (heterozygous for ADRB2 resulting in one arginine and one glycine 
at amino acid 16), and Gly/Gly = genotype (homozygous for ADRB2 resulting in glycine 
at amino acid 16). BMI = body mass index; BSA = body surface area; VO2 = maximal 
oxygen consumption; VO2/KG = maximal oxygen consumption corrected for kilogram. 
There were no statistically significant differences in demographic data. 
Table 2. 
HR = heart rate; RPE = rating of perceived exertion; RER = respiratory exchange ratio; 
RR = respiratory rate.  
*p< 0.05  
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ABSTRACT 
Background: As respiratory care in Duchenne muscular dystrophy (DMD) patients 
improve, cardiomyopathies are emerging as significant contributors to mortality. The 
Gly389 polymorphism of the β1-adrenergic receptor (ADRB1) has been associated with 
favorable cardiac outcomes and decreased mortality risk in heart failure patients.  
Purpose: The aim of this study was to determine the influence of ADRB1 genotype on 
risk of cardiac events in DMD patients.  
Methods: Data from CINRG-DNHS including 175 DMD patients (ages 3-25 yrs) with 
up to 9.7 years follow-up were analyzed focusing on ADRB2 functional variants 
(Arg389, n = 80; Gly389, n = 95).  We performed Cox proportional hazard and Kaplan-
Meier time to event analyses for the risk of cardiac events in DMD patients.  
Results: There were no differences between ADRB1 genotype groups in age, height, 
weight, number of ambulatory patients, or age of loss of ambulation in our DMD cohort. 
The Arg389 polymorphism demonstrated a higher mean corticosteroid use compared 
with the Gly389 polymorphism (3.89±0.50 yrs vs 3.03±0.38 yrs, respectively, P=0.05). 
There were differences between ADRB1 genotype groups in risk of congestive heart 
failure or prescription of cardiac medication including inotropic agents, beta-blockers 
(BB), and idebenone for cardiac issues at any given age. The genotype groups differed 
significantly in the incidence of diuretics use with the Gly389 polymorphism 
demonstrating a 5.01-fold increased risk of diuretics use at any age compared with the 
Arg389 polymorphism.  
Conclusion: These data suggest ADRB1 genotype may influence the incidence of 
diuretics use in DMD patients. However, the variability of cardiac management in 
patients with DMD may confound these findings and explain the lack of findings for 
other cardiac events included in this analysis. 
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1. INTRODUCTION 
As respiratory care for Duchenne muscular dystrophy (DMD) patients improves, an 
emerging source of morbidity and mortality is cardiomyopathy leading to heart failure 
(HF) and dangerous arrhythmias [9]. In fact, an estimated 20% of DMD patients will die 
of congestive HF [6]. Subclinical cardiomyopathies, most typically left ventricular 
failure, associated with DMD are first evident at ten years of age and are present in 90% 
of DMD patients over the age of 18 [8]. However, approximately 70% of patients with 
DMD remain asymptomatic at cardiomyopathy diagnosis [9]. While cardiomyopathy in 
DMD patients is less often treated at diagnosis than other cardiomyopathies, treatment 
rates have increased [9]. Unfortunately, it has been demonstrated that the DMD 
cardiomyopathy has higher mortality rates than other dilated cardiomyopathies [9]. 
Additionally, there is a concomitant decline in respiratory and cardiac function in DMD 
patients, either from dependent or independent pathologies [4, 10, 11]. Further, left 
ventricular dysfunction secondary to cardiomyopathy is a strong predictor of mortality in 
patients with DMD [7]. Therefore, understanding the factors that affect the incidence of 
cardiac events in patients with DMD may provide therapuetic targets to delay the 
development of cardiomyopathy and decrease the risk of mortality in this population.   
The cardiac-specific mechanisms of dystrohpin deficiency result in disruption of 
membrane ion channel function, particularly the sarcolemmal stretch-activated channels 
— further increasing Ca2+ flux, activating calpains, and increasing cardiomyocyte 
necrosis [13, 14]. This cardiomyocyte necrosis initiates an inflammatory response and the 
replacement of cardiomyocyte tissue with fibrofatty tissue [12]. The myocardial fibrosis 
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associated with DMD, initially appearing in the left ventricular and gradually spreading 
to encompass the entire ventricle, gradually stretches, becomes thinner, and loses 
contractility [13]. The result of this systolic dysfunction is decreased cardiac output and 
hemodynamic decompensation and is the major contributor to the left ventricular 
dysfunction accompanying DMD [13]. Furthermore, previous work has estimated that 
71% of DMD patients had evidence of electocardiographic abnormalities with 32% of 
those having frequent premature ventricular complexes, 28% with ventricular late 
polarizations, and 35% having left ventricular systolic dysfunction [7]. The systolic 
dysfunction associated with DMD cardiomyopathy can be attributed to two main 
mechanisms: increased cardiac work and altered Ca
2+
 handling [12-14]. Due to the 
progressive nature of the cardiac involvement in DMD, it is imperative that target 
pathways are identified to slow cardiomyocyte degradation and decrease the risk of 
adverse cardiac events. 
One pathway that has been identified as capable of preserving cardiac function in 
cardiomyopathies is the β1-adrenergic receptor (ADRB1) coupled pathway [16-20]. The 
ADRB1 subtype is found primarily in the heart, comprising about 80% of total beta 
adrenergic receptors found in the heart and playing a role in cardiac function [16, 21-23]. 
Furthermore, ADRB1 activity has been shown to influence cardiac: (i) inotropy, 
lusitropy, and chronotropy [24, 25]; (ii) nuclear and perinuclear Ca
2+
 handling [26]; (iii) 
reuptake of cytosolic Ca
2+
 [27]; and (iv) cardiomyocyte relaxation [22, 28]. Given the 
above mentioned mechanisms, the ADRB1 may play a role in preserving cardiac function 
in patients with DMD. 
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A polymorphism of the ADRB1 that affects functionality includes a glycine (Gly) for 
arginine (Arg) substitution at amino acid 389 [16, 17, 22, 23]. Specifically, the Gly389 
polymorphism demonstrates decreased receptor density and cAMP accumulation and a 
dampening response to norepinephrine infusion [16, 24, 261]. Functionally, HF patients 
with the Gly389 polymorphism have significantly lower diastolic, systolic, and mean 
arterial blood pressure — contributing to improved cardiac function and decreased 
mortality risk [17-19, 29]. Furthermore, literature demonstrates autoantibodies against 
ADRB1 are associated with more favorable myocardial recovery in patients with recent-
onset cardiomyopathy [20]. The association between the Gly389 polymorphism and more 
favorable cardiac measures and outcomes in HF patients suggest a therapeutic target for 
preserving cardiac function and delaying cardiomyopathy in patients with DMD. 
However, to date, there is no literature investigating the relationship between ADRB1 
genotype and cardiac events in DMD patients. 
The aim of this study was to investigate the influence of ADRB1 genotype on the 
incidence of cardiac events in patients with DMD at any given age. Given the ADRB1 
Gly389 polymorphism is associated with improved cardiac function and favorable 
outcomes in HF patients, we hypothesize DMD patients with the Gly389 polymorphism 
would have a lower incidence of cardiac events when compared with DMD patients with 
the Arg389 polymorphism. 
2. METHODS 
2.1 Participants 
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Data analyzed for this study were a part of a larger dataset from the Cooperative 
International Neuromuscular Research Group Duchenne Natural History Study (CINRG-
DNHS). All participants included in this study and/or their legal guardians 
consented/assented specifically to genotyping of genetic variants for research purposes, 
and the study was approved by local institutional or ethics review boards at each 
participating institution. One-hundred seventy-five patients with a clinical diagnosis of 
DMD (ages 3-25 years at entry into the study) were identified and included in the dataset 
used in this study. Patients were followed for a maximum of 9.7 years. This study 
focused on a functional ADRB1 protein altering variant at codon 389 employing an 
Exome Chip (a technique for sequencing all of the protein-coding genes in a genome). 
Exome Chip genotyping and data cleaning methods in the CINRG-DNHS cohorts have 
been previously described [3]. Patients were homozygous for arginine (AA, n = 11), 
glycine (GG, n = 95), or heterozygous (AG, n = 69) at codon 389.  
2.2 Data Analyses 
Patient age, height, weight, corticosteroid use, and ambulatory status at entry into the 
study were obtained from the CINRG-DNHS database. All reported patient heights were 
calculated from ulnar length, as described by others [262]. Corticosteroid use was derived 
from clinically reported start and stop dates. Cardiac events in the analyses included age 
of: congestive HF hospitalization, other cardiovascular issues (tachycardia, arrhythmia, 
and elective admission for cardiac prophylactic), and prescription of cardiovascular 
medication (i.e. angiotensin converting enzyme inhibitor (ACEI) or angiotensin-receptor 
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blocker (ARB), diuretics, cardiac inotropic agents, beta-blockers (BBs), idebenone for 
cardiac issues, and other cardiovascular medications).9 
2.3 Statistical Analyses 
Group demographics were compared using a one-way analysis of variance (ANOVA). 
Genotype differences in the incidence of cardiac events at any given age were estimated 
by a Kaplan-Meier analysis and the log-rank test. A Cox proportional hazard (PH) model 
was used to examine the effects of genotype variant on the incidence of cardiac events in 
DMD patients, after adjusting for patient height, weight, ambulatory status, and 
corticosteriod use. An additional Cox PH analysis with the inclusion of clinic site (20 
clinic sites) as a covariate was used to examine the variability of medication prescription 
between clinic sites. Time dependence of the covariates was ruled out after inspection of 
the Schoenfeld residuals scores [263]. We chose to group genotypes as Gly389 and 
Arg389 because preliminary analyses of the data demonstrated no difference between 
polymorphisms containing at least one arginine. This genotype grouping is consistent 
with previous literature [16-19, 22, 23, 29]. When we collapsed the genotype groups into 
functionally similar groups, patients were homozygous for glycine (Gly389, n = 95) or 
homozygous for arginine or heterozygous (Arg389, n = 80). This genotype grouping 
improves ease of interpretation. For all covariates entered into the Kaplan-Meier and Cox 
PH analyses, outliers were identified as observations above or below the 1.5 times 
interquartile range (IQR). All statistical comparisons were made using a statistical 
software packages (RStudio; RStudio Inc., Boston, MA, USA, version 1.1.456). 
Statistical analyses were considered significant if P<0.05. 
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3. RESULTS 
3.1 Subject Characteristics 
There was no difference in age, height, weight, number of patients on corticosteroids, 
number of ambulatory patients, or age of loss of ambulation between genotype groups 
(Table 1). There was no significant difference between genotype groups for corticosteroid 
use in years (3.03 ± 0.38 vs. 3.85 ± 0.50 for Arg389 and Gly389 respectively).  
3.2 Kaplan-Meier Analysis 
The Kaplan-Meier analysis did not identify a difference in probability of cardiac events 
in DMD patients for age of congestive HF and other cardiovascular issues or prescription 
of cardiovascular medication including: ACEI, ARB, cardiac inotropic agents, BBs, 
idebenone for cardiac issues, and other cardiovascular medications. For the age of 
diuretics use, three observations were identified as outliers in a preliminary analysis of 
the Kaplan-Meier analysis and omitted from further analyses (172 observations 
remaining). The results of the Kaplan-Meier analysis for age of diuretics use are 
illustrated in Figure 1. Kaplan-Meier mean and median ages of first use of diuretics are 
presented in Table 2. The Gly389 polymorphism demonstrated a higher probability 
(P<0.05) for the use of diuretics at any given age compared with the Arg389 
polymorphism (22.06±3.12 yrs. vs. 19.03±1.73 yrs respectively). 
3.3 Cox Proportional Hazard 
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The Cox PH analysis did not identify a difference in the incidence of congestive heart 
failure or prescription of cardiac medication including inotropic agents, BBs, and 
idebenone for cardiac issues at any given age. The Cox PH analysis determined a 
significant difference in the incidence for other cardiac issues and use of ACEI, ARB, 
and other cardiovascular medications at any given age. 
3.3.1 Diuretics 
Eleven observations were identified as outliers in a preliminary analysis of the PH 
analysis and omitted from further analyses (164 observations remaining). The results of 
the Cox PH are presented in Table 3. Height and weight were strong, negative predictors 
of the incidence of diuretics use at any given age in patients with DMD (P<0.05). 
ADRB1 genotype was identified as a strong, positive predictor of diuretic use (P<0.05). 
Specifically, DMD patients with the Gly389 polymorphism were 5.01 times more likely 
to be given diuretics at any given age compared with patients with the Arg389 
polymorphism.  
3.3.2 Other Cardiac Issues 
Twelve observations were identified as outliers in a preliminary analysis of the PH 
analysis and omitted from further analyses (163 observations remaining). Corticosteroid 
use was a strong, negative predictor of the incidence of other cardiac issues at any given 
age in patients with DMD (P<0.05).  
3.3.3 Angiotensin Converting Enzyme Inhibitor and Angiotensin-Receptor Blocker 
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Ten observations were identified as outliers in a preliminary analysis of the PH analysis 
and omitted from further analyses (165 observations remaining). Corticosteroid use and 
height were strong, negative predictors of the incidence of ACEI and ARB use at any 
given age in patients with DMD (P<0.05). 
 3.3.4 Other Cardiovascular Medications 
Ten observations were identified as outliers in a preliminary analysis of the PH analysis 
and omitted from further analyses (163 observations remaining). Height was a strong, 
negative predictors of the incidence of the use of other cardiovascular medications at any 
given age in patients with DMD (P<0.05). 
4. DISCUSSION 
Our original hypothesis was that DMD patients with the Gly389 polymorphism would 
have a lower incidence of cardiac events compared with those expressing Arg389 
polymorphism. The principle findings of this study were that DMD patients with the 
Gly389 polymorphism of the ADRB1 had a higher incidence of diuretics use compared 
with those patients expressing the Arg389 polymorphism. Specifically, patients with the 
Gly389 polymorphism were 5.01 times more likely to be on diuretics compared with 
patients with the Arg389 polymorphism at any given age. Furthermore, ADRB1 genotype 
had no influence on the incidence of other cardiac events included in this study. 
However, corticosteroid use was a negative predictor of the incidence of other cardiac 
issues and ACEI and ARB use and height was a negative predictor of the incidence of 
ACEI, ARB, and other cardiovascular medications use. The present study refutes our 
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hypothesis and demonstrates DMD patients with the Gly389 polymorphism may have an 
increased incidence of diuretics use compared with patients with the Arg389 
polymorphism and that ADRB1 genotype has no influence on other cardiac events in 
these patients. 
As respiratory management in DMD patients improves, the development of 
cardiomyopathies and the accompanying left ventricular dysfunction is emerging as a 
significant contributor to mortality in this population [6-8]. While cardiomyopathies are 
present in 90% of DMD patients over the age of 18, only 30% of patients present with 
symptoms at the time of diagnosis [8, 9]. Furthermore, a majority of DMD patients with 
normal left ventricular function exhibited dysfunctional myocardial strain at the 
posterolateral wall (the initial site of fibrofatty deposition in myocardium), suggesting 
abnormal myocardial contraction before left ventricular decompensation [13, 264]. The 
cardiomyopathy associated with DMD has a higher mortality than other dilated 
cardiomyopathies but often remain less treated at diagnosis [9]. Further, left ventricular 
dysfunction secondary to cardiomyopathy is a strong predictor of mortality in patients 
with DMD [7]. Therefore, understanding the factors that affect the incidence of cardiac 
events in patients with DMD may provide therapuetic targets to delay the development of 
cardiomyopathy and decrease the incidence of mortality in this population.   
The multifactorial nature of the cardiac involvement in DMD necessitates a battery of 
therapy options to treat cardiomyopathy symptoms and limit the side-effect profile [82]. 
Both the DMD Care Considerations Working Group and the European Society of 
Cardiology guidelines recommend ACEI as first-line therapy for dilated cardiomyopathy 
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and/or congestive heart failure in DMD patients [82, 91, 101]. However, the side-effect 
profile of ACEI, such as cough, renal dysfunction, hyperkalemia, and angioedema, led 
to the testing of ARBs as a replacement therapy for cardiac dysfunction [265-267]. 
These findings have led to ACEIs and ARBs becoming more mainstream therapy in 
patients with DMD [9]. Additionally, the American Academy of Pediatrics recommends 
considerations to be given to the use of diuretics in the treatment of cardiomyopathy in 
DMD patients [97]. Secondary to cardiomyopathy, DMD patients also present with 
tachycardia and other arrhythmias [98]. These additional complications present further 
clinical care considerations and signal the emergence of extensive fibrofatty deposition 
and conduction disorders [268]. Additional therapies used to address these clinical 
considerations in our cohort included Ca
2+
 channel blockers, blood thinners, and 
cholesterol lowering drugs.  
Current research and clinical findings in the literature has led investigators to suggest the 
use of diuretics to treat tachycardia and lipothymia in later stages of cardiac involvement 
in DMD patients [98]. Despite the efficacy of diuretic therapy in the treatment of HF and 
recommendations for diuretic considerations in DMD patients, clinical adoption is slow 
[99]. In our study population, only 18 patients were prescribed a diuretic at any point (14 
and four for Gly389 and Arg389 respectively). However, the Cox PH analysis determined 
genotype, height, and weight to be strong predictors of diuretic use in DMD patients. 
Specifically, DMD patients with the Gly389 polymorphism were approximately 5 times 
more likely to be on diuretics compared with patients with the Arg389 polymorphism at 
any given age.  
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In light of the burden of literature demonstrating the beneficial influence of the Gly389 
polymorphism in cardiac outcomes and mortality in HF patients, the contradictory 
findings of this study may be difficult to explain. One explanation is the lack of 
widespread clinical adoption of specific guidelines for treatment of cardiomyopathy in 
patients with DMD. Despite a greater appreciation for the clinical importance of DMD 
cardiomyopathy, cardiac management strategies are highly variable and remain 
underutilized in this population [9, 100]. Currently, there is no consensus on the proper 
pharmacological therapy class and timing for treatment of cardiomyopathy in DMD 
patients [101]. This is demonstrated by the Cox PH model including clinic site as an 
additional covariate with 5 clinic sites differing significantly in the prevalence of 
diuretics prescription at any given age. Given this, the variability of cardiac management 
for DMD patients in different clinics may explain these contradictory findings. 
Other factors influencing incidence of cardiac events in DMD patients 
The Cox regression analysis also demonstrated that corticosteroid use and height were 
significant predictors of diuretics use in DMD patients. Firstly, it is not surprising that 
corticosteroid use decreases the incidence of diuretics use in our cohort, given that 
corticosteroid use has been demonstrated to delay the emergence of cardiomyopathy and 
decrease cardiac-associated mortality [10]. That height was a negative predictor of 
diuretics use is harder to explain; height has been positively correlated with cardiac 
function, but this relationship has not been demonstrated in DMD patients [269]. 
Furthermore, the Cox regression analysis demonstrated that corticosteroid use was a 
significant predictor of ACEI and ARB use, and was a significant predictor of the 
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incidence of presenting with other cardiac issues (i.e. tachycardia, arrhythmia, and 
elective admission for cardiac prophylactic). Height was also identified as a strong 
predictor of ACEI, ARB, and other cardiac medications use in our cohort. 
 Limitations 
Our cohort included DMD patients who were homozygous for arginine (AA, n = 11), 
glycine (GG, n = 95), or heterozygous (AG, n = 69) at codon 389 and were collapsed into 
two study groups (Gly389, n = 95 and Arg389, n = 90). This even genotype distribution 
is surprising given the frequency in the healthy population (0.70 and 0.30 for Arg389 and 
Gly389 respectively) [270]. However, there is no data available regarding ADRB1 389 
genotype frequency in a DMD population. Furthermore, the DNHS protocol did not 
specify when clinicians should prescribe diuretics to a patient. The variability of diuretic 
prescription between clinicians is demonstrated by the influence of clinic site on the 
prevalence of diuretics prescription. A second consideration is the number of events in 
our data. It is generally recommended that for each covariate, a minimum of 10 events 
are needed to ensure statistical power. In our analysis including 5 variables, 50 events are 
needed. Our cohort only had 18 DMD patients who were prescribed diuretics, violating 
this rule. However, literature has demonstrated a range of circumstances in which 
coverage and bias standards were adequate with fewer than 10 events per variable, 
suggesting the rule of 10 events per variable may be relaxed [271]. Another consideration 
is the longitudinal nature of the study. As such, the data acquisition utilized a rolling 
accrual, resulting in left-truncated data, which may influence the accuracy of the Cox 
model to identify the age of first diuretics use and therefore the incidence of diuretics use. 
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However, the aim of this study was to determine the influence of ADRB1 genotype on 
the incidence of diuretics use and there is no reason to believe genotype as a covariate 
would influence the model’s accuracy to identify the timing of first use of diuretics in our 
cohort. 
5. CONCLUSION 
 
The findings of this study suggest that DMD patients with the Gly389 polymorphism 
have a significantly higher incidence of diuretics use compared with patients expressing 
the Arg389 polymorphism. Specifically, the Gly389 polymorphism is 5 times more likely 
to use diuretics compared with the Arg389 polymorphism. However, there remains high 
variability in the type and timing of implementation of cardiac management therapies for 
DMD patients. This variability may present complications in studies of this nature in the 
future. With cardiomyopathies continuing to emerge as a significant contributor to 
mortality and the related decline in cardiac and respiratory function, it is important to 
identify the factors that contribute to cardiac dysfunction in DMD patients. Therefore, it 
is important that clinical guidelines are established and clinically adopted regarding 
cardiac management in the DMD population. 
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FIGURE CAPTIONS 
 
Figure 1. Cumulative risk of diuretics use in Duchenne muscular dystrophy (DMD) 
patients stratisfied by β1-adrenergic receptor genotype (Arg389 and Gly389). The 
risk incidence of diuretics use in DMD patients was calculated from the survival curve 
produced by the Kaplan-Meier analysis. 
Figure 2. The cumulative risk of diuretics use in Duchenne muscular dystrophy 
(DMD) patients stratisfied by β1-adrenergic receptor genotype (Arg389 and 
Gly389). The cumulative risk function was obtained from Cox regression modeling of 
the risk of diuretics use, where genotype group, ambulatory status, corticosteroid-use, and 
height were entered into the model as covariates. The risk curve was produced for each 
genotype variant by holding all other covariates in the Cox model constant at their 
respective means (Height = 140.87cm, weight = 42.99kg, corticosteroid use = 3.4yrs, 
ambulatory status = 0.55).   
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TABLES 
Table 1. Subject characteristics, corticosteroid use status, corticosteroid use in 
years, ambulatory status, and age of loss of ambulation. 
  N (%) Mean SE p-value 
Age (yrs)      
 Arg389 — 12.72 0.69 0.55 
 Gly389 — 12.19 0.55  
 Total — 12.43 0.44  
Height (cm)      
 Arg389 — 140.19 2.45 0.70 
 Gly389 — 141.44 2.29  
 Total — 140.86 1.67  
Weight (kg)      
 Arg389 — 42.78 2.57 0.91 
 Gly389 — 43.18 2.31  
 Total — 42.99 1.71  
Corticosteroid Use Status and       
Corticosteroid Use (yrs) Arg389 57 (71%) 3.85 0.50 0.05 
 Gly389 65 (68%) 3.03 0.38  
 Total 122 (70%) 3.40 0.31  
Ambulatory Status and      
Age of Loss of Ambulation (yrs) Arg389 46 (58%) 9.97 0.57 0.98 
 Gly389 51 (54%) 9.99 0.49  
 Total 97 (55%) 9.98 0.37  
SE: standard error; Arg389: patients who were homozygous for the β1-adrenergic 
receptor (ADRB2) resulting in an arginine substitution at amino acid 389 (n = 90), 
Gly389: patients who were homozygous or heterozygous for the β1-adrenergic receptor 
(ADRB1) resulting in at least one glycine substitution at amino acid 389 (n = 95); N are 
reported as number of non-ambulatory patients and patients on corticosteroids and 
percent of the total study population. 
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Table 2. Kaplan-Meier mean and median ages at first use of diuretics in patients 
with Duchenne muscular dystrophy (DMD).  
 Mean Age Median Age 
 Estimate 
(yrs) 
SE 95% CI Estimate (yrs) SE 95% CI 
  
Arg389 
  22.06* 3.12 15.94 – 28.18   22.99* 2.07 18.94 – 27.03 
  Gly389 19.03 1.73 16.09 – 21.97 16.86 0.78 15.33 – 18.38 
  
Overall 
19.70 1.49 16.76 – 22.64 18.47 1.01 16.49 – 20.44 
SE: standard error; CI: confidence interval; Arg389: patients who were homozygous for 
the β1-adrenergic receptor (ADRB1) resulting in an arginine substitution at amino acid 
389 (n = 90), Gly389: patients who were homozygous or heterozygous for the β1-
adrenergic receptor (ADRB1) resulting in at least one glycine substitution at amino acid 
389 (n = 95); *P <0.05 
 
. 
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Table 3. Cox regression analysis for risk of diuretics use at any given age in patients 
with Duchenne muscular dystrophy (DMD). 
 β SE Wald p-value HR 95% CI 
Genotype 1.61 0.78 2.06 <0.05 5.01 1.08 – 23.2
8 
Ambulatory Status 0.23 0.85 0.27 0.79 1.26 0.24 – 6.65 
Corticosteroid Use (yrs) – 
0.17 
0.09 –1.91 0.06 0.84 0.70 – 1.00 
Height (cm) – 
0.13 
0.04 –3.54 <0.05 0.88 0.83 – 0.95 
Weight (kg) 0.07 0.02 2.83 <0.05 1.07 1.02 – 1.13 
SE: standard error; HR: hazard ratio; CI: confidence interval; genotype was coded as: 0 = 
Arg389: patients who were homozygous for the β1-adrenergic receptor (ADRB2) 
resulting in an arginine substitution at amino acid 389 (n = 90), 1 = Gly389: patients who 
were homozygous or heterozygous for the β1-adrenergic receptor (ADRB1) resulting in at 
least one glycine substitution at amino acid 389 (n = 95); ambulatory status was coded as: 
0 = non-ambulatory, 1 = ambulatory; there was a significant influence of genotype, 
height, and weight on risk of diuretics use. 
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FIGURES 
Figure 1. Cumulative risk of diuretics use in Duchenne muscular dystrophy (DMD) 
patients stratified by β1-adrenergic receptor genotype (Arg389 and Gly389). 
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Figure 2. The cumulative risk of diuretics use in Duchenne muscular dystrophy 
(DMD) patients stratified by β1-adrenergic receptor genotype (Arg389 and Gly389). 
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ABSTRACT 
The purpose of this study was to identify the influence of beta-2 adrenergic receptor 
(ADRB2) genotype on the risk of nocturnal ventilatory use in Duchenne muscular 
dystrophy (DMD). Data from CINRG-DNHS including 175 DMD patients (3-25 yrs) 
with up to 9.7 years follow-up were analyzed focusing on ADRB2 genotype variants. 
Time-to-event analyses were used to examine differences in the age at “first use” of 
nocturnal ventilation (NV) differed between genotypes. There were no differences 
between genotype groups in age, height, weight, corticosteroid use, or number of 
ambulatory patients, or age of loss of ambulation. DMD patients expressing the Gly16 
polymorphism had a significantly (P<0.05) lower mean age at “first use” of NV 
compared with those patients expressing the Arg16 polymorphism (21.80±0.59 yrs vs 
25.91±1.31 yrs, respectively). In addition, a covariate-adjusted Cox model revealed that 
the Gly16 variant group possessed a 2.77-fold higher risk of using NV at any given age 
compared with the Arg16 polymorphism group. These data suggest that genetic 
variations in the ADRB2 gene may influence the age at which DMD patients are first 
prescribed NV , whereby patients with the Gly16 polymorphism are more likely to 
require NV assistance at an earlier age than their Arg16 counterparts.  
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1. INTRODUCTION 
It is estimated that 32% of Duchenne muscular dystrophy (DMD) patients suffer from 
nighttime alveolar hypoventilation as a result of sleep-disordered breathing [3]. Sleep-
disordered breathing in this population is a result of respiratory weakness, and is 
associated with cardiac morbidity, neurocognitive deficits, and impaired lung function [3, 
30]. As disease status worsens, the progressive weakening of respiratory muscles results 
in a loss of sufficient respiratory pressure generation to maintain adequate alveolar 
ventilation, leading to constant alveolar hypoventilation [31]. Sleep-disordered breathing 
tends to precede daytime hypoventilation in patients with DMD, the latter of which is a 
significant contributor to hospitalization and mortality rates in this population [116]. The 
age at first use of NV is therefore considered an important clinical milestone in these 
patients, and indicates significant respiratory derangement [3, 4]. It is therefore important 
to understand the factors which affect the risk of NV use, such that we may identify novel 
therapeutic interventions to delay its prescription, and offset the progression to day-time 
ventilator assistance, ultimately decreasing hospitalization and mortality rates, and 
improving quality-of-life. 
Respiratory muscle weakness in DMD is characterized by a progressive loss in the ability 
to generate respiratory pressures, resulting in severe ventilatory derangements [33, 34]. 
Decreases in respiratory pressure and airflow generation can be attributed to a primary 
weakness of the diaphragm secondary to intramuscular remodeling in DMD [33]. This 
remodeling is characterized by an increased resting diaphragm thickness due to an 
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infiltration and deposition of non-contractile elements (pseudo-hypertrophy), concomitant 
with the loss of sarcomeres in series [35, 36]. Diaphragm pseudo-hypertrophy, and the 
loss of sarcomeres in series, together adversely affect the length-tension relationship and 
contractility of the diaphragm [35]. Due to the progressive nature of respiratory weakness 
in DMD, it is imperative that therapeutic targets are identified to slow respiratory muscle 
degradation, and thus decrease the risk of NV prescription.  
One novel pathway that has been identified as capable of attenuating skeletal muscle 
degradation in DMD is the β2-adrenergic receptor (ADRB2) coupled pathway [42, 43, 45, 
46]. β2-adrenergic receptors influence bulk muscle size, strength and regeneration [12, 
13]. ADRB2 stimulation has also been shown to: (i) increase diaphragmatic cross-
sectional area, strength, and contractility [43, 45, 46]; (ii) improve mucociliary clearance 
[47, 50, 51]; (iii) inhibit inflammatory pathways [53, 54, 56, 58, 60]; and to (iv) inhibit 
calpain activity and decrease concentration [62, 63, 65, 66, 69]. In light of the above, the 
functionality of ADRB2 may play a significant role in the protection of respiratory 
muscles from dystrophic pathways, and provide a novel therapeutic target in DMD to 
delay the use of NV. 
A polymorphism of the ADRB2 that improves receptor functionality includes the 
substitution of glycine (Gly) for arginine (Arg) at amino acid 16. The Gly16 
polymorphism is globally expressed, has a higher receptor density, and is more resistant 
to receptor down-regulation than its Arg16 counterpart [202, 272]. The Gly16 
polymorphism is associated with sustained bronchodilation at rest and following intense 
exercise, and improved lung function in healthy pediatric patients and patients with heart 
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failure [29, 273, 274]. The association between the Gly16 polymorphism and improved 
lung function in healthy and diseased populations suggests a possible therapeutic target 
for preserving respiratory function and the delaying of NV usage in DMD patients. 
However, to date, no studies have investigated the influence of ADRB2 genotype and the 
risk of NV use in this clinical population. 
The aim of this study was to examine the influence of ADRB2 genotype on the risk of 
NV prescription in patients with DMD. Given that ADRB2 stimulation may provide 
several benefits to respiratory function (e.g., increased diaphragmatic contractility, 
improved mucociliary clearance, inhibited inflammatory pathways and calpain activity), 
we hypothesized that DMD patients with the more “functional” ADRB2 polymorphism 
(i.e., Gly16) would demonstrate a lower risk of NV use compared with DMD patients 
expressing the less functional polymorphism (i.e., Arg16). 
2. METHODS 
2.1 Participants 
Data analyzed for this study were a part of a larger dataset from the Cooperative 
International Neuromuscular Research Group Duchenne Natural History Study (CINRG-
DNHS). All participants included in this study and/or their legal guardians consented 
specifically to genotyping of genetic variants for research purposes, and the study was 
approved by local institutional or ethics review boards at each participating institution. 
One-hundred seventy-five patients with a clinical diagnosis of DMD (ages 3-25 years at 
entry into the study) were identified and included in the dataset used in this study. 
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Patients were followed for a maximum of 9.7 years. This study focused on a functional 
ADRB2 protein altering variant at codon 16 employing an Exome Chip (a technique for 
sequencing all of the protein-coding genes in a genome). Exome Chip genotyping and 
data cleaning methods in the CINRG-DNHS cohorts have been previously described 
[275]. Patients were homozygous for arginine (AA, n = 26), glycine (GG, n = 59), or 
heterozygous (AG, n = 90) at codon 16.  
 
2.2 Data Analyses 
Patient age, height, weight, corticosteroid use, and ambulatory status at entry into the 
study were obtained from the CINRG-DNHS database. All reported patient heights were 
calculated from ulnar length, as described by others [262]. Corticosteroid use was derived 
from clinically reported start and stop dates. Nocturnal ventilation status was determined 
by the clinic visit at which full-time NV (e.g., Bi-PAP mask, n = 40; Bi-PAP nasal 
pillows, n = 9; C-PAP, n = 3; and mouthpiece, n = 3) was first prescribed to the patient.  
2.3 Statistical Analyses 
Group demographics were compared using a one-way analysis of variance (ANOVA). To 
investigate differences among the specific genotype groups, a Tukey honest significant 
difference (HSD) post-hoc comparison was used. Genotype differences in the risk of NV 
use at any given age were estimated by a Kaplan-Meier analysis and the log-rank test. A 
Cox proportional hazard (PH) model was used to examine the effects of genotype variant 
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on the risk of NV in DMD patients, after adjusting for patient height, weight, ambulatory 
status, and corticosteriod use. Time dependence of the covariates was ruled out after 
inspection of the Schoenfeld residuals scores [263]. We chose to group ADRB2 
genotypes as homozygous for arginine at amino acid spot 16 (Arg16, n = 26) and 
homozygous or heterozygous for ADRB2 resulting in at least one glycine at amino acid 
16 (Gly16, n = 149) because preliminary analyses of the data demonstrated no difference 
between polymorphisms containing at least one glycine. This genotype grouping 
improves ease of interpretation and is consistent with previous literature [273, 274, 276]. 
For all covariates entered into the Kaplan-Meier and Cox PH analyses, outliers were 
identified as observations above or below the 1.5 times interquartile range (IQR). All 
statistical comparisons were made using a statistical software packages (RStudio; 
RStudio Inc., Boston, MA, USA, version 1.1.456). Statistical analyses were considered 
significant if P<0.05. 
3. RESULTS 
3.1 Subject Characteristics 
There were no differences in age, height, weight, corticosteroid use, number of 
ambulatory patients, or age of loss of ambulation between genotype groups (Table 1). 
Further, there was no difference in age at loss of ambulation between Gly16 and Arg16 
genotype groups (10.96±0.23 yrs vs 11.93±0.75 yrs, respectively). A total of 78 patients 
were non-ambulatory at entry into the study, consisting of 65 patients in the Gly16 group, 
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and 13 patients in the Arg16 group (72% and 50% of the genotype sample populations, 
respectively). 
3.2 Kaplan-Meier Analysis 
Two observations were identified as outliers in a preliminary analysis of the Kaplan-
Meier analysis, and were omitted from further analyses (173 observations remaining). 
The results of the Kaplan-Meier analysis are illustrated in Figure 1. The mean and 
median age at first use of NV are presented in Table 2. DMD patients with the Gly16 
polymorphism demonstrated a higher risk (P<0.05) of use of NV at any given age 
compared with those patients expressing the Arg16 polymorphism (21.80±0.59 yrs vs 
25.91±1.31 yrs, respectively).  
3.3 Cox Proportional Hazard 
Eleven observations were identified as outliers in a preliminary analysis of the Cox PH 
model. These outliers were omitted from further analyses (164 observations remaining). 
The results of the Cox PH analysis are presented in Table 3. Ambulatory status, 
corticosteroid use and patient height were strong, negative predictors of the risk of NV 
assistance in patients with DMD at any given age (P<0.05). In contrast, ADRB2 
genotype was identified as a strong, positive predictor of NV use in DMD patients 
(P<0.05). Specifically, those DMD patients with the Gly16 genotype variant were 
approximately 2.77 times more likely to be given NV assistance at any given age than 
those patients with the Arg16 polymorphism.  
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4. DISCUSSION 
The original hypothesis of this study was that DMD patients with the Gly16 
polymorphism would have a reduced risk of using NV at any given age compared with 
those patients expressing the Arg16 polymorphism. Our rationale for this hypothesis was 
constructed on the basis that ADBR2 stimulation may: increase diaphragmatic cross-
sectional area, strength, and contractility [43, 45, 46]; improve mucociliary clearance [47, 
50, 51]; inhibit inflammatory pathways [53, 54, 56, 58, 60]; and inhibit calpain activity 
and decrease concentration [62, 63, 65, 66, 69]. As such, it was expected that possessing 
the “functional” ADBR2 genotype (i.e., Gly16) would confer a positive effect on 
retarding the progressive loss of respiratory function and, by extension, delaying the age 
at first use of NV in DMD patients. Our results did not support this hypothesis. Instead, 
the present study demonstrated DMD patients with the Gly16 polymorphism display an 
almost 3-fold increase in the risk of NV than those with the Arg16 variant. Certainly, our 
finding that the Gly16 polymorphism confers a higher (not lower) risk of NV use is 
difficult to explain at first. To this end, we propose two potential explanations for these 
unexpected findings; namely that the Gly16 polymorphism may (i) increase the rate of 
contraction-induced injuries and (ii) may increase intracellular [Ca
2+
]. 
ADRB2 stimulation increases myofibril expression of type IIa myosin heavy chain 
isoform in animal models, promoting a fiber-type shift from slow-oxidative to more fast-
glycolytic muscle fibers [277, 278]. Type II fibers have an increased peak contractile 
strength compared with type I fibers [279]. Indeed, healthy adults expressing the Gly16 
polymorphism often display increased muscular strength and power relative to their 
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Arg16 counterparts [276]. While it may seem at first that increased strength is beneficial 
for respiratory muscle fatigue and weakness, the augmentation of contractile force likely 
increases the number, and rate of contraction-induced injurious events in DMD patients. 
Dystrophin-deficient muscle fibers lack adequate membrane stability to efficiently 
distribute forces associated with myofibril contraction across the sarcolemma [2]. As a 
result, dystrophin-deficient muscle fibers are highly susceptible to contraction-induced 
injuries — a significant component of muscle fiber degradation in DMD [280]. Further, 
the type I to type II fiber type shift renders the muscle fiber more susceptible to eccentric 
contraction-induced damage, and increased fatigability [281, 282]. In light of the above, 
it is at least conceivable that the Gly16 polymorphism, by increasing the rate of 
contraction-induced injuries, hastens the progression of respiratory muscle weakness in 
DMD patients, leading to a higher risk of NV use than those patients expressing the 
Arg16 polymorphism. 
A secondary explanation for our current findings is that DMD patients with the Gly16 
polymorphism, by virtue of increased ADRB2 activity [202, 272], may have incurred 
additional skeletal muscle damage due to relatively higher intracellular concentrations of 
Ca
2+
 ([Ca
2+
]). Certainly, ADRB2 stimulation enhances Ca
2+
 efflux from the sarcoplasmic 
reticulum via a G-protein linked pathway [250], promoting a rise in intracellular [Ca
2+
]. 
This facilitatory effect of ADRB2 stimulation on rising intracellular [Ca
2+
] is amplified 
by the abnormally low gene expression of regucalcin in DMD patients, i.e., the principal 
Ca
2+
-binding protein in the diaphragm [105]. Further to the above, the potentially higher 
rate of contraction-induced injuries in DMD patients with the Gly16 polymorphism (see 
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explanation above) may promote further Ca
2+
 influx into the cytosol from the 
extracellular space [40]. It is emphasized that increased intracellular [Ca
2+
] promotes 
calpain activity, upregulating proteolytic cellular damage and myofibril degradation [105, 
250]. As such, we speculate that the Gly16 polymorphism is associated with poorer 
intracellular [Ca
2+
] homeostasis and greater calpain activity, the result of which may 
hasten the onset of respiratory muscle weakness, leading to a higher risk of NV use than 
those patients expressing the Arg16 polymorphism. 
Implications of our findings 
Pilot studies have shown an improvement in isometric knee-extensor strength and manual 
muscle test scores in DMD patients following 12 weeks of ADRB2 agonist treatment 
[283]. A larger follow-up study also demonstrated that ADRB2 agonist treatment 
improves lean body mass and time to walk/run 30 ft. in patients with DMD [284]. 
Importantly, however, both study populations consisted of young DMD patients whose 
ages ranged between 5 to 11 years. We emphasize here that although our findings 
demonstrate that the Gly16 polymorphism confers a higher risk of NV use at any given 
age, the absolute difference in risk between Gly16 and Arg16 groups was marginal for 
patients aged between 5 to 11 years (Figure 2B). Indeed, the absolute risk difference 
between genotype groups was less than 1.4% up to 15 years of age in our cohort of DMD 
patients. The difference in risk of NV between groups widened thereafter to reach >40% 
at patient ages of 25 years and older. One may infer from these observations that the 
increase in risk of NV use in the Gly16 compared with the Arg16 polymorphism is 
relatively trivial below the adolescent years, and becomes more important when DMD 
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patients enter the second decade of life. Further studies are needed to examine whether 
the effects of the Gly16 polymorphism on respiratory outcomes in DMD are indeed 
dependent on patient age.   
Other factors influencing risk of nocturnal ventilation in DMD 
Our Cox regression analysis demonstrated that ambulatory status, corticosteroid-use, and 
height were also significant predictors of the risk of NV in DMD patients. Firstly, it is not 
surprising that ambulatory status decreased the risk of NV in our cohort, seeing that 
DMD patients who are ambulatory typically display a better clinical prognosis [285]. 
Secondly, it is expected that height should confer a protective effect on the risk of NV 
use in DMD, given that height is strongly correlated with vital capacity in these patients 
[33, 286]. However, that a greater corticosteroid-use also reduced the risk of NV is harder 
to explain. It is possible that a greater corticosteroid usage delayed the loss of ambulation 
and emergence of cardiomyopathy, reduced the risk of scoliosis, together preserving 
respiratory function for a longer period of time in our cohort of patients [285].  
Methodological considerations 
Our cohort included DMD patients who were homozygous for arginine (AA, n = 26), 
glycine (GG, n = 59), or heterozygous (AG, n = 90) at codon 16 and were collapsed into 
two study groups (Arg16, n = 26 and Gly16, n = 149). While it is certain that this 
distribution is not representative of a typical healthy population (0.40 and 0.60 for Arg16 
and Gly16 respectively), no data is available regarding ADRB2 16 genotype distribution 
in the DMD population [287]. Thus, we do not currently know whether the genotype 
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frequency observed in our cohort is representative of the wider DMD patient population. 
A second consideration is the retrospective nature of the data and the rolling accrual of 
patients used for data collection. As a result, our cohort did include left-censored data 
which may influence the accuracy of the Cox model to identify the age of first NV use 
and therefore the risk of NV use. However, the aim of this study was to determine the 
influence of ADRB2 genotype on the risk of NV use. At present, we do not believe that 
genotype status, per se, would have influenced the model’s accuracy to identify the 
timing of first NV use. 
5. CONCLUSIONS 
The findings of the present study indicate that DMD patients with the Gly16 ADRB2 
polymorphism are almost 3 times more likely to require NV assistance at a given age 
compared with those patients expressing the Arg16 polymorphism. It is emphasized, 
however, that the absolute difference in risk of NV between genotypes is relatively trivial 
(<2%) below the age of 15 years. Despite prior speculation that ADRB2 stimulation may 
be a useful therapeutic approach, our data suggest that ADRB2 agonist treatment may be 
inappropriate for post-adolescent DMD patients.  
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FIGURE CAPTIONS 
Figure 1. The cumulative risk of nocturnal ventilation in Duchenne muscular 
dystrophy (DMD) patients stratified by β2-adrenergic receptor genotype (Arg16 and 
Gly16). The cumulative risk of nocturnal ventilation in DMD patients was calculated 
from the survival curve produced by the Kaplan-Meier analysis.     
Figure 2. The cumulative risk (A) and absolute difference in risk (B) of nocturnal 
ventilation in Duchenne muscular dystrophy (DMD) patients stratified by β2-
adrenergic receptor genotype (Arg16 and Gly16). The cumulative risk function was 
obtained from Cox regression modeling of the risk of nocturnal ventilation, where 
genotype group, ambulatory status, corticosteroid-use, and height were entered into the 
model as covariates. The risk curves in panels A and B were produced for each genotype 
variant by holding all other covariates in the Cox model constant at their respective 
means (Height = 141 cm; Mass = 43 kg; Corticosteroid-use = 3.4 yrs; Ambulatory status 
= 0.55).  The reference lines in Panel B denote the absolute difference in risk between 
genotype variants at the ages of 15, 20 and 25 years of age. Note that the difference in 
risk of NV between Arg16 and Gly16 genotype groups is marginal (<1%) at ages below 
15, yet widens greatly to over 40% by the age of 25 years.  
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
Table 1. Subject characteristics. 
  Mean SE p-value 
Age (yrs)     
 Arg16 12.97 1.23 0.61 
 Gly16 12.34 0.47  
 Total 12.43 0.44  
Height (cm)     
 Arg16 138.85 4.27 0.62 
 Gly16 141.22 1.82  
 Total 140.87 1.67  
Weight (kg)     
 Arg16 42.91 4.12 0.98 
 Gly16 43.01 1.89  
 Total 42.99 1.71  
Corticosteroid Use (yrs)     
 Arg16 3.47 0.72 0.93 
 Gly16 3.39 0.34  
 Total 3.40 0.31  
SE: standard error; Arg16: patients who were homozygous or heterozygous for the β2-
adrenergic receptor (ADRB2) resulting in at least one arginine substitution at amino acid 
16 (n = 26); Gly16: patients who were homozygous for ADRB2 resulting in a glycine 
substitution at amino acid 16 (n =149). 
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Table 2. Kaplan-Meier mean and median ages at first use of nocturnal ventilation 
(NV) in patients with Duchenne muscular dystrophy (DMD). 
 Mean Age Median Age 
 Estimate (yrs) SE 95% CI Estimate (yrs) SE 95% CI 
  Arg16   25.91* 1.31 23.35 – 28.49   28.30* 4.14 20.19 – 36.41 
  Gly16 21.80 0.59 20.86 – 23.42 22.17 0.40 21.38 – 22.96 
Overall 22.71 0.62 21.49 – 23.93 22.48 0.39 21.72 – 23.24 
SE: standard error; CI: confidence interval; Arg16: patients who were homozygous or 
heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least one arginine 
substitution at amino acid 16 (n = 26); Gly16: patients who were homozygous for 
ADRB2 resulting in a glycine substitution at amino acid 16 (n =147). *Significant 
difference in mean or median age at first use of NV between genotype groups, P <0.05. 
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Table 3. Cox regression analysis of the risk of using nocturnal ventilation (NV) at 
any given age in patients with Duchenne muscular dystrophy (DMD). 
 β SE Wald p-value HR 95% CI 
Genotype 1.02 0.50 2.04 <0.05 2.77 1.04 – 7.39 
Ambulatory Status –1.45 0.57 –2.56 <0.05 0.23 0.07 – 0.71 
Corticosteroid-use (yrs) –0.21 0.05 –4.11 <0.05 0.81 0.73 – 0.89 
Height (cm) –0.04 0.02 –2.41 <0.05 0.96 0.93 – 0.99 
Weight (kg) 0.004 0.01 –0.34 0.73 1.01 0.98 – 1.03 
SE: standard error; HR: hazard ratio; CI: confidence interval; Arg16: patients who were 
homozygous or heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least 
one arginine substitution at amino acid 16 (n = 26); Gly16: patients who were 
homozygous for ADRB2 resulting in a glycine substitution at amino acid 16 (n =147); 
genotype was coded as: 0 = Arg16, 1 = Gly16; ambulatory status was coded as: 0 = non-
ambulatory, 1 = ambulatory; there was a significant influence of genotype, ambulatory 
status, corticosteroid use, and height on risk of NV use. 
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Figure 1. The cumulative risk of nocturnal ventilation in Duchenne muscular 
dystrophy (DMD) patients stratified by β2-adrenergic receptor genotype (Arg16 and 
Gly16). 
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Figure 2. The cumulative risk (A) and absolute difference in risk (B) of nocturnal ventilation in Duchenne muscular 
dystrophy (DMD) patient stratified by β2-adrenergic receptor genotype (Arg16 and Gly16). 
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CHAPTER 4: DISCUSSION 
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DMD is a debilitating disorder caused by a deletion of the dystrophin gene. 
Dystrophin deficiency renders muscle fibers fragile and susceptible to contraction-
mediated injuries which affect skeletal, diaphragmatic, and cardiac muscles. The result is 
a majority of DMD patients dying from dilated cardiomyopathy and restrictive 
pulmonary pathologies. Therefore, it is important to further understand the factors that 
affect respiratory and cardiac health in patients with DMD. Understanding these factors 
may aid in identifying therapeutic interventions to delay the loss of respiratory and 
cardiac function and decrease hospitalization rates and mortality in this population. 
Two primary pathways have been identified as possible therapeutic targets to 
preserve respiratory and cardiac function in DMD patients. These pathways are the 
ADRB1 and ADRB2 coupled pathways. Polymorphisms of these receptors that influence 
functionality include the Ser49Gly and Arg389Gly of the ADRB1 and Arg16Gly of the 
ADRB2. These ADRB1 polymorphisms (Ser49Gly and Arg389Gly) have been 
demonstrated to influence cardiac measures and response to beta-blockers. The ADRB2 
polymorphism (Arg16Gly) has been demonstrated to influence skeletal muscle size, 
strength, and respiratory function. 
 
4.1 Beta-1 Adrenergic Receptor Genotype in Healthy Patients 
The ADRB1 subtype is found primarily in the heart and comprises 75-80% of 
total β-AR found in the heart and approximately 95% of β-AR in the SA node [21]. The 
G-protein signaling pathway associated with the β-AR is important in the modulation of 
several key target proteins. When activated, cardiomyocyte ADRB1 preferentially binds 
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to the Gas protein which phosphorylates AC, generating the secondary messenger cAMP. 
Increased cAMP accumulation activates PKA [25]. Activated PKA then phosphorylates 
troponin I, the L-type Ca
2+
 channel and phospholamban (PLB), increasing cardiac 
inotropy, chronotropy, and lusitropy [24].  
Research has also shown Gs activation can increase L-type Ca
2+
 current directly 
[166]. These L-type Ca
2+
 channels play an integral role in cardiomyocyte excitability and 
contractility [156]. Phosphorylation of cardiac L-type Ca
2+
 channels by PKA results in an 
influx of Ca
2+
 into cardiomyocytes. The Ca
2+
 then binds to the sarco/endoplasmic 
reticulum Ca
2+
-ATPase (SERCA) triggering further sarcoplasmic Ca
2+
 loading which 
results in the removal of troponin and tropomyosin inhibition of myosin binding sites 
[105, 167]. Additionally, research suggests the phosphorylation of phospholamban (PLB) 
via PKA, a downstream protein from β-AR stimulation, results in the removal of 
inhibition of SERCA. This increases the quantity and rate of reuptake of cytosolic Ca
2+
 in 
the sarcoplasmic reticulum [27]. Recent research also suggests PLB pools exist in the 
nuclear envelope which allows them to regulate perinuclear/nuclear Ca
2+
 handling [26]. 
Troponin I is a regulatory protein of cardiac myofibrils and its phosphorylation by PKA 
inhibits actomyosin ATPase activity resulting in relaxation of cardiomyocytes in response 
to catecholamines [22, 28]. Research has demonstrated that genetic variants of the 
ADRB1 modulate the cardiac responses to catecholamine binding and the 
aforementioned mechanisms; the Gly49 polymorphism has been shown to produce a 
dampening effect to these responses. These data suggest genetic variation of the ADRB1 
may influence cardiovascular responses to exercise in healthy subjects.  
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Our original hypothesis was that healthy patients expressing the Gly49 
polymorphism would have decreased cardiac output, stroke volume, and blood pressure 
at maximal exercise compared with patients with the Ser49 polymorphism. Furthermore, 
we hypothesized that healthy patients expressing the Gly49 polymorphism would have 
decreased cardiac index, heart rate, and systemic vascular resistance at maximal exercise 
compared with patients with the Ser49 polymorphism. The principle findings of project 1 
were that patients with the Gly49Ser demonstrated an improved cardiac response to 
exercise. Specifically, patients with the Gly49Ser polymorphism had a significantly 
improved cardiac index as compared to the Ser49Ser polymorphism at rest; this 
difference is abolished at peak exercise. This suggests improved cardiac function at rest 
with no deleterious effect on cardiac function at peak exercise. Additionally, there is a 
significant difference between the two polymorphisms for HRmax and no difference in HR 
at rest, with the Gly49Ser polymorphism demonstrating a higher HRmax. This suggests the 
Gly49Ser polymorphism has an improved HR reserve, suggesting a higher capacity for 
cardiac work. This polymorphism (Gly49Ser) also demonstrated a lower SVR at rest, 
suggesting the Gly49Ser polymorphism has decreased cardiac work at rest. This coupled 
with the abolishment of this difference at peak exercise suggests subjects with the 
Gly49Ser polymorphism have an improved cardiac work reserve. Furthermore, the trend 
towards significance in change in SV from rest to peak exercise – with the Gly49Ser 
polymorphism presenting a dampened increase – in addition to there being no difference 
in HR at rest and improved CI at rest, suggest an improved left ventricular contractility in 
the Gly49Ser polymorphism. The clinically significant difference between genotype 
140 
 
groups in change in BPdias rest to peak exercise may suggest a systemic influence of the 
ADRB1 genotype, particularly in the arterial vasodilation observed in response to aerobic 
exercise. These data support our original hypothesis and suggest the Gly49Ser 
polymorphism to have improved cardiovascular function at rest and peak exercise. 
 
4.2 Beta-1 Adrenergic Receptor Genotype in Duchenne Patients 
ADRB1 signaling has been shown to play an important role in HF with the degree 
of sympathetic activity being inversely correlated with survival [211]. Deleterious effects 
of ADRB1 signaling include apoptosis, myocyte growth, fibroblast hyperplais, 
myopathy, fetal gene induction, and proarrythmia [206, 212]. As an adaptive mechanism 
in HF, cardiac ADRB1s become less responsive, either downregulating or uncoupling 
from the Gs pathway [214]. This suggests the less functional variants of the ADRB1 to be 
clinically important in HF and other HF=like cardiomyopathies.  
Literature has identified the ADRB1 coupled pathway as capable of preserving 
cardiac function in cardiomyopathies [16-20]. The ADRB1 subtype is found primarily in 
the heart, comprising about 80% of total beta adrenergic receptors found in the heart and 
playing a role in cardiac function [16, 21-23]. Research has demonstrated ADRB1 
activity influences cardiac: (i) inotropy, lusitropy, and chronotropy [24, 25]; (ii) nuclear 
and perinuclear Ca
2+
 handling [26]; (iii) reuptake of cytosolic Ca
2+
 [27]; and (iv) 
cardiomyocyte relaxation [22, 28]. Given the above mentioned mechanisms, the ADRB1 
may play a role in preserving cardiac function in patients with DMD. 
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A polymorphism of the ADRB1 that affects functionality includes a glycine (Gly) 
for arginine (Arg) substitution at amino acid 389 [16, 17, 22, 23]. Specifically, the 
Gly389 polymorphism demonstrates: decreased receptor density and cAMP accumulation 
as well as a dampening response to norepinephrine infusion [16, 22, 23]. Functionally, 
HF patients with the Gly389 polymorphism have significantly lower diastolic, systolic, 
and mean arterial blood pressure — contributing to improved cardiac function and 
decreased mortality risk [17-19, 29]. Furthermore, literature demonstrates autoantibodies 
against ADRB1 are associated with more favorable myocardial recovery in patients with 
recent-onset cardiomyopathy [20]. The association between the Gly389 polymorphism 
and more favorable cardiac measures and outcomes in HF patients suggest a therapeutic 
target for preserving cardiac function and delaying cardiomyopathy in patients with 
DMD. To date, however, there is no literature investigating the relationship between 
ADRB1 genotype and cardiac events in DMD patients. 
Our original hypothesis was that DMD patients with the Gly389 polymorphism 
would have a lower risk of cardiac events compared with those expressing Arg389 
polymorphism. The principal findings of project 3 were that DMD patients with the 
Gly389 polymorphism of the ADRB1 had a higher incidence of diuretics use compared 
with those patients expressing the Arg389 polymorphism. Specifically, patients with the 
Gly389 polymorphism were 5.01 times more likely to be on diuretics compared with 
patients with the Arg389 polymorphism at any given age. Furthermore, ADRB1 genotype 
had no influence on the risk of other cardiac events included in project 3 in patients with 
DMD. However, corticosteroid use was a negative predictor of the risk of other cardiac 
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issues and ACEI and ARB use and height was a negative predictor of the incidence of 
ACEI, ARB, and other cardiovascular medications use. The present study refutes our 
hypothesis and demonstrates DMD patients with the Gly389 polymorphism may have an 
increased incidence of diuretics use compared with patients with the Arg389 
polymorphism and that ADRB1 genotype has no influence on other cardiac events in 
these patients. 
As respiratory management in DMD patients improves, the development of 
cardiomyopathies and the accompanying left ventricular dysfunction are emerging as 
significant contributors to mortality in this population [6-8]. While cardiomyopathies are 
present in 90% of DMD patients over the age of 18, only 30% of patients present with 
symptoms at the time of diagnosis [8, 9]. Additionally, a majority of DMD patients with 
normal left ventricular function exhibited dysfunctional myocardial strain at the 
posterolateral wall (the initial site of fibrofatty deposition in myocardium), suggesting 
abnormal myocardial contraction before left ventricular decompensation [13, 264]. The 
cardiomyopathy associated with DMD has a higher mortality than other dilated 
cardiomyopathies but often remains less treated at diagnosis [9]. Further, left ventricular 
dysfunction secondary to cardiomyopathy is a strong predictor of mortality in patients 
with DMD [7]. Therefore, understanding the factors that affect the risk of cardiac events 
in patients with DMD may provide therapeutic targets to delay the development of 
cardiomyopathy and decrease the risk of mortality in this population.   
Both the DMD Care Considerations Working Group and the European Society of 
Cardiology guidelines recommend ACEI as first-line therapy for dilated cardiomyopathy 
143 
 
and/or congestive heart failure in DMD patients [82, 91, 101]. However, the side-effect 
profile of ACEI, such as cough, renal dysfunction, hyperkalemia, and angioedema, led 
to the testing of ARBs as a replacement therapy for cardiac dysfunction [265]. The 
Evaluation of Losartan in the Elderly (ELITE) 1 and 2 trials determined ARB therapy 
to be as effective as ACEI in the treatment of HF [266, 267]. These findings have led to 
ACEIs and ARBs becoming more mainstream therapy in patients with DMD [9]. 
Although the age of initiation of these therapies remains an important clinical question, 
the use of ACEIs and ARBs is an important milestone in cardiac therapy in DMD 
patients [9]. The Cox PH analysis identified corticosteroid use and height as strong, 
negative predictors of the incidence of ACEI and ARB use in patients with DMD. That a 
greater corticosteroid use decreased incidence of ACEI and ARB use in DMD patients is 
not surprising as corticosteroid use delays the emergence of cardiomyopathy [10]. 
The American College of Cardiology and American Heart Association have long 
recommended the use of diuretics in the treatment of HF with reduced left ventricular 
function [96]. Consequently, the American Academy of Pediatrics recommends 
considerations to be given to the use of diuretics in the treatment of cardiomyopathy in 
DMD patients [97]. Current literature has led investigators to suggest the use of diuretics 
to treat tachycardia and lipothymia in later stages of cardiac involvement in DMD 
patients [98]. Despite the efficacy of diuretic therapy in the treatment of HF and 
recommendations for diuretic considerations in DMD patients, clinical adoption is slow 
[99]. In our study population, only 18 patients were prescribed a diuretic at any point (14 
and four for Gly389 and Arg389 respectively). However, the Cox PH analysis determined 
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genotype, height, and weight to be strong predictors of diuretic use in DMD patients. 
Specifically, DMD patients with the Gly389 polymorphism were approximately 5 times 
more likely to be on diuretics compared with patients with the Arg389 polymorphism at 
any given age. Further, height and weight were identified as strong, negative predictors of 
diuretics use in our population of DMD patients. 
The multifactorial nature of the cardiac involvement in DMD necessitates a 
battery of therapy options to treat cardiomyopathy symptoms and limit the side-effect 
profile [82]. Literature supports the use of ACEIs and ARBs as first-line therapy and 
considerations for BBs and diuretics in the treatment of cardiomyopathy in DMD patients 
and recommends the adoption of clinical guidelines for HF management [82, 96, 97]. 
Additional therapies used in our clinical population included Ca
2+
 channel blockers, 
blood thinners, and cholesterol lowering drugs. In our population, height was a negative 
predictor for the incidence of use of the above mentioned therapies. 
Secondary to cardiomyopathy, DMD patients also present with tachycardia and 
other arrhythmias [98]. These additional complications present further clinical care 
considerations and signal the emergence of extensive fibrofatty deposition and 
conduction disorders [268]. Further, sinus tachycardia is correlated with cardiac 
dysfunction in DMD patients and other conduction abnormalities present more 
commonly in DMD patients with left ventricular ejection fraction <35% [288, 289]. 
These findings demonstrate the clinical importance of the emergence of arrhythmias in 
DMD patients. These conditions may point to advanced myocardial fibrosis and 
decompensated left ventricular ejection fraction and thus provide important clinical 
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milestones in cardiac management in this population. Corticosteroid use was identified as 
a negative predictor of a DMD patient’s risk of cardiac issues including tachycardia and 
other arrhythmias. As mentioned previously, corticosteroid use has been shown to delay 
cardiomyopathy in DMD patients [10]. 
In light of the burden of literature demonstrating the beneficial influence of the 
Gly389 polymorphism in cardiac outcomes and mortality in HF patients, the 
contradictory findings of this study may be difficult to explain. One explanation is the 
lack of widespread clinical adoption of specific guidelines for treatment of 
cardiomyopathy in patients with DMD. Despite a greater appreciation for the clinical 
importance of DMD cardiomyopathy, cardiac management strategies are highly variable 
and remain underutilized in this population [9, 100]. Currently, there is no consensus on 
the proper pharmacological therapy class and timing for treatment of cardiomyopathy in 
DMD patients [101]. In fact, when clinic site was entered into the Cox PH analysis as an 
additional covariate, 5 clinic sites differed significantly from the other sites in the 
prevalence of diuretics prescription at any given age. Given this, the variability of cardiac 
management for DMD patients in different clinics may explain these contradictory 
findings. 
 
4.3 Beta-2 Adrenergic Receptor Genotype in Healthy Patients 
Research suggests Β2-AR agonist supplementation may have an efficacious effect 
on respiratory function, primarily as a mechanism of improved diaphragmatic strength 
and contractility. This improved diaphragmatic function is demonstrated by increased 
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diaphragmatic myofibril protein concentration and  maximal tetanic force production 
following Β2-AR  agonist  [45]. Furthermore, ADRB2 treatment has been shown to 
increase diaphragm cross-sectional area and myosin heavy chain concentration with an 
increased transdiaphragmatic pressure [46, 290]. These beneficial effects have been 
demonstrated in other clinical populations, such as chronic obstructive pulmonary 
disease, with improved respiratory strength and endurance following B2-AR agonist 
treatment [291]. These data suggest the ADRB2 may play a role in the regulation and 
preservation of diaphragm strength and respiratory function. 
The ADRB2 may also play an important role in skeletal muscle size and strength 
through multiple internal mechanisms. Free C-subunits of PKA, a downstream product of 
ADBR2 stimulation, are capable of phosphorylating multiple regulator genes of CREB 
[162]. CREB is ubiquitously expressed and influences cell proliferation, differentiation, 
adaptation, and survival [164]. Further, CREB plays an integral role in mediating MEF2, 
SIK1, and myostatin activity, pathways that regulate skeletal muscle turnover [161, 292]. 
An additional pathway influenced by ADRB2 stimulation is the PI3K-Akt signaling 
pathway which regulates protein synthesis, gene transcription, cell proliferation, and cell 
survival [170-172]. The primary mechanism of skeletal muscle regulation through the 
PI3K-Akt pathway is via FOXO inhibition, thereby decreasing FOXO-mediated cellular 
apoptosis [293]. ADRB2 activation is also associated with an increased expression of 
NOR-1 and peroxisome-activated receptor γ coactivator-1α4 (PGC-1α4), both negative 
regulators of myostatin expression [163, 165, 251]. Collectively, these data suggest the 
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ADRB2 plays multiple roles in regulating skeletal muscle growth through downstream 
regulation. 
In addition to the mediation of internal cell signaling, stimulation of the ADRB2 
can also regulate Ca
2+
-mediated proteolysis. Both cAMP and phosphorylated PKA have 
been shown to directly and indirectly inhibit calpain activity [40]. Specifically, research 
suggests cAMP and PKA may directly phosphorylate calpains to an inactive state to 
inhibit activity [63, 65, 196, 246]. Additionally, research has identified calpastatin (a 
calpain-specific inhibitor) binding sites for both cAMP and PKA, suggesting the capacity 
for direct phosphorylation and increased expression of calpastatin [66, 244, 245]. The 
multiple pathways whereby ADRB2 stimulation may improve skeletal and diaphragmatic 
muscle function and protect against calpain-mediated atrophy suggest an effective 
therapeutic target for preservation of respiratory function in DMD patients. Project 2 
demonstrates that genetic variation of the ADRB2 is associated with differences in 
muscular power, efficiency and intensity. Our original hypothesis was that healthy 
patients expressing the Gly16 polymorphism would have increased absolute and relative 
power output compared with patients expressing the Arg16 polymorphism. We further 
hypothesized those healthy patients expressing the Gly16 polymorphism would report 
decreased indices of relative and perceived intensity at a given workload compared with 
patients expressing the Arg16 polymorphism. 
The principal findings of study 2 support our original hypothesis. Specifically, 
patients with theArg16Gly polymorphism demonstrated significantly higher peak power, 
relative power, muscular efficiency, and exercise intensity during heavy, steady-state 
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exercise. Additionally, subjects with this polymorphism (Arg16Gly) reported 
significantly lower RPE despite producing higher peak watts, suggesting improved 
muscular efficiency. While not statistically significant, Gly16 subjects were heavier than 
Arg16 subjects. Project 2 suggests the Arg16Gly polymorphism may improve power 
measures, muscular efficiency, and exercise intensity in healthy subjects compared with 
the Arg16Arg polymorphism. Considering the beneficial influence of the Gly16 
polymorphism on skeletal muscle, it is conceivable to posit there are also positive 
influences of this polymorphism on the diaphragm and accessory respiratory muscles. 
 
4.4 Beta-2 Adrenergic Receptor Genotype in Duchenne Patients 
The results of Project 2 suggest ADRB2 genotype, specifically the Gly16 
polymorphism, may play a functional role in improving skeletal muscle strength and 
function. Additionally, a pilot study has shown an improvement in isometric knee 
extensor strength and manual muscle test scores in DMD patients following 12 weeks of 
Β2-AR  agonist treatment [283]. A larger, follow-up study further demonstrated Β2-AR  
agonist treatment improves lean body mass and time to walk/run 30 feet in patients with 
DMD [284]. There were no improvements in isometric knee moments or manual muscle 
tests following Β2-AR agonist treatment in this study population. Collectively, these data 
suggest ADRB2 genotype may influence skeletal muscle function in patients with DMD. 
However, to date there has been no investigation into the influence of ADRB2 genotype 
on respiratory function and the age of important clinical respiratory milestones, 
particularly NV. 
149 
 
 An estimated 32% of DMD patients present with nighttime alveolar 
hypoventilation [3]. The negative effects of SBD include increased cardiac morbidity, 
neurocognitive deficits, decreased lung function, and increased hospitalization rates and 
mortality [3, 30, 31, 294]. Once patients with DMD present with SBD and abnormal 
overnight oximetry, patients are prescribed NV —— the age at which this occurs is an 
important clinical milestone in this population [3, 151]. Clinically, NV in DMD patients 
is indicated by progressive respiratory muscle weakness, the primary contributor of 
which is a loss of diaphragmatic contractility due to diaphragm remodeling [33, 35]. 
Diaphragmatic remodeling in DMD can be attributed to two main mechanisms: increased 
inflammatory response and an increased calpain activity [34, 36, 58, 59, 229]. The 
deleterious effect of these mechanisms on diaphragm function suggests the abatement of 
these mechanisms would prove clinically important in DMD patients. Given ADRB2 
stimulation has been shown to: increase diaphragmatic cross-sectional area, strength, and 
contractility [43, 45, 46]; improve mucociliary clearance [47-52]; inhibit inflammatory 
pathways [53-61]; and to inhibit calpain activity and decrease concentration [62-69], we 
reasoned DMD patients with the Gly16 polymorphism would have a reduced risk of NV 
use. 
One of the main respiratory concerns in DMD is the loss of diaphragmatic 
contractility due to increased diaphragm fibrosis and pseudo-hypertrophy [33]. The 
increase in diaphragm fibrosis in patients with DMD is a function of two main 
mechanisms: a decrease in mucociliary clearance and the resultant increased 
inflammatory response and the upregulation of Ca
2+
-modulated proteolytic pathways [34, 
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36, 58, 59, 229]. Impaired mucociliary clearance is also associated with increased fibrosis 
and hospitalization due to pulmonary complications in DMD patients [37]. Ineffective 
clearance has been shown to upregulate inflammatory pathways and hasten the onset of 
respiratory failure in neuromuscular disorders [37]. Dystrophin-deficient muscle cells 
have been shown to have increased IL-1β levels and research suggests significant levels 
of TNF-α were detected in 62% of human DMD tissue biopsies [53, 54, 58, 59]. 
Furthermore, decreased sarcolemmal integrity, mechanical cell membrane tears, and Ca
2+
 
channel dysregulation associated with DMD have been shown to result in increased Ca
2+
 
flux and increased calpain concentration and activity [40]. Calpains, Ca
2+
-dependent, 
non-lysosomal proteases, initiate myofibrillar protein degradation thereby decreasing 
myofibrillar protein integrity [40]. The increased activation of these pathways is 
considered a primary contributor to muscle degradation and fiber necrosis in DMD [41].  
Β2-AR agonist treatment has been shown to improve airway clearance by 3-4 
times in humans and have anti-inflammatory properties by inhibiting cytokine production 
including: TNF-α, IL-6, and interleukin-1β (IL-1β) [49, 50, 53, 54]. It has also been 
demonstrated that Β2-AR agonist treatment can increase calpastatin, a calpain-specific 
inhibitor, and decrease calpain concentration and activity [64, 67-69].  Β2-AR agonist 
supplementation has also been shown to increase diaphragm protein concentration, 
maximal tetanic force production, and transdiaphragmatic pressure in the mouse model 
[45, 46, 229]. Functionally, the increased receptor density and resistance to 
downregulation associated with the Gly16 polymorphism results in increased cAMP 
accumulation, further upregulating these mechanisms [43]. Cumulatively, these data 
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suggest the Gly16 polymorphism may result in: improved mucociliary clearance, 
decreased inflammatory pathways, inhibition of Ca
2+
-dependent proteolysis, and 
improved diaphragmatic function in DMD.  
Our original hypothesis was that DMD patients expressing the Gly16 
polymorphism would have a lower risk of NV use at any given age when compared with 
patients expressing the Arg16 polymorphism. However, the principal findings of project 
4 directly contradict this hypothesis, with the Gly16 polymorphism demonstrating an 
almost 3-fold increase in the risk of NV use at any given age. The finding that the Gly16 
polymorphism confers a higher (not lower) risk of NV use is difficult to explain at first. 
When considering the aforementioned benefits of ADRB2 stimulation on respiratory and 
skeletal muscle strength, literature has suggested Β2-AR agonist therapy may be 
efficacious in stymying muscle degradation in DMD patients and preserving respiratory 
function [295, 296]. The findings of study 4 contradicting these speculations can be 
explained by two main mechanisms: increased contraction-induced injuries and Ca
2+
 
flux. 
ADRB2 stimulation results in a phenotypic shift from type I oxidative to type II 
glycolytic muscle fibers, resulting in increased conduction velocity and contraction 
strength [277-279]. Secondary to increased type II fiber concentrations, Β2-AR  agonists 
have been shown to have inotropic effects in animal diaphragms resulting in increased 
speed and force of contraction [297]. Furthermore, the Gly16 polymorphism is associated 
with increased muscular strength and power [276]. While increased strength and 
contractility may seem beneficial for respiratory muscle fatigue and weakness, this likely 
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increases the number and likelihood of contraction-mediated injurious events in DMD 
patients — a significant component of muscle fiber degradation in DMD [280]. 
Additionally, type II fast oxidative-glycolytic fibers are more susceptible to eccentric 
contraction-induced damage [281]. In addition to increased contraction-induced injuries, 
the inotropic effect of ADRB2 stimulation may also increase intracellular Ca
2+
 
concentrations, further increasing calpain activity and muscle fiber degradation [250]. 
These data present mechanisms whereby the Gly16 polymorphism may have deleterious 
effects on respiratory function and risk of NV use in DMD patients. 
While the Gly16 polymorphism may have a positive influence on skeletal muscle 
function (as demonstrated in study 2) and respiratory function in various populations, 
study 4 suggests this polymorphism may have a negative effect on respiratory function 
and risk for NV compared with the Arg16 polymorphism in patients with DMD. 
Specifically, DMD patients with Gly16 polymorphism present an almost 3-fold increase 
in risk of NV compared to patients with the Arg16 polymorphism. 
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CHAPTER 5: LIMITATIONS 
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There are inherent limitations regarding genetics studies including sample size 
and genotype distribution. Limited statistical power because of the modest sample size 
and different genotype distribution in project 1 and 2 (N = 71 and 77 respectively) may 
have played a role in limiting the significance of some of the statistical comparisons 
conducted. Post hoc power analyses for project 1 revealed the power to detect statistically 
significant differences between groups for CI at rest and HRmax to be .625 and .613 
respectively at α = 0.05. For project 2, post hoc power analyses revealed the power to 
detect statistically significant differences between groups for watts, watts/kg, and 
watts/VO2 to be .84, .95, and 1.00 respectively at α = 0.05. These post hoc analyses 
suggest a sufficient sample size for both project 1 and 2.  
Furthermore, the sample population for project 1 was void of the Gly49Gly 
genotype. This can be explained by the genotype frequency of the three genotypes 
present at amino acid 49 (0.69, 0.29, and 0.04 for Ser49Ser, Gly49Ser, and Gly49Gly 
respectively) but may vary among different racial/ethnic groups [260]. However, 
literature has demonstrated the Gly49Ser and Gly49Gly polymorphisms function 
similarly and that the Gly49Ser polymorphism may be representative of the Gly49 
polymorphism as a whole for ADRB1 [176, 208]. Additionally, time of day and time of 
year for testing as well as training background were not controlled for in project 2, which 
may affect test-retest reliability. An intraclass correlation coefficient analysis revealed the 
test-retest reliability for watts, watts/kg, and watts/VO2 to be 0.52, 0.49, and 0.59 
respectively, suggesting fair test-retest reliability.  
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Project 3 included DMD patients who were homozygous for arginine (AA, n = 
11), glycine (GG, n = 95), or heterozygous (AG, n = 69) at codon 389 and were collapsed 
into two study groups (Gly389, n = 95 and Arg389, n = 80). This even genotype 
distribution is surprising given the frequency in the healthy population (0.70 and 0.30 for 
Arg389 and Gly389 respectively) [270]. However, there is no data available regarding 
ADRB1 389 genotype frequency in a DMD population. A second consideration is the 
number of events in our data. It is generally recommended that for each covariate, a 
minimum of 10 events are needed to ensure statistical power. In our analysis including 5 
variables, 50 events are needed. Our cohort only had 18 DMD patients who were 
prescribed diuretics, violating this rule. However, literature has demonstrated a range of 
circumstances in which coverage and bias standards were adequate with fewer than 10 
events per variable, suggesting the rule of 10 events per variable may be relaxed [271]. A 
second consideration is the retrospective nature of the data and the rolling accrual of 
patients used for data collection. As a result, our cohort did include left-censored data 
which may influence the accuracy of the Cox model to identify the age of first diuretics 
use and therefore the incidence of diuretics use. However, the aim of this study was to 
determine the influence of ADRB1 genotype on the incidence of diuretics use. At 
present, we do not believe that genotype status, per se, would have influenced the 
model’s accuracy to identify the timing of first diuretics use. Further, we used a Kaplan 
Meier analysis, which is more effective when dealing with left-censored data given a 
<50% left-truncated distribution [298], and also identified a difference between 
genotypes in survival without NV use. 
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Project 4 included DMD patients who were homozygous for arginine (AA, n = 
26), glycine (GG, n = 59), or heterozygous (AG, n = 90) at codon 16 and were collapsed 
into two study groups (Arg16, n = 26 and Gly16, n = 149). While this distribution is not 
representative of a healthy population (0.40 and 0.60 for Arg16 and Gly16 respectively), 
no data is available regarding ADRB2 16 genotype distribution in a DMD population 
[287]. A second consideration is the retrospective nature of the data and the rolling 
accrual of patients used for data collection. The rolling accrual resulted in our cohort data 
having a left-truncation which may influence the accuracy of the Cox model to identify 
the age of first NV use and the risk of NV use [see above]. However, the aim of this 
study was to determine the influence of ADRB2 genotype on the risk of NV use. At 
present, we do not believe that genotype status would have influenced the model’s 
accuracy to identify the timing of first NV use. Again, we used a Kaplan Meier analysis, 
which is more suited for data with left truncation, and also identified a difference 
between genotypes groups for age of NV use. 
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CHAPTER 6: FUTURE DIRECTIONS AND CONCLUDING REMARKS 
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The findings of project 3 suggest that DMD patients with the Gly389 
polymorphism have a significantly higher incidence of diuretics use compared to patients 
with the Arg389 polymorphism. Specifically, the Gly389 polymorphism is 5 times more 
likely to use diuretics compared to the Arg389 polymorphism. However, there remains 
high variability in the type and timing of implementation of cardiac management 
therapies for DMD patients, as demonstrated by different incident rates of diuretic 
prescription between the clinics included in our analysis. The current standard of care is 
to treat cardiomyopathies when the patient becomes symptomatic, which poses 
complications as a majority of DMD patients are asymptomatic at cardiomyopathy 
diagnosis [9]. Fortunately, an emerging school of thought recommends treating 
cardiomyopathies before fibrofatty depositions emerge [9]. This variability may present 
complications in studies of this nature in the future. With cardiomyopathies continuing to 
emerge as a significant contributor to mortality and the related decline in cardiac and 
respiratory function, it is important to identify the factors that contribute to cardiac 
dysfunction in DMD patients. Therefore, it is important that clinical guidelines are 
established and adopted regarding cardiac management in the DMD population. Given 
the highly variable nature of cardiomyopathy management, future research aimed at 
investigating the influence of ADRB1 genotype on cardiac measures in DMD patients 
may be best served by focusing on annual and bi-annual ECHO measures. Using 
clinically derived ECHO measures would mitigate the effect of the variability of cardiac 
treatment in the clinic. Therefore, further research is necessary to identify if there is a 
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positive influence of the Arg389 polymorphism on clinically derived ECHO measures in 
DMD patients. 
Preliminary research by our group has demonstrated DMD patients with the 
Gly16 polymorphism have improved FVC, FEV1, and FEFmax as percent predicted 
compared with those expressing the Arg16 polymorphism earlier in life [299]. However, 
this improvement in respiratory function was almost completely abolished as the patient 
ages. Furthermore, a pilot study demonstrated an improvement in isometric knee extensor 
strength and manual muscle test scores in DMD patients following 12 weeks of Β2-AR  
agonist treatment [283]. A larger, follow-up study by this same group supported their 
previous findings with Β2-AR  agonist treatment improving lean body mass and time to 
walk/run 30 feet in patients with DMD — there were no improvements in isometric knee 
moments or manual muscle tests [284]. However, both study populations consisted of 
young DMD patients whose ages ranged between 5 to 11 years. It is important to 
emphasize that our findings demonstrate the Gly16 polymorphism confers a significantly 
higher risk of NV use; however, the absolute difference in risk between the Gly16 and 
Arg16 is marginal for ages between 5 and 11 years (project 4; Figure 2B). Indeed, the 
absolute difference in risk between genotype groups is less than 1.4% up to 15 years of 
age in our cohort of DMD patients. The difference in risk of NV between groups widens 
thereafter to reach >40% at patient ages of 25 years and older. One may infer from these 
observations that the additional risk of NV use associated with the Gly16 is relatively 
trivial below the adolescent years, and becomes more important when DMD patients 
enter the second decade of life. Further studies utilizing longitudinal clinically-derived 
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respiratory measures are needed to examine whether the effects of the Gly16 
polymorphism on respiratory outcomes in DMD are indeed dependent on patient age. 
 Current literature clearly demonstrates the need to further both cardiac and 
respiratory management in DMD patients. The interconnectedness of cardiac and 
respiratory function demonstrates a need for a treatment protocol to preserve the function 
of both in tandem. Our original hypotheses were that the Gly389 polymorphism would 
have a reduced probability and risk of cardiac events and interventions and that the Gly16 
polymorphism would have a reduced probability and risk of NV use in DMD patients. 
The current studies have demonstrated a deleterious influence of the Gly389 
polymorphism on the incidence of diuretics use and the Gly16 polymorphism on risk of 
NV use in patients with DMD. However, the burden of the literature suggests a protective 
effect of these polymorphisms (Gly389 and Gly16) on cardiac and respiratory function 
respectively. The principal findings of our studies refuting our original hypotheses may 
be explained by the aforementioned reasoning. These studies were the first of their kind 
in a DMD population and identified multiple pitfalls and limitations of these types of 
studies in this population. A longitudinal approach implementing more objective 
cardiopulmonary measure (i.e. ECHO and PFT measures) may further elucidate the 
complex relationship between the ADRB1 389 and ADRB2 16 genotypes and 
cardiopulmonary health in DMD patients. 
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